>OF309040.1 KR 1020210091180-A/4623: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF309030.1 KR 1020210091180-A/4613: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF309018.1 KR 1020210091180-A/4601: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF309002.1 KR 1020210091180-A/4585: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF308989.1 KR 1020210091180-A/4572: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF308976.1 KR 1020210091180-A/4559: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF308963.1 KR 1020210091180-A/4546: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF309140.1 KR 1020210091180-A/4723: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF308888.1 KR 1020210091180-A/4471: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF308880.1 KR 1020210091180-A/4463: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF308872.1 KR 1020210091180-A/4455: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF308865.1 KR 1020210091180-A/4448: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF308858.1 KR 1020210091180-A/4441: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF308850.1 KR 1020210091180-A/4433: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF308837.1 KR 1020210091180-A/4420: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF308824.1 KR 1020210091180-A/4407: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF308806.1 KR 1020210091180-A/4389: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF308797.1 KR 1020210091180-A/4380: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF308787.1 KR 1020210091180-A/4370: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF308777.1 KR 1020210091180-A/4360: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF308765.1 KR 1020210091180-A/4348: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF308752.1 KR 1020210091180-A/4335: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF308740.1 KR 1020210091180-A/4323: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF308728.1 KR 1020210091180-A/4311: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF308716.1 KR 1020210091180-A/4299: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF308704.1 KR 1020210091180-A/4287: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF308691.1 KR 1020210091180-A/4274: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF308678.1 KR 1020210091180-A/4261: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF308665.1 KR 1020210091180-A/4248: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF308655.1 KR 1020210091180-A/4238: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF308643.1 KR 1020210091180-A/4226: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF308627.1 KR 1020210091180-A/4210: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF308614.1 KR 1020210091180-A/4197: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF308601.1 KR 1020210091180-A/4184: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF308588.1 KR 1020210091180-A/4171: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF308513.1 KR 1020210091180-A/4096: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF308505.1 KR 1020210091180-A/4088: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF308497.1 KR 1020210091180-A/4080: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF308490.1 KR 1020210091180-A/4073: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF308483.1 KR 1020210091180-A/4066: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF308475.1 KR 1020210091180-A/4058: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF308462.1 KR 1020210091180-A/4045: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF308449.1 KR 1020210091180-A/4032: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF308431.1 KR 1020210091180-A/4014: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF308422.1 KR 1020210091180-A/4005: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF308412.1 KR 1020210091180-A/3995: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF308402.1 KR 1020210091180-A/3985: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF308390.1 KR 1020210091180-A/3973: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF308377.1 KR 1020210091180-A/3960: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF308365.1 KR 1020210091180-A/3948: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF308353.1 KR 1020210091180-A/3936: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF308341.1 KR 1020210091180-A/3924: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF308329.1 KR 1020210091180-A/3912: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF308316.1 KR 1020210091180-A/3899: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF308303.1 KR 1020210091180-A/3886: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF308290.1 KR 1020210091180-A/3873: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF308280.1 KR 1020210091180-A/3863: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF308268.1 KR 1020210091180-A/3851: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF308252.1 KR 1020210091180-A/3835: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF308239.1 KR 1020210091180-A/3822: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF308226.1 KR 1020210091180-A/3809: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF308213.1 KR 1020210091180-A/3796: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF308138.1 KR 1020210091180-A/3721: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF307931.1 KR 1020210091180-A/3514: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF307918.1 KR 1020210091180-A/3501: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF307905.1 KR 1020210091180-A/3488: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF307895.1 KR 1020210091180-A/3478: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF307883.1 KR 1020210091180-A/3466: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF307867.1 KR 1020210091180-A/3450: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF307854.1 KR 1020210091180-A/3437: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF307841.1 KR 1020210091180-A/3424: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF308130.1 KR 1020210091180-A/3713: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF307828.1 KR 1020210091180-A/3411: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF308121.1 KR 1020210091180-A/3704: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF308113.1 KR 1020210091180-A/3696: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF308103.1 KR 1020210091180-A/3686: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF308091.1 KR 1020210091180-A/3674: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF308078.1 KR 1020210091180-A/3661: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF308065.1 KR 1020210091180-A/3648: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF308047.1 KR 1020210091180-A/3630: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF307753.1 KR 1020210091180-A/3336: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF307745.1 KR 1020210091180-A/3328: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF308038.1 KR 1020210091180-A/3621: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF308028.1 KR 1020210091180-A/3611: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF308018.1 KR 1020210091180-A/3601: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF308006.1 KR 1020210091180-A/3589: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF307993.1 KR 1020210091180-A/3576: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF307980.1 KR 1020210091180-A/3563: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF307968.1 KR 1020210091180-A/3551: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF307956.1 KR 1020210091180-A/3539: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF307944.1 KR 1020210091180-A/3527: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF307736.1 KR 1020210091180-A/3319: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF307728.1 KR 1020210091180-A/3311: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF307718.1 KR 1020210091180-A/3301: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF307706.1 KR 1020210091180-A/3289: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF307693.1 KR 1020210091180-A/3276: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF307680.1 KR 1020210091180-A/3263: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF307662.1 KR 1020210091180-A/3245: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF307653.1 KR 1020210091180-A/3236: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF307643.1 KR 1020210091180-A/3226: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF307633.1 KR 1020210091180-A/3216: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF307621.1 KR 1020210091180-A/3204: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF307608.1 KR 1020210091180-A/3191: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF307595.1 KR 1020210091180-A/3178: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF307583.1 KR 1020210091180-A/3166: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF307571.1 KR 1020210091180-A/3154: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF307559.1 KR 1020210091180-A/3142: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF307546.1 KR 1020210091180-A/3129: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF307533.1 KR 1020210091180-A/3116: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF307520.1 KR 1020210091180-A/3103: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF307510.1 KR 1020210091180-A/3093: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF307498.1 KR 1020210091180-A/3081: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF307482.1 KR 1020210091180-A/3065: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF307469.1 KR 1020210091180-A/3052: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF307456.1 KR 1020210091180-A/3039: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF307443.1 KR 1020210091180-A/3026: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF307333.1 KR 1020210091180-A/2916: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF307321.1 KR 1020210091180-A/2904: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF307308.1 KR 1020210091180-A/2891: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF307295.1 KR 1020210091180-A/2878: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF307277.1 KR 1020210091180-A/2860: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF307268.1 KR 1020210091180-A/2851: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF307368.1 KR 1020210091180-A/2951: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF307258.1 KR 1020210091180-A/2841: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF307360.1 KR 1020210091180-A/2943: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF307248.1 KR 1020210091180-A/2831: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF307351.1 KR 1020210091180-A/2934: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF307343.1 KR 1020210091180-A/2926: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF307236.1 KR 1020210091180-A/2819: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF307223.1 KR 1020210091180-A/2806: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF307210.1 KR 1020210091180-A/2793: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF307198.1 KR 1020210091180-A/2781: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF307186.1 KR 1020210091180-A/2769: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF307174.1 KR 1020210091180-A/2757: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF307161.1 KR 1020210091180-A/2744: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF307148.1 KR 1020210091180-A/2731: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF307135.1 KR 1020210091180-A/2718: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF307125.1 KR 1020210091180-A/2708: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF307113.1 KR 1020210091180-A/2696: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF307097.1 KR 1020210091180-A/2680: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF307084.1 KR 1020210091180-A/2667: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF307071.1 KR 1020210091180-A/2654: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF307058.1 KR 1020210091180-A/2641: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF306983.1 KR 1020210091180-A/2566: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF306975.1 KR 1020210091180-A/2558: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF306966.1 KR 1020210091180-A/2549: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF306958.1 KR 1020210091180-A/2541: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF306948.1 KR 1020210091180-A/2531: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF306936.1 KR 1020210091180-A/2519: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF306923.1 KR 1020210091180-A/2506: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF306910.1 KR 1020210091180-A/2493: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF306892.1 KR 1020210091180-A/2475: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF306883.1 KR 1020210091180-A/2466: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF306873.1 KR 1020210091180-A/2456: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF306863.1 KR 1020210091180-A/2446: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF306851.1 KR 1020210091180-A/2434: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF306740.1 KR 1020210091180-A/2323: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF306838.1 KR 1020210091180-A/2421: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF306728.1 KR 1020210091180-A/2311: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF306825.1 KR 1020210091180-A/2408: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF306712.1 KR 1020210091180-A/2295: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF306813.1 KR 1020210091180-A/2396: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF306699.1 KR 1020210091180-A/2282: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF306801.1 KR 1020210091180-A/2384: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF306686.1 KR 1020210091180-A/2269: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF306789.1 KR 1020210091180-A/2372: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF306673.1 KR 1020210091180-A/2256: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF306776.1 KR 1020210091180-A/2359: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF306763.1 KR 1020210091180-A/2346: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF306750.1 KR 1020210091180-A/2333: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF306538.1 KR 1020210091180-A/2121: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF306525.1 KR 1020210091180-A/2108: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF306507.1 KR 1020210091180-A/2090: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF306498.1 KR 1020210091180-A/2081: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF306488.1 KR 1020210091180-A/2071: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF306478.1 KR 1020210091180-A/2061: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF306466.1 KR 1020210091180-A/2049: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF306453.1 KR 1020210091180-A/2036: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF306440.1 KR 1020210091180-A/2023: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF306428.1 KR 1020210091180-A/2011: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF306416.1 KR 1020210091180-A/1999: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF306404.1 KR 1020210091180-A/1987: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF306391.1 KR 1020210091180-A/1974: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF306598.1 KR 1020210091180-A/2181: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF306590.1 KR 1020210091180-A/2173: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF306378.1 KR 1020210091180-A/1961: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF306581.1 KR 1020210091180-A/2164: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF306365.1 KR 1020210091180-A/1948: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF306573.1 KR 1020210091180-A/2156: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF306563.1 KR 1020210091180-A/2146: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF306355.1 KR 1020210091180-A/1938: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF306551.1 KR 1020210091180-A/2134: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF306343.1 KR 1020210091180-A/1926: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF306327.1 KR 1020210091180-A/1910: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF306314.1 KR 1020210091180-A/1897: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF306301.1 KR 1020210091180-A/1884: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF306288.1 KR 1020210091180-A/1871: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF306213.1 KR 1020210091180-A/1796: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF306205.1 KR 1020210091180-A/1788: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF306196.1 KR 1020210091180-A/1779: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF306188.1 KR 1020210091180-A/1771: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF306178.1 KR 1020210091180-A/1761: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF306166.1 KR 1020210091180-A/1749: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF306153.1 KR 1020210091180-A/1736: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF306140.1 KR 1020210091180-A/1723: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF306122.1 KR 1020210091180-A/1705: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF306113.1 KR 1020210091180-A/1696: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF306103.1 KR 1020210091180-A/1686: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF306093.1 KR 1020210091180-A/1676: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF306081.1 KR 1020210091180-A/1664: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF306068.1 KR 1020210091180-A/1651: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF306055.1 KR 1020210091180-A/1638: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF306043.1 KR 1020210091180-A/1626: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF306031.1 KR 1020210091180-A/1614: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF306019.1 KR 1020210091180-A/1602: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF306006.1 KR 1020210091180-A/1589: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF305993.1 KR 1020210091180-A/1576: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF305980.1 KR 1020210091180-A/1563: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF305970.1 KR 1020210091180-A/1553: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF305958.1 KR 1020210091180-A/1541: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF305942.1 KR 1020210091180-A/1525: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF305929.1 KR 1020210091180-A/1512: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF305916.1 KR 1020210091180-A/1499: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF305903.1 KR 1020210091180-A/1486: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF305828.1 KR 1020210091180-A/1411: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF305820.1 KR 1020210091180-A/1403: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF305812.1 KR 1020210091180-A/1395: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF305805.1 KR 1020210091180-A/1388: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF305798.1 KR 1020210091180-A/1381: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF305790.1 KR 1020210091180-A/1373: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF305779.1 KR 1020210091180-A/1362: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF305766.1 KR 1020210091180-A/1349: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF305748.1 KR 1020210091180-A/1331: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF305739.1 KR 1020210091180-A/1322: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF305729.1 KR 1020210091180-A/1312: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF305719.1 KR 1020210091180-A/1302: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF305707.1 KR 1020210091180-A/1290: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF305694.1 KR 1020210091180-A/1277: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF305682.1 KR 1020210091180-A/1265: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF305670.1 KR 1020210091180-A/1253: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF305658.1 KR 1020210091180-A/1241: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF305646.1 KR 1020210091180-A/1229: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF305633.1 KR 1020210091180-A/1216: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF305543.1 KR 1020210091180-A/1126: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF305530.1 KR 1020210091180-A/1113: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF305455.1 KR 1020210091180-A/1038: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF305447.1 KR 1020210091180-A/1030: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF305438.1 KR 1020210091180-A/1021: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF305430.1 KR 1020210091180-A/1013: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF305420.1 KR 1020210091180-A/1003: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF305409.1 KR 1020210091180-A/992: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF305620.1 KR 1020210091180-A/1203: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF305398.1 KR 1020210091180-A/981: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF305607.1 KR 1020210091180-A/1190: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF305385.1 KR 1020210091180-A/968: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF305597.1 KR 1020210091180-A/1180: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF305585.1 KR 1020210091180-A/1168: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF305367.1 KR 1020210091180-A/950: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF305358.1 KR 1020210091180-A/941: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF305569.1 KR 1020210091180-A/1152: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF305556.1 KR 1020210091180-A/1139: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF305348.1 KR 1020210091180-A/931: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF305338.1 KR 1020210091180-A/921: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF305326.1 KR 1020210091180-A/909: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF305313.1 KR 1020210091180-A/896: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF305300.1 KR 1020210091180-A/883: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF305288.1 KR 1020210091180-A/871: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF305276.1 KR 1020210091180-A/859: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF305264.1 KR 1020210091180-A/847: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF305251.1 KR 1020210091180-A/834: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF305238.1 KR 1020210091180-A/821: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF305225.1 KR 1020210091180-A/808: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF305215.1 KR 1020210091180-A/798: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF305203.1 KR 1020210091180-A/786: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF305187.1 KR 1020210091180-A/770: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF305174.1 KR 1020210091180-A/757: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF305161.1 KR 1020210091180-A/744: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF305148.1 KR 1020210091180-A/731: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF305073.1 KR 1020210091180-A/656: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF305065.1 KR 1020210091180-A/648: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF305057.1 KR 1020210091180-A/640: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF305050.1 KR 1020210091180-A/633: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF305043.1 KR 1020210091180-A/626: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF305035.1 KR 1020210091180-A/618: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF305022.1 KR 1020210091180-A/605: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF305009.1 KR 1020210091180-A/592: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF304991.1 KR 1020210091180-A/574: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF304982.1 KR 1020210091180-A/565: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF304950.1 KR 1020210091180-A/533: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF304972.1 KR 1020210091180-A/555: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF304937.1 KR 1020210091180-A/520: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF304962.1 KR 1020210091180-A/545: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF304925.1 KR 1020210091180-A/508: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF304913.1 KR 1020210091180-A/496: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF304901.1 KR 1020210091180-A/484: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF304889.1 KR 1020210091180-A/472: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF304876.1 KR 1020210091180-A/459: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF304863.1 KR 1020210091180-A/446: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF304850.1 KR 1020210091180-A/433: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF304840.1 KR 1020210091180-A/423: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF304828.1 KR 1020210091180-A/411: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF304812.1 KR 1020210091180-A/395: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ATCAAGGAAGATG
>OF304799.1 KR 1020210091180-A/382: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CATCAAGGAAGAT
>OF304786.1 KR 1020210091180-A/369: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
ACATCAAGGAAGA
>OF304773.1 KR 1020210091180-A/356: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AACATCAAGGAAG
>OF304698.1 KR 1020210091180-A/281: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCATTTCT
>OF304690.1 KR 1020210091180-A/273: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCATTTC
>OF304681.1 KR 1020210091180-A/264: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGCATTT
>OF304673.1 KR 1020210091180-A/256: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATGGCATT
>OF304663.1 KR 1020210091180-A/246: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATGGCAT
>OF304651.1 KR 1020210091180-A/234: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGATGGCA
>OF304638.1 KR 1020210091180-A/221: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGATGGC
>OF304625.1 KR 1020210091180-A/208: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAGATGG
>OF304607.1 KR 1020210091180-A/190: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CCAGTCGGTAAGT
>OF304598.1 KR 1020210091180-A/181: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAGTCGGTAAGTT
>OF304588.1 KR 1020210091180-A/171: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTCGGTAAGTTC
>OF304578.1 KR 1020210091180-A/161: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTCGGTAAGTTCT
>OF304566.1 KR 1020210091180-A/149: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGTTCTG
>OF304553.1 KR 1020210091180-A/136: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTTCTGT
>OF304540.1 KR 1020210091180-A/123: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTCTGTC
>OF304528.1 KR 1020210091180-A/111: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCTGTCC
>OF304516.1 KR 1020210091180-A/99: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTGTCCA
>OF304504.1 KR 1020210091180-A/87: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGTCCAA
>OF304491.1 KR 1020210091180-A/74: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTCCAAG
>OF304478.1 KR 1020210091180-A/61: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCCAAGC
>OF304465.1 KR 1020210091180-A/48: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAGCCCG
>OF304455.1 KR 1020210091180-A/38: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAAGCCC
>OF304443.1 KR 1020210091180-A/26: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCAAGCC
>OF299744.1 KR 1020210131243-A/21: USE OF DOWNREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
AGCCGTGTATGAC
>OF299731.1 KR 1020210131243-A/8: USE OF DOWNREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
GAGCCGTGTATGA
>OF299700.1 KR 1020210131242-A/21: USE OF UPREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
AGCCGTGTATGAC
>OF299687.1 KR 1020210131242-A/8: USE OF UPREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
GAGCCGTGTATGA
>pdb|7W27|B Chain B, Crystal structure of BEND3-BEN4-DNA complex
NGCTGCGTGGGTC
>pdb|7W27|A Chain A, Crystal structure of BEND3-BEN4-DNA complex
NGACCCACGCAGC
>pdb|4QWC|E Chain E, Ternary Crystal Structures of a Y-family DNA polymerase DPO4 from Sulfobus Solfataricus in Comples with DNA and L-DCDP
GGCTACAGGACTN
>pdb|4QWC|B Chain B, Ternary Crystal Structures of a Y-family DNA polymerase DPO4 from Sulfobus Solfataricus in Comples with DNA and L-DCDP
GGCTACAGGACTN
>pdb|2ROU|B Chain B, Stereospecific Conformations of N2-dG 1R-trans-anti-Benzo[c]phenanthrene DNA Adducts: 3'-Intercalation of the 1R Adduct and 5'-Minor Groove Orientation of the 1S Adduct in an Iterated (CG)3 Repeat
CATGCCGCGCGAT
>pdb|2ROU|A Chain A, Stereospecific Conformations of N2-dG 1R-trans-anti-Benzo[c]phenanthrene DNA Adducts: 3'-Intercalation of the 1R Adduct and 5'-Minor Groove Orientation of the 1S Adduct in an Iterated (CG)3 Repeat
ATCGCGCGGCATG
>pdb|2O7Y|B Chain B, Duplex DNA containing an abasic site with an opposite T (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
CCCGGTTCTTTGG
>pdb|2O7Y|A Chain A, Duplex DNA containing an abasic site with an opposite T (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
CCAAAGNACCGGG
>pdb|2O7W|B Chain B, Duplex DNA containing an abasic site with an opposite G (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
CCCGGTGCTTTGG
>pdb|2O7W|A Chain A, Duplex DNA containing an abasic site with an opposite G (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
CCAAAGNACCGGG
>pdb|2D2L|A Chain A, Crystal Structure of a minimal, all-RNA hairpin ribozyme with a propyl linker (C3) at position U39
TCCCNGTCCACCG
>pdb|5GAT|C Chain C, SOLUTION NMR STRUCTURE OF THE WILD TYPE DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13BP DNA CONTAINING A CGATA SITE, 35 STRUCTURES
GTCTCTATCGCTG
>pdb|5GAT|B Chain B, SOLUTION NMR STRUCTURE OF THE WILD TYPE DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13BP DNA CONTAINING A CGATA SITE, 35 STRUCTURES
CAGCGATAGAGAC
>pdb|2KH0|B Chain B, 2-Hydroxy-7-nitrofluorene covalently linked into a 13mer DNA duplex - solution structure of the face-down orientation
CGACGTNTGCAGC
>pdb|2KH0|A Chain A, 2-Hydroxy-7-nitrofluorene covalently linked into a 13mer DNA duplex - solution structure of the face-down orientation
GCTGCANACGTCG
>PA370138.1 WO 2022019303-A/1: Pyrrole-Imidazole Polyamide, TGF- beta Gene Expression Inhibitor, and Pharmaceutical Composition
AGGTGACCTTTTC
>pdb|2KH1|B Chain B, 2-Hydroxy-7-nitrofluorene covalently linked into a 13mer DNA duplex - solution structure of the face-up orientation
CGACGTNTGCAGC
>pdb|2KH1|A Chain A, 2-Hydroxy-7-nitrofluorene covalently linked into a 13mer DNA duplex - solution structure of the face-up orientation
GCTGCANACGTCG
>pdb|2JX1|C Chain C, Structure of the fifth zinc finger of Myelin Transcription Factor 1 in complex with RARE DNA
GTGAACTTTCGGT
>pdb|2JX1|B Chain B, Structure of the fifth zinc finger of Myelin Transcription Factor 1 in complex with RARE DNA
ACCGAAAGTTCAC
>pdb|2O80|B Chain B, Duplex DNA containing an abasic site with an opposite dC (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
CCCGGTCCTTTGG
>pdb|2O80|A Chain A, Duplex DNA containing an abasic site with an opposite dC (alpha anomer) in 5'-G_AC-3' (10 structure ensemble and averaged structure)
CCAAAGNACCGGG
>pdb|4GAT|C Chain C, SOLUTION NMR STRUCTURE OF THE WILD TYPE DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13BP DNA CONTAINING A CGATA SITE, REGULARIZED MEAN STRUCTURE
GTCTCTATCGCTG
>pdb|4GAT|B Chain B, SOLUTION NMR STRUCTURE OF THE WILD TYPE DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13BP DNA CONTAINING A CGATA SITE, REGULARIZED MEAN STRUCTURE
CAGCGATAGAGAC
>MY787100.1 Sequence 128 from patent US 11208689
GCTGCGTGATGAG
>MY786990.1 Sequence 18 from patent US 11208689
AAGGCCTGCTGAA
>MY786989.1 Sequence 17 from patent US 11208689
CTGGTGGCGTAGG
>MY786988.1 Sequence 16 from patent US 11208689
GGAGACGCTCTGG
>MY786987.1 Sequence 15 from patent US 11208689
GGAGACGGTCTGG
>MY786986.1 Sequence 14 from patent US 11208689
TGGTCGCGTAGGC
>MY786985.1 Sequence 13 from patent US 11208689
TGGTAGCGTAGGC
>MY786984.1 Sequence 12 from patent US 11208689
TGGTGTCGTAGGC
>MY786983.1 Sequence 11 from patent US 11208689
TGGTGCCGTAGGC
>MY786982.1 Sequence 10 from patent US 11208689
TGGTGACGTAGGC
>MY786981.1 Sequence 9 from patent US 11208689
TGGTTGCGTAGGC
>MY786980.1 Sequence 8 from patent US 11208689
AGCTGTTGGCGTA
>MY786979.1 Sequence 7 from patent US 11208689
AGCTAGTGGCGTA
>MY786978.1 Sequence 6 from patent US 11208689
GAGCTCTTGGCGT
>MY786977.1 Sequence 5 from patent US 11208689
GAGCTATTGGCGT
>MY786976.1 Sequence 4 from patent US 11208689
AGCTTGTGGCGTA
>MY786975.1 Sequence 3 from patent US 11208689
AGCTGATGGCGTA
>MY786974.1 Sequence 2 from patent US 11208689
AGCTCGTGGCGTA
>MY786973.1 Sequence 1 from patent US 11208689
AGCTGCTGGCGTA
>MY775138.1 Sequence 48 from patent US 11208496
CGTAAGTGGATCC
>MY773663.1 Sequence 3 from patent US 11208430
GGAAGGGGAGAGA
>MY773510.1 Sequence 82 from patent US 11207416
GCAAAAACAAAGG
>MY773509.1 Sequence 81 from patent US 11207416
GCAAAAACAAAGG
>MY773507.1 Sequence 79 from patent US 11207416
GCAAAAACAAAGG
>MY773505.1 Sequence 77 from patent US 11207416
GCAAAAACAAAGG
>MY773503.1 Sequence 75 from patent US 11207416
GCAAAAACAAAGG
>MY773502.1 Sequence 74 from patent US 11207416
GCAAAAACAAAGG
>MY773500.1 Sequence 72 from patent US 11207416
GCAAAAACAAAGG
>MY773499.1 Sequence 71 from patent US 11207416
GCAAAAACAAAGG
>MY773488.1 Sequence 60 from patent US 11207416
TTTTTTTTTTTTT
>MY773487.1 Sequence 59 from patent US 11207416
AAAAAAAAAAAAA
>MY773486.1 Sequence 58 from patent US 11207416
TTTTTTTTTTTTT
>MY773485.1 Sequence 57 from patent US 11207416
AAAAAAAAAAAAA
>MY773484.1 Sequence 56 from patent US 11207416
TTTTTTTTTTTTT
>MY773483.1 Sequence 55 from patent US 11207416
AAAAAAAAAAAAA
>MY773476.1 Sequence 48 from patent US 11207416
TTTTTTTTTTTTT
>MY773475.1 Sequence 47 from patent US 11207416
AAAAAAAAAAAAA
>MY773474.1 Sequence 46 from patent US 11207416
TTTTTTTTTTTTT
>MY773473.1 Sequence 45 from patent US 11207416
AAAAAAAAAAAAA
>MY773472.1 Sequence 44 from patent US 11207416
TTTTTTTTTTTTT
>MY773471.1 Sequence 43 from patent US 11207416
AAAAAAAAAAAAA
>MY773464.1 Sequence 36 from patent US 11207416
TTTTTTTTTTTTT
>MY773463.1 Sequence 35 from patent US 11207416
AAAAAAAAAAAAA
>MY773462.1 Sequence 34 from patent US 11207416
TTTTTTTTTTTTT
>MY773461.1 Sequence 33 from patent US 11207416
AAAAAAAAAAAAA
>MY773460.1 Sequence 32 from patent US 11207416
TTTTTTTTTTTTT
>MY773459.1 Sequence 31 from patent US 11207416
AAAAAAAAAAAAA
>MY773452.1 Sequence 24 from patent US 11207416
TTTTTTTTTTTTT
>MY773451.1 Sequence 23 from patent US 11207416
AAAAAAAAAAAAA
>MY773450.1 Sequence 22 from patent US 11207416
TTTTTTTTTTTTT
>MY773449.1 Sequence 21 from patent US 11207416
AAAAAAAAAAAAA
>MY773448.1 Sequence 20 from patent US 11207416
TTTTTTTTTTTTT
>MY773447.1 Sequence 19 from patent US 11207416
AAAAAAAAAAAAA
>MY773440.1 Sequence 12 from patent US 11207416
TTTTTTTTTTTTT
>MY773439.1 Sequence 11 from patent US 11207416
AAAAAAAAAAAAA
>MY773438.1 Sequence 10 from patent US 11207416
TTTTTTTTTTTTT
>MY773437.1 Sequence 9 from patent US 11207416
AAAAAAAAAAAAA
>MY773436.1 Sequence 8 from patent US 11207416
TTTTTTTTTTTTT
>MY773435.1 Sequence 7 from patent US 11207416
AAAAAAAAAAAAA
>MY770181.1 Sequence 36 from patent US 11206777
CAACTGGAAAGCC
>MY764714.1 Sequence 469 from patent US 11203611
TCGTCGTGACGTT
>MY764704.1 Sequence 444 from patent US 11203611
AACGACACGACGA
>MY764692.1 Sequence 432 from patent US 11203611
TCGTCGTGTCGTT
>MY764691.1 Sequence 431 from patent US 11203611
TCGTCGTGTCGTT
>MY764690.1 Sequence 430 from patent US 11203611
TCGTCGTGTCGTT
>MY764689.1 Sequence 429 from patent US 11203611
TCGTCGTGTCGTT
>MY764688.1 Sequence 428 from patent US 11203611
TCGTCGTGTCGTT
>MY764687.1 Sequence 427 from patent US 11203611
TCGTCGTGTCGTT
>MY764686.1 Sequence 426 from patent US 11203611
CCGTCGTGTCGTT
>MY764684.1 Sequence 424 from patent US 11203611
TCGTCGTGTCGTT
>MY764683.1 Sequence 423 from patent US 11203611
TCGTCGTGTCGTT
>MY764682.1 Sequence 422 from patent US 11203611
TCGTCGTGTCGTT
>MY764681.1 Sequence 421 from patent US 11203611
TCGTCGTGTCGTT
>MY764680.1 Sequence 420 from patent US 11203611
TCGTCGTGTCGTT
>MY764679.1 Sequence 419 from patent US 11203611
TCGTCGTGTCGTT
>MY764678.1 Sequence 418 from patent US 11203611
TCGTCGTGTCGTT
>MY764677.1 Sequence 417 from patent US 11203611
TCGTCGTGTCGTT
>MY764676.1 Sequence 416 from patent US 11203611
TCGTCGTGTCGTT
>MY764675.1 Sequence 415 from patent US 11203611
TCGTCGTGTCGTT
>MY764674.1 Sequence 414 from patent US 11203611
TCGTCGTGTCGTT
>MY764673.1 Sequence 413 from patent US 11203611
TCGTCGTGTCGTT
>MY764672.1 Sequence 412 from patent US 11203611
TCGTCGTGTCGTT
>MY764671.1 Sequence 411 from patent US 11203611
TCGTCGTGTCGTT
>MY764670.1 Sequence 410 from patent US 11203611
TCGTCGTGTCGTT
>MY764668.1 Sequence 408 from patent US 11203611
TCGTCGTGTCGTT
>MY764667.1 Sequence 407 from patent US 11203611
TCGTCGTGTCGTT
>MY764663.1 Sequence 403 from patent US 11203611
TCGTCGTGTCGTT
>MY764662.1 Sequence 402 from patent US 11203611
TCGTCGTGTCGTT
>MY764661.1 Sequence 401 from patent US 11203611
TCGTCGTGTCGTT
>MY764660.1 Sequence 400 from patent US 11203611
TCGTCGTGTCGTT
>MY764659.1 Sequence 399 from patent US 11203611
TCGTCGTGTCGTT
>MY764658.1 Sequence 398 from patent US 11203611
TCGTCGTGTCGTT
>MY764657.1 Sequence 397 from patent US 11203611
TCGTCGTGTCGTT
>MY764656.1 Sequence 396 from patent US 11203611
TCGTCGTGTCGTT
>MY764655.1 Sequence 395 from patent US 11203611
TCGTCGTGTCGTT
>MY764654.1 Sequence 394 from patent US 11203611
TCGTCGTGTCGTT
>MY764653.1 Sequence 393 from patent US 11203611
TCGTCGTGTCGTT
>MY764652.1 Sequence 392 from patent US 11203611
TCGTCGTGTCGTT
>MY764651.1 Sequence 391 from patent US 11203611
TCGTCGTGTCGTT
>MY764650.1 Sequence 390 from patent US 11203611
TCGTCGTGTCGTT
>MY764649.1 Sequence 389 from patent US 11203611
TTCGCGTGACGTT
>MY764648.1 Sequence 388 from patent US 11203611
TTCGCGTGACGTT
>MY764632.1 Sequence 372 from patent US 11203611
TCGTCGTGTCGTT
>MY764631.1 Sequence 371 from patent US 11203611
TCGTCGTGTCGTT
>MY764630.1 Sequence 370 from patent US 11203611
TCGTCGTGTCGTT
>MY764629.1 Sequence 369 from patent US 11203611
TCGTCGTGTCGTT
>MY764628.1 Sequence 368 from patent US 11203611
TCGTCGTGTCGTT
>MY764627.1 Sequence 367 from patent US 11203611
TCGTCGTGTCGTT
>MY764626.1 Sequence 366 from patent US 11203611
TCGTCGTGTCGTT
>MY764625.1 Sequence 365 from patent US 11203611
TCGTCGTGTCGTT
>MY764624.1 Sequence 364 from patent US 11203611
TCGTCGTGTCGTT
>MY764623.1 Sequence 363 from patent US 11203611
TCGTCGTGTCGTT
>MY764622.1 Sequence 362 from patent US 11203611
TCGTCGTGTCGTT
>MY764621.1 Sequence 361 from patent US 11203611
TCGTCGTGTCGTT
>MY764620.1 Sequence 360 from patent US 11203611
TCGTCGTGTCGTT
>MY764619.1 Sequence 359 from patent US 11203611
TCGTCGTGTCGTT
>MY764618.1 Sequence 358 from patent US 11203611
TCGTCGTGTCGTT
>MY764617.1 Sequence 357 from patent US 11203611
TCGTCGTGTCGTT
>MY764616.1 Sequence 356 from patent US 11203611
TCGTCGTGTCGTT
>MY764615.1 Sequence 355 from patent US 11203611
TCGTCGTGTCGTT
>MY764612.1 Sequence 352 from patent US 11203611
TCGTCGTGTCGTT
>MY764611.1 Sequence 351 from patent US 11203611
TCGTCGTGTCGTT
>MY764610.1 Sequence 350 from patent US 11203611
TCGTCGTGTCGTT
>MY764609.1 Sequence 349 from patent US 11203611
TCGTCGTGTCGTT
>MY764608.1 Sequence 348 from patent US 11203611
TCGTCGTGTCGTT
>MY764597.1 Sequence 337 from patent US 11203611
TCGTCGTGTCGTT
>MY764596.1 Sequence 336 from patent US 11203611
TCGTCGTGTCGTT
>MY764595.1 Sequence 335 from patent US 11203611
TCGTCGTGTCGTT
>MY764594.1 Sequence 334 from patent US 11203611
TCGTCGTGTCGTT
>MY764593.1 Sequence 333 from patent US 11203611
TCGTCGTGTCGTT
>MY764592.1 Sequence 332 from patent US 11203611
TCGTCGTGTCGTT
>MY764591.1 Sequence 331 from patent US 11203611
TCGTCGTGTCGTT
>MY764590.1 Sequence 330 from patent US 11203611
TCGTCGTGTCGTT
>MY764589.1 Sequence 329 from patent US 11203611
TGCAGCTGAGCTT
>MY764588.1 Sequence 328 from patent US 11203611
TGCTGCTGAGCTT
>MY764579.1 Sequence 319 from patent US 11203611
TCGACGTGTCGTT
>MY764578.1 Sequence 318 from patent US 11203611
TCGACGTGACGTT
>MY764577.1 Sequence 317 from patent US 11203611
TCGACGTGTCGTT
>MY764575.1 Sequence 315 from patent US 11203611
TCGTCGTGACGTT
>MY764572.1 Sequence 312 from patent US 11203611
TCGTCGTGTCGTT
>MY764571.1 Sequence 311 from patent US 11203611
TCGTCGTGTCGTT
>MY764570.1 Sequence 310 from patent US 11203611
TCGTCGTGTCGTT
>MY764569.1 Sequence 309 from patent US 11203611
TCGTCGTGTCGTT
>MY764566.1 Sequence 306 from patent US 11203611
TCGTCGTGTCGTT
>MY764565.1 Sequence 305 from patent US 11203611
TCGACGTGACGTT
>MY764564.1 Sequence 304 from patent US 11203611
TCGTCGTGACGTT
>MY764563.1 Sequence 303 from patent US 11203611
TCGTCGTGTCGTT
>MY764562.1 Sequence 302 from patent US 11203611
TCGTCGTGTCGTT
>MY764561.1 Sequence 301 from patent US 11203611
TCGTCGTGTCGTT
>MY764553.1 Sequence 293 from patent US 11203611
TCGACGTGACGTT
>MY764552.1 Sequence 292 from patent US 11203611
TCGTCGTGACGTT
>MY764551.1 Sequence 291 from patent US 11203611
TCGTCGTGTCGTT
>MY764550.1 Sequence 290 from patent US 11203611
TCGTCGTGTCGTT
>MY764549.1 Sequence 289 from patent US 11203611
TCGTCGTGTCGTT
>MY764548.1 Sequence 288 from patent US 11203611
TCGTCGTGTCGTT
>MY764547.1 Sequence 287 from patent US 11203611
TCGTCGTGTCGTT
>MY764546.1 Sequence 286 from patent US 11203611
TCGTCGTGTCGTT
>MY764545.1 Sequence 285 from patent US 11203611
TCGTCGTGTCGTT
>MY764544.1 Sequence 284 from patent US 11203611
ACGACGTGACGTT
>MY764543.1 Sequence 283 from patent US 11203611
ACGACGTGACGTT
>MY764542.1 Sequence 282 from patent US 11203611
TCGTCGTGTCGTT
>MY764541.1 Sequence 281 from patent US 11203611
TCGTCGTGTCGTT
>MY764540.1 Sequence 280 from patent US 11203611
TCGTCGTGTCGTT
>MY764539.1 Sequence 279 from patent US 11203611
TCGTCGTGTCGTT
>MY764538.1 Sequence 278 from patent US 11203611
ACGACGTGACGTT
>MY764537.1 Sequence 277 from patent US 11203611
ACGACGTGACGTT
>MY764536.1 Sequence 276 from patent US 11203611
TCGACGTGACGTT
>MY764535.1 Sequence 275 from patent US 11203611
TCGTCGTGACGTT
>MY764534.1 Sequence 274 from patent US 11203611
TCGAGCTGTCGTT
>MY764533.1 Sequence 273 from patent US 11203611
TGCTGCTGTGCTT
>MY764532.1 Sequence 272 from patent US 11203611
TCGTCGTGTCGTT
>MY764531.1 Sequence 271 from patent US 11203611
TCGTCGTGTCGTT
>MY764530.1 Sequence 270 from patent US 11203611
TCGTCGTGTCGTT
>MY764529.1 Sequence 269 from patent US 11203611
TCGTCGTGTCGTT
>MY764526.1 Sequence 266 from patent US 11203611
TCGTCGTGTCGTT
>MY764523.1 Sequence 263 from patent US 11203611
TCGTCGTGTCGTT
>MY764522.1 Sequence 262 from patent US 11203611
TCGTCGTGTCGTT
>MY764521.1 Sequence 261 from patent US 11203611
TCGTCGTGTCGTT
>MY764520.1 Sequence 260 from patent US 11203611
TCGTCGTGTCGTT
>MY764519.1 Sequence 259 from patent US 11203611
TCGTCGTGTCGTT
>MY764518.1 Sequence 258 from patent US 11203611
TCGTCGTGTCGTT
>MY764517.1 Sequence 257 from patent US 11203611
TCGTCGTGTCGTT
>MY764516.1 Sequence 256 from patent US 11203611
TCGTCGTGTCGTT
>MY764515.1 Sequence 255 from patent US 11203611
TCGTCGTGTCGTT
>MY764514.1 Sequence 254 from patent US 11203611
TCGTCGTGTCGTT
>MY764513.1 Sequence 253 from patent US 11203611
TCGTCGTGTCGTT
>MY764512.1 Sequence 252 from patent US 11203611
TCGTCGTGTCGTT
>MY764511.1 Sequence 251 from patent US 11203611
TCGTCGTGTCGTT
>MY764510.1 Sequence 250 from patent US 11203611
TCGTCGTGTCGTT
>MY764506.1 Sequence 246 from patent US 11203611
TCGTCGTGTCGTT
>MY764505.1 Sequence 245 from patent US 11203611
TCGTCGTGTCGTT
>MY764504.1 Sequence 244 from patent US 11203611
TCGTCGTGTCGTT
>MY764503.1 Sequence 243 from patent US 11203611
TCGTCGTGTCGTT
>MY764502.1 Sequence 242 from patent US 11203611
TCGTCGTGTCGTT
>MY764501.1 Sequence 241 from patent US 11203611
TCGTCGTGTCGTT
>MY764500.1 Sequence 240 from patent US 11203611
TCGTCGTGTCGTT
>MY764499.1 Sequence 239 from patent US 11203611
TCGTCGTGTCGTT
>MY764498.1 Sequence 238 from patent US 11203611
TCGTCGTGTCGTT
>MY764497.1 Sequence 237 from patent US 11203611
TCGTCGTGTCGTT
>MY764491.1 Sequence 231 from patent US 11203611
TCGTCGTGTCGTT
>MY764490.1 Sequence 230 from patent US 11203611
TCGTCGTGTCGTT
>MY764489.1 Sequence 229 from patent US 11203611
TCGTCGTGTCGTT
>MY764488.1 Sequence 228 from patent US 11203611
TCGTCGTGTCGTT
>MY764487.1 Sequence 227 from patent US 11203611
TCGTCGTGTCGTT
>MY764486.1 Sequence 226 from patent US 11203611
TCGTCGTGTCGTT
>MY764485.1 Sequence 225 from patent US 11203611
TCGTCGTGTCGTT
>MY764482.1 Sequence 222 from patent US 11203611
GGGACGATCGTCT
>MY764475.1 Sequence 215 from patent US 11203611
TCGTTTTGTCGTT
>MY764474.1 Sequence 214 from patent US 11203611
TCGTCGTGTTTTT
>MY764473.1 Sequence 213 from patent US 11203611
TCGTCGTGTCGTT
>MY764453.1 Sequence 189 from patent US 11203611
TCGTCGTGTCGTT
>MY764030.1 Sequence 73 from patent US 11202839
CCAGGGGACCTGC
>MY764027.1 Sequence 70 from patent US 11202839
CGTCCAGGGGACC
>MY764026.1 Sequence 69 from patent US 11202839
GCAGGTCCCCTGG
>MY761041.1 Sequence 6301 from patent US 11198882
TTCACGTCATGCT
>MY760920.1 Sequence 6180 from patent US 11198882
AGCTTCAATAGTA
>MY760827.1 Sequence 5402 from patent US 11198882
TGCATGCGCAGTA
>MY754832.1 Sequence 69 from patent US 11198875
TTAAGCAATCTGG
>MY748177.1 Sequence 73 from patent US 11197935
CCAGGGGACCTGC
>MY748174.1 Sequence 70 from patent US 11197935
CGTCCAGGGGACC
>MY748173.1 Sequence 69 from patent US 11197935
GCAGGTCCCCTGG
>MY745388.1 Sequence 7 from patent US 11193161
CCAGGATAGTTCA
>MY742227.1 Sequence 120 from patent US 11193125
CCGCCATTTCTCA
>MY742226.1 Sequence 119 from patent US 11193125
GTGTCTTTCTGAG
>MY742049.1 Sequence 7 from patent US 11193121
GAACNNNNNNTAC
>MY742047.1 Sequence 5 from patent US 11193121
GAAGNNNNNNTAC
>MY742046.1 Sequence 4 from patent US 11193121
GAACNNNNNNTCC
>MY742043.1 Sequence 1 from patent US 11193121
GGCCNNNNNGGCC
>MY741933.1 Sequence 24 from patent US 11193115
GTTTGAGAGTGTT
>MY734005.1 Sequence 1481 from patent US 11186829
GCCGCCRCCATGG
>MY731707.1 Sequence 73 from patent US 11185596
CCAGGGGACCTGC
>MY731704.1 Sequence 70 from patent US 11185596
CGTCCAGGGGACC
>MY731703.1 Sequence 69 from patent US 11185596
GCAGGTCCCCTGG
>MY731603.1 Sequence 15 from patent US 11185586
GCCGCCRCCATGG
>MY722328.1 Sequence 59 from patent US 11180795
CGCGGCCAATGCT
>MY722304.1 Sequence 35 from patent US 11180795
CTGCCCCGGATTG
>MY714172.1 Sequence 46 from patent US 11180744
AATTCGGCTCGAG
>MY700622.1 Sequence 344 from patent US 11174488
CTTGTGNCATGTG
>MY699460.1 Sequence 24 from patent US 11174471
GTTTGAGAGTGTT
>MY680438.1 Sequence 22 from patent US 11168373
CANANNNANNCAT
>MY680437.1 Sequence 21 from patent US 11168373
AGNGNNCANNCAT
>MY680434.1 Sequence 18 from patent US 11168373
TGNCNNANGNNCC
>MY680431.1 Sequence 15 from patent US 11168373
TAANNGNTNNTGN
>MY680428.1 Sequence 12 from patent US 11168373
CANANNACNTTCG
>MY680422.1 Sequence 6 from patent US 11168373
CACCTNNANCACC
>MY680352.1 Sequence 42 from patent US 11168369
AGAGAAGAATCCC
>MY680351.1 Sequence 41 from patent US 11168369
GGGATTCTTCTCT
>MY680350.1 Sequence 40 from patent US 11168369
CAGCAGTATGTAT
>MY680308.1 Sequence 29 from patent US 11168365
TAGGTAATCGTAT
>MY680306.1 Sequence 27 from patent US 11168365
TAGGGGTAGCGTA
>MY680214.1 Sequence 84 from patent US 11168357
GGGAGGGTGGGTG
>MY680111.1 Sequence 11 from patent US 11168353
GATCCACGGGACG
>MY680109.1 Sequence 9 from patent US 11168353
TGACGACTGCATT
>MY680047.1 Sequence 44 from patent US 11168350
TAAAAGGGCGTGC
>MY680044.1 Sequence 41 from patent US 11168350
GTGAAACGGCACG
>MY680024.1 Sequence 21 from patent US 11168350
ATTTTCCCGCACG
>MY680021.1 Sequence 18 from patent US 11168350
CACTTTGCCGTGC
>MY680007.1 Sequence 4 from patent US 11168350
CGGCCATCCATTA
>MY679801.1 Sequence 6 from patent US 11168337
GCCGCCNCCATGG
>MY678972.1 Sequence 9 from patent US 11168325
TGTAAGCACTTTG
>MY677006.1 Sequence 11 from patent US 11167027
GGCGCGCCGCACC
>MY676457.1 Sequence 158 from patent US 11166996
GCGGGGGGCTCCG
>MY676450.1 Sequence 151 from patent US 11166996
GCGGGGGGCTCCG
>MY676183.1 Sequence 3 from patent US 11166994
GACATGAGGTTGC
>MY672283.1 Sequence 96 from patent US 11162146
GTCATTTAGCAAG
>MY671161.1 Sequence 464 from patent US 11162114
GAACCCCGGCTTA
>MY671160.1 Sequence 463 from patent US 11162114
ACTTCCTCCAGCC
>MY669397.1 Sequence 18 from patent US 11162104
ATGTCGAGTACAC
>MY668398.1 Sequence 1015 from patent US 11162102
TATCTTTCTAGGG
>MY668397.1 Sequence 1014 from patent US 11162102
CCCTAGAAAGATA
>MY668117.1 Sequence 712 from patent US 11162102
GCTACTGCTAGGC
>MY668114.1 Sequence 709 from patent US 11162102
GTCAGCAGTGCCT
>MY668097.1 Sequence 692 from patent US 11162102
TGGTCCCCTCCCC
>MY668094.1 Sequence 689 from patent US 11162102
TGTTTAGTTATCT
>MY668091.1 Sequence 686 from patent US 11162102
CTGGGCTCAGACC
>MY667367.1 Sequence 82 from patent US 11162101
TGCTAGCTGAGGA
>MY667353.1 Sequence 68 from patent US 11162101
TAGCAGGTAAGCA
>MY667335.1 Sequence 50 from patent US 11162101
GAGCAGGTAAGCT
>MY661731.1 Sequence 27 from patent US 11160260
GAAACCCATTCCC
>MY661730.1 Sequence 26 from patent US 11160260
AGGGGACATTCCC
>MY661685.1 Sequence 60 from patent US 11160225
TGGGAGGCAATTC
>MY660645.1 Sequence 16 from patent US 11155871
GAGAGGAAGGAAA
>MY660398.1 Sequence 47 from patent US 11155857
GCGCCCGCCATGG
>MY659126.1 Sequence 35 from patent US 11155816
GCATTGGTATTCA
>MY659125.1 Sequence 34 from patent US 11155816
GCATTGGTATTCA
>MY659123.1 Sequence 32 from patent US 11155816
GCATTGGTATTCA
>MY659122.1 Sequence 31 from patent US 11155816
GCATTGGTATTCA
>MY659120.1 Sequence 29 from patent US 11155816
GCATTGGTATTCA
>MY659119.1 Sequence 28 from patent US 11155816
GCATTGGTATTCA
>MY659117.1 Sequence 26 from patent US 11155816
GCATTGGTATTCA
>MY659116.1 Sequence 25 from patent US 11155816
GCATTGGTATTCA
>MY659113.1 Sequence 20 from patent US 11155816
GCATTGGTATTCA
>MY659104.1 Sequence 8 from patent US 11155816
GTCTGTGGAAGCG
>MY659103.1 Sequence 7 from patent US 11155816
GTCTGTGGAAGCG
>MY659099.1 Sequence 3 from patent US 11155816
GCATTGGTATTCA
>MY659098.1 Sequence 2 from patent US 11155816
GCATTGGTATTCA
>MY659097.1 Sequence 1 from patent US 11155816
GCATTGGTATTCA
>MY658083.1 Sequence 383 from patent US 11155803
TTGACCAATAGCC
>MY657417.1 Sequence 17 from patent US 11155792
AGAGTATGGTTGT
>MY657414.1 Sequence 14 from patent US 11155792
AGAGTATGGTTGT
>MY656128.1 Sequence 92 from patent US 11155622
GCCGCCRCCATGG
>MY653939.1 Sequence 355 from patent US 11149320
TAACACCCTGATA
>MY653938.1 Sequence 354 from patent US 11149320
TAACATCCTGATA
>MY653832.1 Sequence 248 from patent US 11149320
TCAGGGTGTTAAC
>MY653831.1 Sequence 247 from patent US 11149320
TCAGGATGTTAAC
>MY651133.1 Sequence 75 from patent US 11149289
TCAAAACCACGTG
>MY651132.1 Sequence 74 from patent US 11149289
CACGTGGTTTTGA
>MY651131.1 Sequence 73 from patent US 11149289
AGTTTTGGTGCAC
>MY651130.1 Sequence 72 from patent US 11149289
GTGCACCAAAACT
>MY650908.1 Sequence 7413 from patent US 11149287
AAAGTGTCATGCC
>MY650907.1 Sequence 7412 from patent US 11149287
GGAGAAACAACTG
>MY615552.1 Sequence 62 from patent US 11149092
CAAACGGAAGTAT
>MY615547.1 Sequence 54 from patent US 11149092
TAGCCCGGTCCCT
>MY615545.1 Sequence 51 from patent US 11149092
TCCTCATTACTTG
>MY615024.1 Sequence 15 from patent US 11149053
AGATCGGAAGAGC
>MY613825.1 Sequence 41 from patent US 11147830
GTTTTTGTACTCT
>MY613820.1 Sequence 29 from patent US 11147830
AAAATCATTTGAG
>MY613819.1 Sequence 28 from patent US 11147830
AAATTCATTTGAG
>MY606649.1 Sequence 295 from patent US 11142760
TTGACCAATAGCC
>MY606190.1 Sequence 14 from patent US 11142580
GCCGCCRCCATGG
>MY605991.1 Sequence 3 from patent US 11142566
TCAAGAACTGCCT
>MY605935.1 Sequence 20 from patent US 11142555
TGAATGCATGATC
>MY605757.1 Sequence 50 from patent US 11142544
GAGTCACTATAGG
>MY602677.1 Sequence 1390 from patent US 11141476
GCCGCCACCATGG
>MY602676.1 Sequence 1389 from patent US 11141476
GCCGCCACCATGG
>MY601405.1 Sequence 39712 from patent US 11141474
GCCGCCACCATGG
>MY601404.1 Sequence 39711 from patent US 11141474
GCCGCCACCATGG
>MY564381.1 Sequence 28 from patent US 11136595
AAGCAGTTAAGAC
>MY560862.1 Sequence 364140 from patent US 11136386
CGGTGCCTCGTCC
>MY560857.1 Sequence 364135 from patent US 11136386
TCGGGCTCAGCTC
>MY560852.1 Sequence 364130 from patent US 11136386
CGGTGCTTCGTCC
>MY560850.1 Sequence 364128 from patent US 11136386
TAGTTAAGCCCAT
>MY560507.1 Sequence 3 from patent US 11136361
TATCTTGTCTTTA
>MY560363.1 Sequence 13 from patent US 11135312
GCCGCCACCATGG
>MY560103.1 Sequence 35 from patent US 11135273
TTTTAGAGCTATG
>MY557966.1 Sequence 265 from patent US 11130995
AGCACTGCAGGTA
>MY545757.1 Sequence 14 from patent US 11129829
CAGGTTTAAGTAT
>pdb|7TQB|B Chain B, Crystal structure of monoclonal S9.6 Fab bound to DNA-RNA hybrid
NGTGTCAGACAAG
>pdb|7TQB|A Chain A, Crystal structure of monoclonal S9.6 Fab bound to DNA-RNA hybrid
NTTGTCTGACACG
>pdb|7EDB|F Chain F, EcoT38I restriction endonuclease complexed with DNA
CCGTGAGCTCTGC
>pdb|7EDB|E Chain E, EcoT38I restriction endonuclease complexed with DNA
GGCAGAGCTCACG
>pdb|1VOP|A Chain A, CONSERVED RNA COMPONENT OF THE PEPTIDYL TRANSFERASE CENTER, NMR, 33 STRUCTURES
NACTGGGGCGGTC
>pdb|1ZQ3|B Chain B, NMR Solution Structure of the Bicoid Homeodomain Bound to the Consensus DNA Binding Site TAATCC
CGGGGATTAGAGC
>pdb|1ZQ3|A Chain A, NMR Solution Structure of the Bicoid Homeodomain Bound to the Consensus DNA Binding Site TAATCC
GCTCTAATCCCCG
>pdb|1VFC|C Chain C, Solution Structure Of The DNA Complex Of Human Trf2
CCCTAACCCTAAC
>pdb|1VFC|B Chain B, Solution Structure Of The DNA Complex Of Human Trf2
GTTAGGGTTAGGG
>pdb|1S88|B Chain B, NMR structure of a DNA duplex with two INA nucleotides inserted opposite each other, dCTCAACXCAAGCT:dAGCTTGXGTTGAG
AGCTTGNGTTGAG
>pdb|1S88|A Chain A, NMR structure of a DNA duplex with two INA nucleotides inserted opposite each other, dCTCAACXCAAGCT:dAGCTTGXGTTGAG
CTCAACNCAAGCT
>pdb|1I4C|A Chain A, THE SOLUTION STRUCTURE OF THE MINOR FAMILY OF THE MUTANT STEM LOOP C 5'UUA3' TRILOOP OF BROME MOSAIC VIRUS (+) STRAND RNA
GGTGCTTAGCACC
>pdb|1HT4|A Chain A, SOLUTION STRUCTURE OF A BISTRAND ABASIC SITE LESION STAGGERED IN A 3'-ORIENTATION.
CGCATGNGTACGC
>pdb|1AO9|A Chain A, INTRAMOLECULAR DNA DUPLEX CONTAINING A NON-NUCLEOTIDE LINKER (GAGAGA-X-TCTCCT), NMR, 12 STRUCTURES
GAGAGANTCTCTC
>pdb|1HT7|A Chain A, STRUCTURE OF A DNA DUPLEX CONTAINING A BISTRAND ABASIC SITE LESION STAGGERED IN A 5'-ORIENTATION.
CGCATGNGTACGC
>pdb|1ELH|B Chain B, NMR ANALYSIS OF HELIX I FROM THE 5S RNA OF ESCHERICHIA COLI
AACTGCCAGGCAT
>pdb|1A3M|B Chain B, PAROMOMYCIN BINDING INDUCES A LOCAL CONFORMATIONAL CHANGE IN THE A SITE OF 16S RRNA, NMR, 20 STRUCTURES
NGGTGAAGTCGCC
>pdb|1I4B|A Chain A, The solution structure of the major family of the mutant stem loop C 5'UUA3' triloop of brome mosaic virus (+) strand RNA
GGTGCTTAGCACC
>pdb|1JZC|A Chain A, THE SOLUTION STRUCTURE OF THE MUTANT 5'AUG3' TRILOOP IN THE RNA PROMOTER REGION OF THE BROME MOSAIC VIRUS GENOMIC (+)-RNA
GGTGCATGGCACC
>pdb|1HS8|A Chain A, SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UCAAUU AS PART OF HAIRPIN R(GCGUCAAUUCGCA)
GCGTCAATTCGCA
>pdb|1HS4|A Chain A, SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UUAAAU AS PART OF HAIRPIN R(GCGUUAAAUCGCA)
GCGTTAAATCGCA
>pdb|1HS3|A Chain A, SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UUAAUU AS PART OF HAIRPIN R(GCGUUAAUUCGCA)
GCGTTAATTCGCA
>pdb|1HS1|A Chain A, SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UUAACU AS PART OF HAIRPIN R(GCGUUAACUCGCA)
GCGTTAACTCGCA
>pdb|1P0U|A Chain A, Sheared G/C Base Pair
GCATCGACGATGC
>pdb|1N0O|C Chain C, NMR Structure of d(CCAAGGXCTTGGG), X is a 3'-phosphoglycolate, 5'-phosphate gapped lesion, 10 structures
CCCAAGGCCTTGG
>pdb|1N0K|C Chain C, NMR Structure of duplex DNA d(CCAAGGXCTTGGG), X is a 3' phosphoglycolate, 5'phosphate gapped lesion
CCCAAGGCCTTGG
>pdb|1GJ1|C Chain C, NMR structure of d(CCAAAGXACTGGG), X is a 3'phosphoglycolate, 5'phosphate gapped lesion
CCCAGTACTTTGG
>pdb|1G5K|C Chain C, NMR Structrure of d(CCAAAGXACTGGG), X is a 3'-phosphoglycolate, 5'-phosphate gapped lesion, 10 structures
CCCAGTACTTTGG
>pdb|1N17|B Chain B, Structure and Dynamics of Thioguanine-modified Duplex DNA
GGCTTTCCTTAGC
>pdb|1N17|A Chain A, Structure and Dynamics of Thioguanine-modified Duplex DNA
GCTAAGNAAAGCC
>pdb|1N14|B Chain B, Structure and Dynamics of Thioguanine-modified Duplex DNA in Comparison with Unmodified DNA; Structure of Unmodified Duplex DNA
GGCTTTCCTTAGC
>pdb|1N14|A Chain A, Structure and Dynamics of Thioguanine-modified Duplex DNA in Comparison with Unmodified DNA; Structure of Unmodified Duplex DNA
GCTAAGGAAAGCC
>pdb|1LEJ|B Chain B, NMR Structure of a 1:1 Complex of Polyamide (Im-Py-Beta-Im-Beta-Im-Py-Beta-Dp) with the Tridecamer DNA Duplex 5'-CCAAAGAGAAGCG-3'
CGCTTCTCTTTGG
>pdb|1LEJ|A Chain A, NMR Structure of a 1:1 Complex of Polyamide (Im-Py-Beta-Im-Beta-Im-Py-Beta-Dp) with the Tridecamer DNA Duplex 5'-CCAAAGAGAAGCG-3'
CCAAAGAGAAGCG
>pdb|1LAS|B Chain B, Solution Structure of the B-DNA Duplex CGCGGTXTCCGCG (X=PdG) Containing the 1,N2-propanodeoxyguanosine Adduct with the Deoxyribose at C20 Opposite PdG in the C3' Endo Conformation.
CGCGGANACCGCG
>pdb|1LAS|A Chain A, Solution Structure of the B-DNA Duplex CGCGGTXTCCGCG (X=PdG) Containing the 1,N2-propanodeoxyguanosine Adduct with the Deoxyribose at C20 Opposite PdG in the C3' Endo Conformation.
CGCGGTNTCCGCG
>pdb|1LAQ|B Chain B, Solution Structure of the B-DNA Duplex CGCGGTXTCCGCG (X=PdG) Containing the 1,N2-propanodeoxyguanosine Adduct with the Deoxyribose at C20 Opposite PdG in the C2' Endo Conformation.
CGCGGANACCGCG
>pdb|1LAQ|A Chain A, Solution Structure of the B-DNA Duplex CGCGGTXTCCGCG (X=PdG) Containing the 1,N2-propanodeoxyguanosine Adduct with the Deoxyribose at C20 Opposite PdG in the C2' Endo Conformation.
CGCGGTNTCCGCG
>pdb|1LAI|B Chain B, Solution Structure of the B-DNA Duplex CGCGGTGTCCGCG.
CGCGGACACCGCG
>pdb|1LAI|A Chain A, Solution Structure of the B-DNA Duplex CGCGGTGTCCGCG.
CGCGGTGTCCGCG
>pdb|1LAE|A Chain A, Solution Structure of the DNA 13-mer Hairpin CGCGGTXTCCGCG (X=PdG) Containing the 1,N2-propanodeoxyguanosine Adduct at the Seventh Position
CGCGGTNTCCGCG
>pdb|1LA8|A Chain A, Solution structure of the DNA hairpin 13-mer CGCGGTGTCCGCG
CGCGGTGTCCGCG
>pdb|1IV6|C Chain C, Solution Structure of the DNA Complex of Human TRF1
CCCTAACCCTAAC
>pdb|1IV6|B Chain B, Solution Structure of the DNA Complex of Human TRF1
GTTAGGGTTAGGG
>pdb|1K29|A Chain A, Solution Structure of a DNA Duplex Containing M1G Opposite a 2 Base Pair Deletion
ATCGCNCGGCATG
>pdb|1K8S|A Chain A, BULGED ADENOSINE IN AN RNA DUPLEX
GGCAGAGTGCCGC
>pdb|1GJ0|B Chain B, NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: BETA ANOMER
CCCAGTACTTTGG
>pdb|1GJ0|A Chain A, NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: BETA ANOMER
CCAAAGNACTGGG
>pdb|1GIZ|B Chain B, NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: ALPHA ANOMER
CCCAGTACTTTGG
>pdb|1GIZ|A Chain A, NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: ALPHA ANOMER
CCAAAGNACTGGG
>pdb|1G5E|B Chain B, NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: BETA ANOMER
CCCAGTACTTTGG
>pdb|1G5E|A Chain A, NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: BETA ANOMER
CCAAAGNACTGGG
>pdb|1G5D|B Chain B, NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: ALPHA ANOMER
CCCAGTACTTTGG
>pdb|1G5D|A Chain A, NMR STRUCTURE OF AN OLIGONUCLEOTIDE CONTAINING AN ABASIC SITE: ALPHA ANOMER
CCAAAGNACTGGG
>pdb|1HS2|A Chain A, SOLUTION STRUCTURE OF RNA HAIRPIN LOOP UUAAGU AS PART OF HAIRPIN R(GCGUUAAGUCGCA)
GCGTTAAGTCGCA
>pdb|1GJ2|C Chain C, CO(III)-BLEOMYCIN-OOH BOUND TO AN OLIGONUCLEOTIDE CONTAINING A PHOSPHOGLYCOLATE LESION
CCCAGTACTTTGG
>pdb|1G5L|C Chain C, CO(III)-BLEOMYCIN-OOH BOUND TO AN OLIGONUCLEOTIDE CONTAINING A PHOSPHOGLYCOLATE LESION
CCCAGTACTTTGG
>pdb|1HT7|B Chain B, STRUCTURE OF A DNA DUPLEX CONTAINING A BISTRAND ABASIC SITE LESION STAGGERED IN A 5'-ORIENTATION.
GCGTANACATGCG
>pdb|1HT4|B Chain B, SOLUTION STRUCTURE OF A BISTRAND ABASIC SITE LESION STAGGERED IN A 3'-ORIENTATION.
GCGTACANATGCG
>pdb|1FZS|B Chain B, DNA WITH PYRENE PAIRED AT ABASIC SITE
GTGCNTGTTTGTG
>pdb|1FZL|B Chain B, DNA WITH PYRENE PAIRED AT ABASIC SITES
GTGCNTGTTTGTG
>pdb|1FZL|A Chain A, DNA WITH PYRENE PAIRED AT ABASIC SITES
CACAAACANGCAC
>pdb|1ESH|A Chain A, THE SOLUTION STRUCTURE OF THE STEM LOOP C 5'AUA3' TRILOOP OF BROME MOSAIC VIRUS (+) STRAND RNA
GGTGCATAGCACC
>pdb|1C0Y|A Chain A, SOLUTION STRUCTURE OF THE [AF]-C8-DG ADDUCT POSITIONED OPPOSITE DA AT A TEMPLATE-PRIMER JUNCTION
AACGCTACCATCC
>pdb|1AXO|A Chain A, STRUCTURAL ALIGNMENT OF THE (+)-TRANS-ANTI-[BP]DG ADDUCT POSITIONED OPPOSITE DC AT A DNA TEMPLATE-PRIMER JUNCTION, NMR, 6 STRUCTURES
AACGCTACCATCC
>pdb|1AX7|A Chain A, SOLUTION STRUCTURE OF THE [AF]-C8-DG ADDUCT POSITIONED AT A TEMPLATE-PRIMER JUNCTION, NMR, 6 STRUCTURES
AACGCTACCATCC
>pdb|1AG3|A Chain A, DUPLEX OLIGODEOXYNUCLEOTIDE CONTAINING PROPANODEOXYGUANOSINE OPPOSITE A TWO-BASE DELETION, NMR, MINIMIZED AVERAGE STRUCTURE
ATCGCNCGGCATG
>pdb|142D|B Chain B, SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
CTCAAGGCAAGCT
>pdb|142D|A Chain A, SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
AGCTTGCCTTGAG
>pdb|141D|B Chain B, SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
CTCAAGGCAAGCT
>pdb|141D|A Chain A, SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
AGCTTGCCTTGAG
>pdb|140D|B Chain B, SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
CTCAAGGCAAGCT
>pdb|140D|A Chain A, SOLUTION STRUCTURE OF A CONSERVED DNA SEQUENCE FROM THE HIV-1 GENOME: RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE RESTRAINTS DERIVED FROM TWO-DIMENSIONAL NMR SPECTRA
AGCTTGCCTTGAG
>PA367632.1 JP 2021528041-A/10: METHODS AND COMPOSITIONS FOR TREATING SKIN DISEASE WITH RECOMBINANT MICROORGANISMS
CAGGTAGGAAATA
>PA352106.1 JP 2021170975-A/50: Oligonucleotide primer for detecting adeno-associated virus vector, and method for detecting the vector using the primer
TTGGGATTCCAGG
>PA352087.1 JP 2021170975-A/31: Oligonucleotide primer for detecting adeno-associated virus vector, and method for detecting the vector using the primer
CTCCATCACTAGG
>pdb|7VBA|U Chain U, Structure of the pre state human RNA Polymerase I Elongation Complex
ACTGTCCTCTGGC
>PA339943.1 JP 2021165233-A/8: Pharmaceutical composition targeting RUNX-binding sequence and RUNX inhibitor
ATATGTGGTAATT
>pdb|7O0H|F Chain F, Structure of the foamy viral protease-reverse transcriptase dRH in complex with ds DNA.
GTGTCGCACTCTG
>PA278539.1 JP 2021519595-A/42: Novel RSV RNA molecules and compositions for vaccination
GCCGCCACCATGG
>PA278538.1 JP 2021519595-A/41: Novel RSV RNA molecules and compositions for vaccination
GCCGCCACCATGG
>PA278385.1 JP 2021518747-A/2: Gold Optimized CAR T-cells
ATTTATTTATTTA
>PA276331.1 WO 2021172370-A/60: Method for detecting single-stranded RNA virus
CAGCAGCAATGCA
>PA276323.1 WO 2021172370-A/52: Method for detecting single-stranded RNA virus
CTCCTTTATTTCC
>PA276322.1 WO 2021172370-A/51: Method for detecting single-stranded RNA virus
TGTCTGTCCATTT
>PA276308.1 WO 2021172370-A/37: Method for detecting single-stranded RNA virus
GATTGGTACCAAG
>PA276293.1 WO 2021172370-A/22: Method for detecting single-stranded RNA virus
ACTCGGAAGCTTG
>PA276292.1 WO 2021172370-A/21: Method for detecting single-stranded RNA virus
GACTCGGAAGCTT
>PA276291.1 WO 2021172370-A/20: Method for detecting single-stranded RNA virus
AGGTTCCCCATCT
>PA276290.1 WO 2021172370-A/19: Method for detecting single-stranded RNA virus
GAAGGTTCCCCAT
>PA276289.1 WO 2021172370-A/18: Method for detecting single-stranded RNA virus
TTGAAGGTTCCCC
>PA276288.1 WO 2021172370-A/17: Method for detecting single-stranded RNA virus
AAGGTTCCCCATC
>PA276287.1 WO 2021172370-A/16: Method for detecting single-stranded RNA virus
CTTGAAGGTTCCC
>PA276286.1 WO 2021172370-A/15: Method for detecting single-stranded RNA virus
TTCTTGAAGGTTC
>PA276285.1 WO 2021172370-A/14: Method for detecting single-stranded RNA virus
TTGAAGGTTCCCC
>PA276284.1 WO 2021172370-A/13: Method for detecting single-stranded RNA virus
TCTTGAAGGTTCC
>PA276283.1 WO 2021172370-A/12: Method for detecting single-stranded RNA virus
GACTTCTTGAAGG
>PA276282.1 WO 2021172370-A/11: Method for detecting single-stranded RNA virus
AGCCAAGACTCCT
>PA276281.1 WO 2021172370-A/10: Method for detecting single-stranded RNA virus
CTAGCCAAGACTC
>PA276280.1 WO 2021172370-A/9: Method for detecting single-stranded RNA virus
ATCTAGCCAAGAC
>pdb|5BKL|qq Chain qq, Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
NTTTTTTTTTTTT
>pdb|5BKL|ll Chain ll, Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
NTTTTTTTTTTTT
>pdb|5BKL|kk Chain kk, Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
NTTTTTTTTTTTT
>pdb|5BKL|WW Chain WW, Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
NTTTTTTTTTTTT
>pdb|5BKL|n Chain n, Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
NTTTTTTTTTTTT
>pdb|5BKL|i Chain i, Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
NTTTTTTTTTTTT
>pdb|5BKL|h Chain h, Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
NTTTTTTTTTTTT
>pdb|5BKL|e Chain e, Crystallographic structure of the cubic crystal form of STMV (77.9 degree rotation) grown from NaCl
NTTTTTTTTTTTT
>OF147549.1 KR 1020210005057-A/2078: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
AGATGGCATTTCT
>OF147540.1 KR 1020210005057-A/2069: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
AGATGGCATTTCT
>OF268210.1 KR 1020210045451-A/7: METHODS AND COMPOSITIONS FOR NUCLEIC ACID ISOLATION
GAAACACCGCCCG
>OF188012.1 KR 1020210005661-A/27: PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED AMINOPEPTIDASE N (ANPEP) GENES
GAAACCCATTCCC
>OF188011.1 KR 1020210005661-A/26: PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED AMINOPEPTIDASE N (ANPEP) GENES
AGGGGACATTCCC
>OF187898.1 KR 1020210011926-A/7: COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
CACCCCGTCCTCG
>OF187897.1 KR 1020210011926-A/6: COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
CACCCCATCCTCG
>OF187832.1 KR 1020210005090-A/22: CHIMERIC VECTORS
TAGTTAATGAAAA
>OF187826.1 KR 1020210005090-A/16: CHIMERIC VECTORS
TAGTTAAATAAAA
>OF187823.1 KR 1020210005090-A/13: CHIMERIC VECTORS
TAGTTAATTAAAA
>OF187820.1 KR 1020210005090-A/10: CHIMERIC VECTORS
TATTTAATTAAAA
>OF187814.1 KR 1020210005090-A/4: CHIMERIC VECTORS
TAGTTAATTAAAA
>OF144913.1 KR 1020210027244-A/2: MODIFIED NUCLEIC ACID EDITING SYSTEMS FOR TETHERING DONOR DNA
WATCAANNNNTTR
>OF265854.1 KR 1020210042128-A/32: NUCLEIC ACID MOLECULES AND USES THEREOF FOR NON-VIRAL GENE THERAPY
GCCGCCACCATGC
>OF263732.1 KR 1020210039421-A/409: COMPOSITIONS AND METHODS BASED ON PMT ENGINEERING FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING ALTERED ALKALOID LEVELS
GGAGCAATTCAAC
>OF263730.1 KR 1020210039421-A/407: COMPOSITIONS AND METHODS BASED ON PMT ENGINEERING FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING ALTERED ALKALOID LEVELS
AACACACAGAGAA
>OF263725.1 KR 1020210039421-A/402: COMPOSITIONS AND METHODS BASED ON PMT ENGINEERING FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING ALTERED ALKALOID LEVELS
TTTCCATACACTG
>OF263724.1 KR 1020210039421-A/401: COMPOSITIONS AND METHODS BASED ON PMT ENGINEERING FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING ALTERED ALKALOID LEVELS
CACAGAGAATGGT
>OF141277.1 KR 1020210053240-A/13: METHOD AND TEST KIT FOR DETECTING PATHOGENIC MICROORGANISM USING NANOPORES
AGCAAAAGCAGGC
>OF141274.1 KR 1020210053240-A/10: METHOD AND TEST KIT FOR DETECTING PATHOGENIC MICROORGANISM USING NANOPORES
GCCTGCTTTTGCT
>OF141008.1 KR 1020210053228-A/54: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTTCTTTTCTTT
>OF141003.1 KR 1020210053228-A/49: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTCTTTCTTTTT
>OF140997.1 KR 1020210053228-A/43: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTTCTTTTTTTT
>OF140990.1 KR 1020210053228-A/36: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTTGTTTTGTTT
>OF140985.1 KR 1020210053228-A/31: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTGTTTGTTTTT
>OF140979.1 KR 1020210053228-A/25: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTTGTTTTTTTT
>OF140972.1 KR 1020210053228-A/18: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTTATTTTATTT
>OF140967.1 KR 1020210053228-A/13: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTATTTATTTTT
>OF140961.1 KR 1020210053228-A/7: An engineered guide RNA for the optimized CRISPR/Cas12f1 system and use thereof
TTTTATTTTTTTT
>OF136939.1 KR 1020210066359-A/21: Composition for detecting antibiotic resistant pathogen of sepsis and uses thereof
ACAGCCAACGGGC
>OF136912.1 KR 1020210066358-A/21: Composition for detecting pathogen of sepsis and uses thereof
ACAGCCAACGGGC
>OF136672.1 KR 1020210063137-A/57: A double-stranded oligonucleotide comprising CTGF specific sequence and a composition for treating and preventing fibrosis related diseases and respiratory related diseases
GCACCTTTCTAGA
>OF296322.1 KR 1020210072831-A/419: RNA-GUIDED GENE EDITING AND GENE REGULATION
CTGGTGACACAAC
>OF135322.1 KR 1020210045755-A/78: SNP marker for discriminating cultivars of sweet potatoes and method for discriminating cultivars using the marker
AAGCAGCCCCCGG
>OF135313.1 KR 1020210045755-A/69: SNP marker for discriminating cultivars of sweet potatoes and method for discriminating cultivars using the marker
TCGTGTCAAGTCT
>OF135309.1 KR 1020210045755-A/65: SNP marker for discriminating cultivars of sweet potatoes and method for discriminating cultivars using the marker
CCAGTTCGTCGCC
>OF135296.1 KR 1020210045755-A/52: SNP marker for discriminating cultivars of sweet potatoes and method for discriminating cultivars using the marker
AGGCGTTTTCGCA
>OF255293.1 KR 1020210038895-A/1: METHODS OF IDENTIFYING PATIENTS LIKELY TO BENEFIT FROM TREATMENT WITH A TELOMERASE INHIBITOR
TAGGGTTAGACAA
>OF255030.1 KR 1020210021111-A/81: TREATMENT OF AMD USING AAV SFLT-1
GGCCCGGGATCCA
>OF254896.1 KR 1020210042107-A/7: USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS
CACCCCGTCCTCG
>OF254895.1 KR 1020210042107-A/6: USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS
CACCCCATCCTCG
>OF254828.1 KR 1020210020174-A/134: METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITION
ATCCTCTTRRRRG
>OF254145.1 KR 1020210030965-A/14: GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
NNNNNNRNNATGG
>OF254138.1 KR 1020210030965-A/6: GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
GCCGCCACCATGG
>OF291726.1 KR 1020210063450-A/62: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
TTCCAGCTCACAC
>OF291725.1 KR 1020210063450-A/61: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
CACACTCAGAGGG
>OF291724.1 KR 1020210063450-A/60: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
TGAAGCTCTGGAC
>OF291699.1 KR 1020210063450-A/35: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
CAGAGAGCGTGAG
>OF291698.1 KR 1020210063450-A/34: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
GGTGTACAGGTCC
>OF291697.1 KR 1020210063450-A/33: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
TGCTCTGTGACAC
>OF291696.1 KR 1020210063450-A/32: MICROFLUIDIC DEVICES AND METHODS FOR USE THEREOF IN MULTICELLULAR ASSAYS OF SECRETION
GTCCTGAGGACTG
>OF291573.1 KR 1020210080470-A/20: SOLANACEOUS PLANT RESISTANT TO VIRUS OF GENUS BEGOMOVIRUS CAUSING TOMATO YELLOW LEAF CURL SYMPTOMS, SOLANACEOUS PLANT CELL, AND METHOD FOR PRODUCING SOLANACEOUS PLANT
TCTACCTTGCAGT
>OF251781.1 KR 1020210014780-A/4313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF251779.1 KR 1020210014780-A/4311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF251777.1 KR 1020210014780-A/4309: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF251261.1 KR 1020210014780-A/3793: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251259.1 KR 1020210014780-A/3791: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251257.1 KR 1020210014780-A/3789: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251255.1 KR 1020210014780-A/3787: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251253.1 KR 1020210014780-A/3785: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251251.1 KR 1020210014780-A/3783: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>OF251249.1 KR 1020210014780-A/3781: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251247.1 KR 1020210014780-A/3779: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251245.1 KR 1020210014780-A/3777: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251243.1 KR 1020210014780-A/3775: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251241.1 KR 1020210014780-A/3773: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251239.1 KR 1020210014780-A/3771: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251237.1 KR 1020210014780-A/3769: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251235.1 KR 1020210014780-A/3767: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251233.1 KR 1020210014780-A/3765: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGATTCAAGTCA
>OF251231.1 KR 1020210014780-A/3763: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAAAACCAA
>OF251229.1 KR 1020210014780-A/3761: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAGCAAAGAA
>OF251227.1 KR 1020210014780-A/3759: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGCAACA
>OF251225.1 KR 1020210014780-A/3757: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>OF251223.1 KR 1020210014780-A/3755: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATCTATGACAA
>OF251221.1 KR 1020210014780-A/3753: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCAAAGATAA
>OF251219.1 KR 1020210014780-A/3751: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCTACCAGAAA
>OF251217.1 KR 1020210014780-A/3749: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCTACCAGAA
>OF251215.1 KR 1020210014780-A/3747: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAAGATAATGA
>OF251213.1 KR 1020210014780-A/3745: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAACTCTACCAGA
>OF251211.1 KR 1020210014780-A/3743: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATATAGCAAA
>OF251209.1 KR 1020210014780-A/3741: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF251207.1 KR 1020210014780-A/3739: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATCTATGACAAA
>OF251205.1 KR 1020210014780-A/3737: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGCAGAGTACA
>OF251203.1 KR 1020210014780-A/3735: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTCAAGCAGA
>OF251201.1 KR 1020210014780-A/3733: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATGACAAGTTCA
>OF251199.1 KR 1020210014780-A/3731: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAACGAAATCTAA
>OF251197.1 KR 1020210014780-A/3729: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>OF251195.1 KR 1020210014780-A/3727: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAAAGATGGAGA
>OF251193.1 KR 1020210014780-A/3725: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>OF251191.1 KR 1020210014780-A/3723: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATATGTTCTTA
>OF251189.1 KR 1020210014780-A/3721: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>OF251187.1 KR 1020210014780-A/3719: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCAACACATCAA
>OF251185.1 KR 1020210014780-A/3717: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCAGAGTACAA
>OF251183.1 KR 1020210014780-A/3715: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTACACACAA
>OF251181.1 KR 1020210014780-A/3713: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>OF251179.1 KR 1020210014780-A/3711: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>OF251177.1 KR 1020210014780-A/3709: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>OF251175.1 KR 1020210014780-A/3707: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACACACAGCATAA
>OF251173.1 KR 1020210014780-A/3705: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>OF251171.1 KR 1020210014780-A/3703: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTCAAGCAA
>OF251167.1 KR 1020210014780-A/3699: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>OF251165.1 KR 1020210014780-A/3697: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>OF251161.1 KR 1020210014780-A/3693: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>OF251159.1 KR 1020210014780-A/3691: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>OF251157.1 KR 1020210014780-A/3689: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>OF251155.1 KR 1020210014780-A/3687: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>OF251151.1 KR 1020210014780-A/3683: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>OF251149.1 KR 1020210014780-A/3681: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>OF251145.1 KR 1020210014780-A/3677: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>OF251141.1 KR 1020210014780-A/3673: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>OF251139.1 KR 1020210014780-A/3671: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>OF251137.1 KR 1020210014780-A/3669: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>OF251135.1 KR 1020210014780-A/3667: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>OF251133.1 KR 1020210014780-A/3665: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>OF251131.1 KR 1020210014780-A/3663: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>OF251129.1 KR 1020210014780-A/3661: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>OF251127.1 KR 1020210014780-A/3659: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>OF251125.1 KR 1020210014780-A/3657: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>OF251123.1 KR 1020210014780-A/3655: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>OF251121.1 KR 1020210014780-A/3653: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>OF251119.1 KR 1020210014780-A/3651: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>OF251117.1 KR 1020210014780-A/3649: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>OF251115.1 KR 1020210014780-A/3647: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>OF251113.1 KR 1020210014780-A/3645: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>OF251111.1 KR 1020210014780-A/3643: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>OF251109.1 KR 1020210014780-A/3641: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>OF251107.1 KR 1020210014780-A/3639: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251105.1 KR 1020210014780-A/3637: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251103.1 KR 1020210014780-A/3635: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251101.1 KR 1020210014780-A/3633: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251099.1 KR 1020210014780-A/3631: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251097.1 KR 1020210014780-A/3629: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251095.1 KR 1020210014780-A/3627: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251093.1 KR 1020210014780-A/3625: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251091.1 KR 1020210014780-A/3623: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251089.1 KR 1020210014780-A/3621: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251087.1 KR 1020210014780-A/3619: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251085.1 KR 1020210014780-A/3617: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251083.1 KR 1020210014780-A/3615: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251081.1 KR 1020210014780-A/3613: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251071.1 KR 1020210014780-A/3603: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>OF251069.1 KR 1020210014780-A/3601: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>OF251067.1 KR 1020210014780-A/3599: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>OF251065.1 KR 1020210014780-A/3597: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>OF251063.1 KR 1020210014780-A/3595: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>OF251061.1 KR 1020210014780-A/3593: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF251059.1 KR 1020210014780-A/3591: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>OF251057.1 KR 1020210014780-A/3589: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>OF251055.1 KR 1020210014780-A/3587: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>OF251053.1 KR 1020210014780-A/3585: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>OF251051.1 KR 1020210014780-A/3583: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>OF251049.1 KR 1020210014780-A/3581: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>OF251047.1 KR 1020210014780-A/3579: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>OF251045.1 KR 1020210014780-A/3577: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>OF251043.1 KR 1020210014780-A/3575: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>OF251041.1 KR 1020210014780-A/3573: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>OF251037.1 KR 1020210014780-A/3569: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>OF251033.1 KR 1020210014780-A/3565: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>OF251029.1 KR 1020210014780-A/3561: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>OF251025.1 KR 1020210014780-A/3557: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>OF251021.1 KR 1020210014780-A/3553: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>OF251017.1 KR 1020210014780-A/3549: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>OF251013.1 KR 1020210014780-A/3545: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>OF251009.1 KR 1020210014780-A/3541: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>OF251005.1 KR 1020210014780-A/3537: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>OF251003.1 KR 1020210014780-A/3535: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>OF251001.1 KR 1020210014780-A/3533: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>OF250999.1 KR 1020210014780-A/3531: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>OF250997.1 KR 1020210014780-A/3529: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>OF250995.1 KR 1020210014780-A/3527: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>OF250993.1 KR 1020210014780-A/3525: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>OF250991.1 KR 1020210014780-A/3523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>OF250989.1 KR 1020210014780-A/3521: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>OF250987.1 KR 1020210014780-A/3519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>OF250985.1 KR 1020210014780-A/3517: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>OF250983.1 KR 1020210014780-A/3515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>OF250981.1 KR 1020210014780-A/3513: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>OF250979.1 KR 1020210014780-A/3511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>OF250977.1 KR 1020210014780-A/3509: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>OF250975.1 KR 1020210014780-A/3507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250973.1 KR 1020210014780-A/3505: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250971.1 KR 1020210014780-A/3503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250969.1 KR 1020210014780-A/3501: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250967.1 KR 1020210014780-A/3499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250965.1 KR 1020210014780-A/3497: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250963.1 KR 1020210014780-A/3495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250961.1 KR 1020210014780-A/3493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250959.1 KR 1020210014780-A/3491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250957.1 KR 1020210014780-A/3489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250955.1 KR 1020210014780-A/3487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250953.1 KR 1020210014780-A/3485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250951.1 KR 1020210014780-A/3483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250949.1 KR 1020210014780-A/3481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250947.1 KR 1020210014780-A/3479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250945.1 KR 1020210014780-A/3477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250943.1 KR 1020210014780-A/3475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250941.1 KR 1020210014780-A/3473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250939.1 KR 1020210014780-A/3471: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250937.1 KR 1020210014780-A/3469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250911.1 KR 1020210014780-A/3443: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250909.1 KR 1020210014780-A/3441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250907.1 KR 1020210014780-A/3439: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250905.1 KR 1020210014780-A/3437: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250903.1 KR 1020210014780-A/3435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250901.1 KR 1020210014780-A/3433: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250899.1 KR 1020210014780-A/3431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250897.1 KR 1020210014780-A/3429: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250895.1 KR 1020210014780-A/3427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250893.1 KR 1020210014780-A/3425: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250891.1 KR 1020210014780-A/3423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250889.1 KR 1020210014780-A/3421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250887.1 KR 1020210014780-A/3419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250885.1 KR 1020210014780-A/3417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250883.1 KR 1020210014780-A/3415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250881.1 KR 1020210014780-A/3413: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250879.1 KR 1020210014780-A/3411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250877.1 KR 1020210014780-A/3409: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250875.1 KR 1020210014780-A/3407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250873.1 KR 1020210014780-A/3405: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250871.1 KR 1020210014780-A/3403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250869.1 KR 1020210014780-A/3401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250837.1 KR 1020210014780-A/3369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250835.1 KR 1020210014780-A/3367: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250833.1 KR 1020210014780-A/3365: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250831.1 KR 1020210014780-A/3363: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250829.1 KR 1020210014780-A/3361: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250827.1 KR 1020210014780-A/3359: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250825.1 KR 1020210014780-A/3357: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250823.1 KR 1020210014780-A/3355: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250821.1 KR 1020210014780-A/3353: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250819.1 KR 1020210014780-A/3351: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250817.1 KR 1020210014780-A/3349: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250815.1 KR 1020210014780-A/3347: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250813.1 KR 1020210014780-A/3345: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250811.1 KR 1020210014780-A/3343: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250809.1 KR 1020210014780-A/3341: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF250807.1 KR 1020210014780-A/3339: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF250805.1 KR 1020210014780-A/3337: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>OF250803.1 KR 1020210014780-A/3335: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF250799.1 KR 1020210014780-A/3331: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>OF250797.1 KR 1020210014780-A/3329: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>OF250793.1 KR 1020210014780-A/3325: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>OF250791.1 KR 1020210014780-A/3323: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>OF250789.1 KR 1020210014780-A/3321: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>OF250785.1 KR 1020210014780-A/3317: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>OF250781.1 KR 1020210014780-A/3313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>OF250779.1 KR 1020210014780-A/3311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>OF250775.1 KR 1020210014780-A/3307: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>OF250771.1 KR 1020210014780-A/3303: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>OF250769.1 KR 1020210014780-A/3301: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>OF250767.1 KR 1020210014780-A/3299: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>OF250765.1 KR 1020210014780-A/3297: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>OF250763.1 KR 1020210014780-A/3295: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>OF250761.1 KR 1020210014780-A/3293: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>OF250759.1 KR 1020210014780-A/3291: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>OF250755.1 KR 1020210014780-A/3287: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>OF250751.1 KR 1020210014780-A/3283: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>OF250747.1 KR 1020210014780-A/3279: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>OF250745.1 KR 1020210014780-A/3277: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGCTGACCTGG
>OF250743.1 KR 1020210014780-A/3275: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATCAAGTTTGAG
>OF250741.1 KR 1020210014780-A/3273: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGCAAGATCGGC
>OF250739.1 KR 1020210014780-A/3271: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACACGTTTGGC
>OF250737.1 KR 1020210014780-A/3269: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTAAATTCTGTGG
>OF250735.1 KR 1020210014780-A/3267: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAAATTCTGTG
>OF250733.1 KR 1020210014780-A/3265: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGACTTCGGC
>OF250731.1 KR 1020210014780-A/3263: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTGCGAAGCTG
>OF250729.1 KR 1020210014780-A/3261: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCGAAGCTGACC
>OF250727.1 KR 1020210014780-A/3259: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACGGAGACATGG
>OF250725.1 KR 1020210014780-A/3257: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGTTCCAAGAC
>OF250723.1 KR 1020210014780-A/3255: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACCAGTGCACG
>OF250721.1 KR 1020210014780-A/3253: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACAACGCC
>OF250719.1 KR 1020210014780-A/3251: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCGAAGCTGAC
>OF250717.1 KR 1020210014780-A/3249: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAAGCTGACCTG
>OF250715.1 KR 1020210014780-A/3247: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCCAAGACCT
>OF250713.1 KR 1020210014780-A/3245: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTATCAAGTTTG
>OF250711.1 KR 1020210014780-A/3243: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACTGGAAGAC
>OF250709.1 KR 1020210014780-A/3241: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCGAAGCTGA
>OF250707.1 KR 1020210014780-A/3239: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCCTTGCGAAGC
>OF250705.1 KR 1020210014780-A/3237: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGGTCATGAAG
>OF250703.1 KR 1020210014780-A/3235: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGACACGTTTGG
>OF250701.1 KR 1020210014780-A/3233: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTAAATTCTG
>OF250699.1 KR 1020210014780-A/3231: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCAGGCCTTGC
>OF250697.1 KR 1020210014780-A/3229: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAGAGAAGCAG
>OF250695.1 KR 1020210014780-A/3227: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGTATGTACC
>OF250693.1 KR 1020210014780-A/3225: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGAACTGCAG
>OF250691.1 KR 1020210014780-A/3223: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGTTTGAGCT
>OF250689.1 KR 1020210014780-A/3221: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTCAGGCCTTG
>OF250687.1 KR 1020210014780-A/3219: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACTTCGGCTCC
>OF250685.1 KR 1020210014780-A/3217: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACTTCGGCTC
>OF250683.1 KR 1020210014780-A/3215: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGATGTACGG
>OF250681.1 KR 1020210014780-A/3213: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAAGCTGACCT
>OF250679.1 KR 1020210014780-A/3211: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAGGCCTTGCGA
>OF250677.1 KR 1020210014780-A/3209: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGGAGACATGGC
>OF250675.1 KR 1020210014780-A/3207: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACGTTTGGCC
>OF250673.1 KR 1020210014780-A/3205: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCGAGGTCATGA
>OF250671.1 KR 1020210014780-A/3203: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGACAACGCCT
>OF250669.1 KR 1020210014780-A/3201: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGATGTACGGAG
>OF250667.1 KR 1020210014780-A/3199: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAAGACACGTT
>OF250665.1 KR 1020210014780-A/3197: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAAATTCTGTGGA
>OF250663.1 KR 1020210014780-A/3195: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCATGAAGA
>OF250661.1 KR 1020210014780-A/3193: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAACGCCTC
>OF250659.1 KR 1020210014780-A/3191: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGAGACATGGCA
>OF250657.1 KR 1020210014780-A/3189: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGTGGAGTATG
>OF250655.1 KR 1020210014780-A/3187: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGCTAAATTCT
>OF250653.1 KR 1020210014780-A/3185: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGGCCTTGCGAA
>OF250651.1 KR 1020210014780-A/3183: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGCAAGATCGG
>OF250649.1 KR 1020210014780-A/3181: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCGACTGGAAG
>OF250647.1 KR 1020210014780-A/3179: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGCCTTGCGAAG
>OF250645.1 KR 1020210014780-A/3177: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGACACGTTTG
>OF250643.1 KR 1020210014780-A/3175: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGTCAGGCCTT
>OF250641.1 KR 1020210014780-A/3173: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCATGAAGAAG
>OF250639.1 KR 1020210014780-A/3171: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCTGACCTGGA
>OF250637.1 KR 1020210014780-A/3169: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGAAGTGTAA
>OF250635.1 KR 1020210014780-A/3167: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGTTCCTTAA
>OF250633.1 KR 1020210014780-A/3165: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAAAGGTTA
>OF250631.1 KR 1020210014780-A/3163: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATACCGAGCTA
>OF250629.1 KR 1020210014780-A/3161: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTTGAGAGTGT
>OF250627.1 KR 1020210014780-A/3159: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATACCGAGCTAAA
>OF250625.1 KR 1020210014780-A/3157: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCCTTTATTA
>OF250623.1 KR 1020210014780-A/3155: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGGACAGCTT
>OF250621.1 KR 1020210014780-A/3153: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATACGAGTAATA
>OF250619.1 KR 1020210014780-A/3151: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATCTAAGTTAA
>OF250617.1 KR 1020210014780-A/3149: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGCTCAGATA
>OF250615.1 KR 1020210014780-A/3147: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTGATCAGTTT
>OF250613.1 KR 1020210014780-A/3145: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGTAGAATGTAA
>OF250611.1 KR 1020210014780-A/3143: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTAAATTCTGT
>OF250609.1 KR 1020210014780-A/3141: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATCAAGTTTGA
>OF250607.1 KR 1020210014780-A/3139: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGACACGTTT
>OF250605.1 KR 1020210014780-A/3137: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTACCAGTGCAC
>OF250603.1 KR 1020210014780-A/3135: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACATCTTT
>OF250601.1 KR 1020210014780-A/3133: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCAGTAGCACA
>OF250599.1 KR 1020210014780-A/3131: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTCTGTGGAG
>OF250597.1 KR 1020210014780-A/3129: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGTATGT
>OF250595.1 KR 1020210014780-A/3127: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTTGAGCTT
>OF250593.1 KR 1020210014780-A/3125: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCCTATCAAGTT
>OF250591.1 KR 1020210014780-A/3123: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACGGAGACAT
>OF250589.1 KR 1020210014780-A/3121: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCTGTGGAGT
>OF250587.1 KR 1020210014780-A/3119: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTATCAAGTTT
>OF250585.1 KR 1020210014780-A/3117: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCGAGGAGTG
>OF250583.1 KR 1020210014780-A/3115: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTTGCGAAGCT
>OF250581.1 KR 1020210014780-A/3113: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTACGGAGACA
>OF250579.1 KR 1020210014780-A/3111: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGACTGGAAGA
>OF250577.1 KR 1020210014780-A/3109: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTGGAGCGCC
>OF250575.1 KR 1020210014780-A/3107: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTACAACTGTC
>OF250573.1 KR 1020210014780-A/3105: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTACAACTGTCC
>OF250571.1 KR 1020210014780-A/3103: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGCCATTACAAC
>OF250569.1 KR 1020210014780-A/3101: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCATTACAACTGT
>OF250567.1 KR 1020210014780-A/3099: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGGTCCAGACC
>OF250565.1 KR 1020210014780-A/3097: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTGGAGCGC
>OF250563.1 KR 1020210014780-A/3095: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACCTGTGCCTG
>OF250561.1 KR 1020210014780-A/3093: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTGCCTGGTCC
>OF250559.1 KR 1020210014780-A/3091: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTGGAAGACACG
>OF250557.1 KR 1020210014780-A/3089: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCCATTACAACT
>OF250555.1 KR 1020210014780-A/3087: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTGAGCTTTCT
>OF250553.1 KR 1020210014780-A/3085: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGCGCCTGTT
>OF250551.1 KR 1020210014780-A/3083: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGAGCGCCTG
>OF250549.1 KR 1020210014780-A/3081: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTTTCTGGCT
>OF250547.1 KR 1020210014780-A/3079: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATTACAACTG
>OF250545.1 KR 1020210014780-A/3077: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAGCGCCTGTTC
>OF250543.1 KR 1020210014780-A/3075: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACTGGAAGACA
>OF250541.1 KR 1020210014780-A/3073: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGGAGCGCCT
>OF250539.1 KR 1020210014780-A/3071: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGGAAGATGTA
>OF250537.1 KR 1020210014780-A/3069: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250535.1 KR 1020210014780-A/3067: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250533.1 KR 1020210014780-A/3065: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250531.1 KR 1020210014780-A/3063: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250499.1 KR 1020210014780-A/3031: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250497.1 KR 1020210014780-A/3029: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250495.1 KR 1020210014780-A/3027: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250493.1 KR 1020210014780-A/3025: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250491.1 KR 1020210014780-A/3023: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250487.1 KR 1020210014780-A/3019: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>OF250483.1 KR 1020210014780-A/3015: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>OF250479.1 KR 1020210014780-A/3011: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>OF250475.1 KR 1020210014780-A/3007: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>OF250473.1 KR 1020210014780-A/3005: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>OF250471.1 KR 1020210014780-A/3003: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>OF250469.1 KR 1020210014780-A/3001: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>OF250467.1 KR 1020210014780-A/2999: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>OF250465.1 KR 1020210014780-A/2997: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>OF250463.1 KR 1020210014780-A/2995: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>OF250459.1 KR 1020210014780-A/2991: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>OF250457.1 KR 1020210014780-A/2989: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>OF250455.1 KR 1020210014780-A/2987: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>OF250453.1 KR 1020210014780-A/2985: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>OF250451.1 KR 1020210014780-A/2983: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>OF250447.1 KR 1020210014780-A/2979: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>OF250445.1 KR 1020210014780-A/2977: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>OF250441.1 KR 1020210014780-A/2973: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>OF250439.1 KR 1020210014780-A/2971: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>OF250437.1 KR 1020210014780-A/2969: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>OF250435.1 KR 1020210014780-A/2967: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>OF250431.1 KR 1020210014780-A/2963: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF250429.1 KR 1020210014780-A/2961: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>OF250425.1 KR 1020210014780-A/2957: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>OF250423.1 KR 1020210014780-A/2955: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>OF250421.1 KR 1020210014780-A/2953: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>OF250419.1 KR 1020210014780-A/2951: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>OF250417.1 KR 1020210014780-A/2949: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>OF250415.1 KR 1020210014780-A/2947: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>OF250413.1 KR 1020210014780-A/2945: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>OF250403.1 KR 1020210014780-A/2935: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>OF250401.1 KR 1020210014780-A/2933: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>OF250399.1 KR 1020210014780-A/2931: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>OF250397.1 KR 1020210014780-A/2929: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>OF250395.1 KR 1020210014780-A/2927: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>OF250393.1 KR 1020210014780-A/2925: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>OF250391.1 KR 1020210014780-A/2923: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>OF250389.1 KR 1020210014780-A/2921: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>OF250387.1 KR 1020210014780-A/2919: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>OF250385.1 KR 1020210014780-A/2917: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>OF250383.1 KR 1020210014780-A/2915: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>OF250381.1 KR 1020210014780-A/2913: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>OF250379.1 KR 1020210014780-A/2911: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>OF250377.1 KR 1020210014780-A/2909: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>OF250375.1 KR 1020210014780-A/2907: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>OF250373.1 KR 1020210014780-A/2905: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>OF250371.1 KR 1020210014780-A/2903: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>OF250369.1 KR 1020210014780-A/2901: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>OF250365.1 KR 1020210014780-A/2897: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>OF250361.1 KR 1020210014780-A/2893: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>OF250357.1 KR 1020210014780-A/2889: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>OF250353.1 KR 1020210014780-A/2885: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>OF250349.1 KR 1020210014780-A/2881: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>OF250345.1 KR 1020210014780-A/2877: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>OF250341.1 KR 1020210014780-A/2873: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>OF250339.1 KR 1020210014780-A/2871: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCCAGCAAC
>OF250337.1 KR 1020210014780-A/2869: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTCGAACGACT
>OF250335.1 KR 1020210014780-A/2867: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGCAATTAATA
>OF250333.1 KR 1020210014780-A/2865: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCCAGCAATTAA
>OF250331.1 KR 1020210014780-A/2863: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGTCTGGAAA
>OF250329.1 KR 1020210014780-A/2861: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGTGTATCTAT
>OF250327.1 KR 1020210014780-A/2859: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCCGTGAAT
>OF250325.1 KR 1020210014780-A/2857: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGTGATTGATA
>OF250323.1 KR 1020210014780-A/2855: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGAGTGCTG
>OF250321.1 KR 1020210014780-A/2853: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTTATGGACT
>OF250319.1 KR 1020210014780-A/2851: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGGTCACTGATT
>OF250317.1 KR 1020210014780-A/2849: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACGAAAGCCA
>OF250315.1 KR 1020210014780-A/2847: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCATGAGAATTG
>OF250313.1 KR 1020210014780-A/2845: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTCAATTGCTTA
>OF250311.1 KR 1020210014780-A/2843: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCCACAGCCA
>OF250309.1 KR 1020210014780-A/2841: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGCATTCCGAT
>OF250307.1 KR 1020210014780-A/2839: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGCTGAAACC
>OF250305.1 KR 1020210014780-A/2837: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAACAGGCTGATT
>OF250303.1 KR 1020210014780-A/2835: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTACCATGAGAA
>OF250301.1 KR 1020210014780-A/2833: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCCGTGAA
>OF250299.1 KR 1020210014780-A/2831: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAGTCAGGAACT
>OF250297.1 KR 1020210014780-A/2829: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCAATGATGA
>OF250295.1 KR 1020210014780-A/2827: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTGTGGTTTAT
>OF250293.1 KR 1020210014780-A/2825: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACTCTGATGA
>OF250291.1 KR 1020210014780-A/2823: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATTAATAAA
>OF250289.1 KR 1020210014780-A/2821: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAATTGCTTAT
>OF250287.1 KR 1020210014780-A/2819: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATCACTGTA
>OF250285.1 KR 1020210014780-A/2817: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATTCTATAGAA
>OF250283.1 KR 1020210014780-A/2815: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAACTAATGTGT
>OF250281.1 KR 1020210014780-A/2813: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCCGATGTGATT
>OF250279.1 KR 1020210014780-A/2811: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATAAGCGGAAAG
>OF250277.1 KR 1020210014780-A/2809: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCTGGATG
>OF250275.1 KR 1020210014780-A/2807: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGAATGGTGC
>OF250273.1 KR 1020210014780-A/2805: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACCTCACACATG
>OF250271.1 KR 1020210014780-A/2803: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGCAACCGAA
>OF250269.1 KR 1020210014780-A/2801: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATGAATAGAAA
>OF250267.1 KR 1020210014780-A/2799: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAATAACTAAT
>OF250265.1 KR 1020210014780-A/2797: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTTGAATGTGTA
>OF250263.1 KR 1020210014780-A/2795: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGGTTGAATGT
>OF250261.1 KR 1020210014780-A/2793: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCATGAATTT
>OF250259.1 KR 1020210014780-A/2791: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAGTGCTGAA
>OF250257.1 KR 1020210014780-A/2789: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGAAACGAGTCA
>OF250255.1 KR 1020210014780-A/2787: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGCATACAAG
>OF250253.1 KR 1020210014780-A/2785: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAGATAGTGCAT
>OF250251.1 KR 1020210014780-A/2783: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATGAGCATT
>OF250249.1 KR 1020210014780-A/2781: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTTCGCAGAC
>OF250247.1 KR 1020210014780-A/2779: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCAACGAAAG
>OF250245.1 KR 1020210014780-A/2777: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTTGTGGCTTC
>OF250243.1 KR 1020210014780-A/2775: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTGGAAATAA
>OF250241.1 KR 1020210014780-A/2773: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCGTGAATTC
>OF250239.1 KR 1020210014780-A/2771: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGACGAGGACAT
>OF250237.1 KR 1020210014780-A/2769: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGACACATATGA
>OF250235.1 KR 1020210014780-A/2767: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTGATGAGTCT
>OF250233.1 KR 1020210014780-A/2765: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCATTTAGTCAA
>OF250231.1 KR 1020210014780-A/2763: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTCAGGAACTT
>OF250229.1 KR 1020210014780-A/2761: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATTCCGATGT
>OF250227.1 KR 1020210014780-A/2759: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATTTAGTCAAA
>OF250225.1 KR 1020210014780-A/2757: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGTCCAGATT
>OF250223.1 KR 1020210014780-A/2755: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGATGGCCGA
>OF250221.1 KR 1020210014780-A/2753: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATGGTGCATAC
>OF250219.1 KR 1020210014780-A/2751: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACCAAGGAAA
>OF250217.1 KR 1020210014780-A/2749: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCATTCTATA
>OF250215.1 KR 1020210014780-A/2747: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCAGTTAAACA
>OF250213.1 KR 1020210014780-A/2745: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATAAGCGGAAA
>OF250211.1 KR 1020210014780-A/2743: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTCCAGATTAT
>OF250209.1 KR 1020210014780-A/2741: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATGAAACGAGT
>OF250207.1 KR 1020210014780-A/2739: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTGAATGTGT
>OF250205.1 KR 1020210014780-A/2737: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGTCCAGATTA
>OF250203.1 KR 1020210014780-A/2735: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGAAAGCGA
>OF250201.1 KR 1020210014780-A/2733: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCCAGCAATT
>OF250199.1 KR 1020210014780-A/2731: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTATAGAAGAA
>OF250197.1 KR 1020210014780-A/2729: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTGTATCTATT
>OF250195.1 KR 1020210014780-A/2727: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATAGTGCATCT
>OF250193.1 KR 1020210014780-A/2725: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATTGATAGTCA
>OF250191.1 KR 1020210014780-A/2723: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAGGAGTTGAA
>OF250189.1 KR 1020210014780-A/2721: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGATGAGAGCAA
>OF250187.1 KR 1020210014780-A/2719: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCAACGAAA
>OF250185.1 KR 1020210014780-A/2717: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCTCATGAATAG
>OF250183.1 KR 1020210014780-A/2715: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCTCATGAAT
>OF250181.1 KR 1020210014780-A/2713: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGCCTTCTGATT
>OF250179.1 KR 1020210014780-A/2711: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATTTCGTATT
>OF250177.1 KR 1020210014780-A/2709: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGATGATAT
>OF250175.1 KR 1020210014780-A/2707: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAGCCATGACCA
>OF250173.1 KR 1020210014780-A/2705: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCGTATTTCT
>OF250171.1 KR 1020210014780-A/2703: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTTCGTATTT
>OF250169.1 KR 1020210014780-A/2701: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGGAAAGCCAAT
>OF250167.1 KR 1020210014780-A/2699: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCATGACCAC
>OF250165.1 KR 1020210014780-A/2697: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATGACCACAT
>OF250163.1 KR 1020210014780-A/2695: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCACATGGATGA
>OF250161.1 KR 1020210014780-A/2693: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAAGCCAA
>OF250159.1 KR 1020210014780-A/2691: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCGGAAAGCCA
>OF250157.1 KR 1020210014780-A/2689: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTCACCATTC
>OF250155.1 KR 1020210014780-A/2687: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACAGCCATGAA
>OF250153.1 KR 1020210014780-A/2685: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGAGGTCAAA
>OF250151.1 KR 1020210014780-A/2683: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTCTCACCATT
>OF250149.1 KR 1020210014780-A/2681: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGACTGAGGTCA
>OF250147.1 KR 1020210014780-A/2679: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATGAATCT
>OF250145.1 KR 1020210014780-A/2677: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCTGGATGA
>OF250143.1 KR 1020210014780-A/2675: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGAGGTCAAT
>OF250141.1 KR 1020210014780-A/2673: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGGTCAATTAA
>OF250139.1 KR 1020210014780-A/2671: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGAGGTCAATT
>OF250137.1 KR 1020210014780-A/2669: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCAATTAAA
>OF250135.1 KR 1020210014780-A/2667: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGAGGTCAATTA
>OF250133.1 KR 1020210014780-A/2665: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCATGAATTAGA
>OF250131.1 KR 1020210014780-A/2663: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>OF250129.1 KR 1020210014780-A/2661: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATCTATGACAAA
>OF250127.1 KR 1020210014780-A/2659: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGCAGAGTACA
>OF250125.1 KR 1020210014780-A/2657: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTCAAGCAGA
>OF250123.1 KR 1020210014780-A/2655: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATGACAAGTTCA
>OF250121.1 KR 1020210014780-A/2653: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAACGAAATCTAA
>OF250119.1 KR 1020210014780-A/2651: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>OF250117.1 KR 1020210014780-A/2649: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAAAGATGGAGA
>OF250115.1 KR 1020210014780-A/2647: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>OF250113.1 KR 1020210014780-A/2645: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATATGTTCTTA
>OF250111.1 KR 1020210014780-A/2643: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>OF250109.1 KR 1020210014780-A/2641: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCAACACATCAA
>OF250107.1 KR 1020210014780-A/2639: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCAGAGTACAA
>OF250105.1 KR 1020210014780-A/2637: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTACACACAA
>OF250103.1 KR 1020210014780-A/2635: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>OF250101.1 KR 1020210014780-A/2633: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>OF250099.1 KR 1020210014780-A/2631: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>OF250097.1 KR 1020210014780-A/2629: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACACACAGCATAA
>OF250095.1 KR 1020210014780-A/2627: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>OF250093.1 KR 1020210014780-A/2625: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTCAAGCAA
>OF250089.1 KR 1020210014780-A/2621: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>OF250087.1 KR 1020210014780-A/2619: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>OF250083.1 KR 1020210014780-A/2615: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>OF250081.1 KR 1020210014780-A/2613: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>OF250079.1 KR 1020210014780-A/2611: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>OF250077.1 KR 1020210014780-A/2609: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>OF250073.1 KR 1020210014780-A/2605: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>OF250071.1 KR 1020210014780-A/2603: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>OF250067.1 KR 1020210014780-A/2599: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>OF250063.1 KR 1020210014780-A/2595: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>OF250061.1 KR 1020210014780-A/2593: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>OF250059.1 KR 1020210014780-A/2591: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>OF250057.1 KR 1020210014780-A/2589: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>OF250055.1 KR 1020210014780-A/2587: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>OF250053.1 KR 1020210014780-A/2585: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>OF250051.1 KR 1020210014780-A/2583: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>OF250049.1 KR 1020210014780-A/2581: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>OF250047.1 KR 1020210014780-A/2579: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>OF250045.1 KR 1020210014780-A/2577: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>OF250043.1 KR 1020210014780-A/2575: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>OF250041.1 KR 1020210014780-A/2573: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>OF250039.1 KR 1020210014780-A/2571: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>OF250037.1 KR 1020210014780-A/2569: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>OF250035.1 KR 1020210014780-A/2567: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>OF250033.1 KR 1020210014780-A/2565: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>OF250031.1 KR 1020210014780-A/2563: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>OF250029.1 KR 1020210014780-A/2561: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>OF250027.1 KR 1020210014780-A/2559: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>OF250025.1 KR 1020210014780-A/2557: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>OF250023.1 KR 1020210014780-A/2555: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>OF250021.1 KR 1020210014780-A/2553: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>OF250019.1 KR 1020210014780-A/2551: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF250017.1 KR 1020210014780-A/2549: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>OF250015.1 KR 1020210014780-A/2547: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>OF250013.1 KR 1020210014780-A/2545: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>OF250011.1 KR 1020210014780-A/2543: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>OF250007.1 KR 1020210014780-A/2539: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>OF250003.1 KR 1020210014780-A/2535: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>OF249999.1 KR 1020210014780-A/2531: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>OF249995.1 KR 1020210014780-A/2527: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>OF249991.1 KR 1020210014780-A/2523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>OF249987.1 KR 1020210014780-A/2519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>OF249983.1 KR 1020210014780-A/2515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>OF249979.1 KR 1020210014780-A/2511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>OF249975.1 KR 1020210014780-A/2507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>OF249971.1 KR 1020210014780-A/2503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>OF249967.1 KR 1020210014780-A/2499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>OF249963.1 KR 1020210014780-A/2495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>OF249959.1 KR 1020210014780-A/2491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>OF249955.1 KR 1020210014780-A/2487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>OF249951.1 KR 1020210014780-A/2483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>OF249947.1 KR 1020210014780-A/2479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>OF249943.1 KR 1020210014780-A/2475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>OF249939.1 KR 1020210014780-A/2471: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>OF249935.1 KR 1020210014780-A/2467: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>OF249931.1 KR 1020210014780-A/2463: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF249927.1 KR 1020210014780-A/2459: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF249923.1 KR 1020210014780-A/2455: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>OF249915.1 KR 1020210014780-A/2447: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>OF249903.1 KR 1020210014780-A/2435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>OF249899.1 KR 1020210014780-A/2431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>OF249895.1 KR 1020210014780-A/2427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>OF249891.1 KR 1020210014780-A/2423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>OF249887.1 KR 1020210014780-A/2419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>OF249883.1 KR 1020210014780-A/2415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>OF249879.1 KR 1020210014780-A/2411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>OF249875.1 KR 1020210014780-A/2407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>OF249871.1 KR 1020210014780-A/2403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGCTGACCTGG
>OF249867.1 KR 1020210014780-A/2399: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTAAATTCTGTGG
>OF249863.1 KR 1020210014780-A/2395: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCGAAGCTGACC
>OF249859.1 KR 1020210014780-A/2391: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACAACGCC
>OF249855.1 KR 1020210014780-A/2387: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTATCAAGTTTG
>OF249851.1 KR 1020210014780-A/2383: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGGTCATGAAG
>OF249847.1 KR 1020210014780-A/2379: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAGAGAAGCAG
>OF249843.1 KR 1020210014780-A/2375: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTCAGGCCTTG
>OF249839.1 KR 1020210014780-A/2371: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAAGCTGACCT
>OF249835.1 KR 1020210014780-A/2367: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCGAGGTCATGA
>OF249831.1 KR 1020210014780-A/2363: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAAATTCTGTGGA
>OF249827.1 KR 1020210014780-A/2359: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGTGGAGTATG
>OF249823.1 KR 1020210014780-A/2355: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCGACTGGAAG
>OF249819.1 KR 1020210014780-A/2351: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCATGAAGAAG
>OF249815.1 KR 1020210014780-A/2347: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAAAGGTTA
>OF249872.1 KR 1020210014780-A/2404: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>OF249868.1 KR 1020210014780-A/2400: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACACGTTTGGC
>OF249864.1 KR 1020210014780-A/2396: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTGCGAAGCTG
>OF249860.1 KR 1020210014780-A/2392: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACCAGTGCACG
>OF249856.1 KR 1020210014780-A/2388: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCCAAGACCT
>OF249852.1 KR 1020210014780-A/2384: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCCTTGCGAAGC
>OF249848.1 KR 1020210014780-A/2380: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCAGGCCTTGC
>OF249844.1 KR 1020210014780-A/2376: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGTTTGAGCT
>OF249840.1 KR 1020210014780-A/2372: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGATGTACGG
>OF249836.1 KR 1020210014780-A/2368: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACGTTTGGCC
>OF249832.1 KR 1020210014780-A/2364: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAAGACACGTT
>OF249828.1 KR 1020210014780-A/2360: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGAGACATGGCA
>OF249824.1 KR 1020210014780-A/2356: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGCAAGATCGG
>OF249820.1 KR 1020210014780-A/2352: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGTCAGGCCTT
>OF249816.1 KR 1020210014780-A/2348: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGTTCCTTAA
>OF250001.1 KR 1020210014780-A/2533: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>OF250005.1 KR 1020210014780-A/2537: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>OF250009.1 KR 1020210014780-A/2541: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>OF249961.1 KR 1020210014780-A/2493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>OF249957.1 KR 1020210014780-A/2489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>OF249953.1 KR 1020210014780-A/2485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>OF249949.1 KR 1020210014780-A/2481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>OF249945.1 KR 1020210014780-A/2477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>OF249941.1 KR 1020210014780-A/2473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>OF249937.1 KR 1020210014780-A/2469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>OF249933.1 KR 1020210014780-A/2465: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF249929.1 KR 1020210014780-A/2461: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>OF249921.1 KR 1020210014780-A/2453: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>OF249917.1 KR 1020210014780-A/2449: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>OF249913.1 KR 1020210014780-A/2445: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>OF249909.1 KR 1020210014780-A/2441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>OF249905.1 KR 1020210014780-A/2437: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>OF249893.1 KR 1020210014780-A/2425: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>OF249889.1 KR 1020210014780-A/2421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>OF249885.1 KR 1020210014780-A/2417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>OF249869.1 KR 1020210014780-A/2401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGCAAGATCGGC
>OF249865.1 KR 1020210014780-A/2397: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGACTTCGGC
>OF249861.1 KR 1020210014780-A/2393: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGTTCCAAGAC
>OF249857.1 KR 1020210014780-A/2389: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAAGCTGACCTG
>OF249853.1 KR 1020210014780-A/2385: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCGAAGCTGA
>OF249849.1 KR 1020210014780-A/2381: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTAAATTCTG
>OF249845.1 KR 1020210014780-A/2377: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGAACTGCAG
>OF249841.1 KR 1020210014780-A/2373: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACTTCGGCTC
>OF249837.1 KR 1020210014780-A/2369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGGAGACATGGC
>OF249833.1 KR 1020210014780-A/2365: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGATGTACGGAG
>OF249829.1 KR 1020210014780-A/2361: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAACGCCTC
>OF249825.1 KR 1020210014780-A/2357: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGGCCTTGCGAA
>OF249821.1 KR 1020210014780-A/2353: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGACACGTTTG
>OF249817.1 KR 1020210014780-A/2349: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGAAGTGTAA
>OF249813.1 KR 1020210014780-A/2345: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTTGAGAGTGT
>OF249870.1 KR 1020210014780-A/2402: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATCAAGTTTGAG
>OF249866.1 KR 1020210014780-A/2398: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAAATTCTGTG
>OF249862.1 KR 1020210014780-A/2394: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACGGAGACATGG
>OF249858.1 KR 1020210014780-A/2390: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCGAAGCTGAC
>OF249854.1 KR 1020210014780-A/2386: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACTGGAAGAC
>OF249850.1 KR 1020210014780-A/2382: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGACACGTTTGG
>OF249846.1 KR 1020210014780-A/2378: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGTATGTACC
>OF249842.1 KR 1020210014780-A/2374: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACTTCGGCTCC
>OF249838.1 KR 1020210014780-A/2370: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAGGCCTTGCGA
>OF249834.1 KR 1020210014780-A/2366: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGACAACGCCT
>OF249830.1 KR 1020210014780-A/2362: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCATGAAGA
>OF249826.1 KR 1020210014780-A/2358: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGCTAAATTCT
>OF249822.1 KR 1020210014780-A/2354: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGCCTTGCGAAG
>OF249818.1 KR 1020210014780-A/2350: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCTGACCTGGA
>OF249814.1 KR 1020210014780-A/2346: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATACCGAGCTA
>OF249812.1 KR 1020210014780-A/2344: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATACCGAGCTAAA
>OF249808.1 KR 1020210014780-A/2340: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATCTAAGTTAA
>OF249804.1 KR 1020210014780-A/2336: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTAAATTCTGT
>OF249800.1 KR 1020210014780-A/2332: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACATCTTT
>OF249796.1 KR 1020210014780-A/2328: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTTGAGCTT
>OF249792.1 KR 1020210014780-A/2324: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTATCAAGTTT
>OF249748.1 KR 1020210014780-A/2280: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>OF249744.1 KR 1020210014780-A/2276: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>OF249740.1 KR 1020210014780-A/2272: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>OF249732.1 KR 1020210014780-A/2264: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>OF249728.1 KR 1020210014780-A/2260: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>OF249720.1 KR 1020210014780-A/2252: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>OF249716.1 KR 1020210014780-A/2248: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>OF249712.1 KR 1020210014780-A/2244: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>OF249680.1 KR 1020210014780-A/2212: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>OF249676.1 KR 1020210014780-A/2208: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>OF249672.1 KR 1020210014780-A/2204: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>OF249668.1 KR 1020210014780-A/2200: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>OF249664.1 KR 1020210014780-A/2196: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>OF249660.1 KR 1020210014780-A/2192: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>OF249656.1 KR 1020210014780-A/2188: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>OF249652.1 KR 1020210014780-A/2184: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>OF249648.1 KR 1020210014780-A/2180: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>OF249644.1 KR 1020210014780-A/2176: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>OF249788.1 KR 1020210014780-A/2320: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGACTGGAAGA
>OF249784.1 KR 1020210014780-A/2316: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGCCATTACAAC
>OF249780.1 KR 1020210014780-A/2312: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACCTGTGCCTG
>OF249776.1 KR 1020210014780-A/2308: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTGAGCTTTCT
>OF249772.1 KR 1020210014780-A/2304: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATTACAACTG
>OF249768.1 KR 1020210014780-A/2300: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGGAGCGCCT
>OF249640.1 KR 1020210014780-A/2172: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>OF249636.1 KR 1020210014780-A/2168: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>OF249632.1 KR 1020210014780-A/2164: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>OF249628.1 KR 1020210014780-A/2160: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>OF249624.1 KR 1020210014780-A/2156: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>OF249620.1 KR 1020210014780-A/2152: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTCGAACGACT
>OF249704.1 KR 1020210014780-A/2236: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>OF249700.1 KR 1020210014780-A/2232: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>OF249696.1 KR 1020210014780-A/2228: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>OF249692.1 KR 1020210014780-A/2224: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>OF249688.1 KR 1020210014780-A/2220: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>OF249684.1 KR 1020210014780-A/2216: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>OF249616.1 KR 1020210014780-A/2148: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCCAGCAATTAA
>OF249809.1 KR 1020210014780-A/2341: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATACGAGTAATA
>OF249805.1 KR 1020210014780-A/2337: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGTAGAATGTAA
>OF249801.1 KR 1020210014780-A/2333: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTACCAGTGCAC
>OF249797.1 KR 1020210014780-A/2329: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGTATGT
>OF249793.1 KR 1020210014780-A/2325: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCTGTGGAGT
>OF249789.1 KR 1020210014780-A/2321: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTACGGAGACA
>OF249785.1 KR 1020210014780-A/2317: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTACAACTGTCC
>OF249781.1 KR 1020210014780-A/2313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTGGAGCGC
>OF249777.1 KR 1020210014780-A/2309: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCCATTACAACT
>OF249773.1 KR 1020210014780-A/2305: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTTTCTGGCT
>OF249706.1 KR 1020210014780-A/2238: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF249710.1 KR 1020210014780-A/2242: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>OF249714.1 KR 1020210014780-A/2246: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>OF249722.1 KR 1020210014780-A/2254: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>OF249794.1 KR 1020210014780-A/2326: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACGGAGACAT
>OF249798.1 KR 1020210014780-A/2330: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTCTGTGGAG
>OF249802.1 KR 1020210014780-A/2334: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGACACGTTT
>OF249806.1 KR 1020210014780-A/2338: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTGATCAGTTT
>OF249810.1 KR 1020210014780-A/2342: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGGACAGCTT
>OF249790.1 KR 1020210014780-A/2322: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTTGCGAAGCT
>OF249786.1 KR 1020210014780-A/2318: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTACAACTGTC
>OF249782.1 KR 1020210014780-A/2314: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGGTCCAGACC
>OF249778.1 KR 1020210014780-A/2310: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTGGAAGACACG
>OF249774.1 KR 1020210014780-A/2306: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGAGCGCCTG
>OF249770.1 KR 1020210014780-A/2302: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACTGGAAGACA
>OF249766.1 KR 1020210014780-A/2298: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGGAAGATGTA
>OF249762.1 KR 1020210014780-A/2294: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>OF249758.1 KR 1020210014780-A/2290: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>OF249754.1 KR 1020210014780-A/2286: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>OF249750.1 KR 1020210014780-A/2282: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>OF249746.1 KR 1020210014780-A/2278: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>OF249742.1 KR 1020210014780-A/2274: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>OF249738.1 KR 1020210014780-A/2270: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>OF249734.1 KR 1020210014780-A/2266: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>OF249730.1 KR 1020210014780-A/2262: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>OF249726.1 KR 1020210014780-A/2258: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>OF249698.1 KR 1020210014780-A/2230: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>OF249694.1 KR 1020210014780-A/2226: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>OF249690.1 KR 1020210014780-A/2222: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>OF249686.1 KR 1020210014780-A/2218: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>OF249682.1 KR 1020210014780-A/2214: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>OF249678.1 KR 1020210014780-A/2210: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>OF249674.1 KR 1020210014780-A/2206: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>OF249670.1 KR 1020210014780-A/2202: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>OF249666.1 KR 1020210014780-A/2198: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>OF249662.1 KR 1020210014780-A/2194: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>OF249658.1 KR 1020210014780-A/2190: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>OF249654.1 KR 1020210014780-A/2186: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>OF249622.1 KR 1020210014780-A/2154: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCCAGCAAC
>OF249618.1 KR 1020210014780-A/2150: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGCAATTAATA
>OF249614.1 KR 1020210014780-A/2146: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGTCTGGAAA
>OF249795.1 KR 1020210014780-A/2327: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCCTATCAAGTT
>OF249799.1 KR 1020210014780-A/2331: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCAGTAGCACA
>OF249803.1 KR 1020210014780-A/2335: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATCAAGTTTGA
>OF249807.1 KR 1020210014780-A/2339: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGCTCAGATA
>OF249811.1 KR 1020210014780-A/2343: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCCTTTATTA
>OF249791.1 KR 1020210014780-A/2323: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCGAGGAGTG
>OF249787.1 KR 1020210014780-A/2319: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTGGAGCGCC
>OF249783.1 KR 1020210014780-A/2315: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCATTACAACTGT
>OF249779.1 KR 1020210014780-A/2311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTGCCTGGTCC
>OF249775.1 KR 1020210014780-A/2307: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGCGCCTGTT
>OF249771.1 KR 1020210014780-A/2303: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAGCGCCTGTTC
>OF249532.1 KR 1020210014780-A/2064: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTTCGCAGAC
>OF249536.1 KR 1020210014780-A/2068: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAGATAGTGCAT
>OF249540.1 KR 1020210014780-A/2072: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGAAACGAGTCA
>OF249544.1 KR 1020210014780-A/2076: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCATGAATTT
>OF249548.1 KR 1020210014780-A/2080: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTTGAATGTGTA
>OF249552.1 KR 1020210014780-A/2084: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATGAATAGAAA
>OF249556.1 KR 1020210014780-A/2088: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACCTCACACATG
>OF249560.1 KR 1020210014780-A/2092: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCTGGATG
>OF249564.1 KR 1020210014780-A/2096: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCCGATGTGATT
>OF249568.1 KR 1020210014780-A/2100: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATTCTATAGAA
>OF249572.1 KR 1020210014780-A/2104: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAATTGCTTAT
>OF249576.1 KR 1020210014780-A/2108: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACTCTGATGA
>OF249580.1 KR 1020210014780-A/2112: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCAATGATGA
>OF249584.1 KR 1020210014780-A/2116: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCCGTGAA
>OF249588.1 KR 1020210014780-A/2120: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAACAGGCTGATT
>OF249592.1 KR 1020210014780-A/2124: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGCATTCCGAT
>OF249596.1 KR 1020210014780-A/2128: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTCAATTGCTTA
>OF249600.1 KR 1020210014780-A/2132: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACGAAAGCCA
>OF249604.1 KR 1020210014780-A/2136: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTTATGGACT
>OF249608.1 KR 1020210014780-A/2140: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGTGATTGATA
>OF249612.1 KR 1020210014780-A/2144: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGTGTATCTAT
>OF249528.1 KR 1020210014780-A/2060: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTTGTGGCTTC
>OF249524.1 KR 1020210014780-A/2056: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCGTGAATTC
>OF249520.1 KR 1020210014780-A/2052: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGACACATATGA
>OF249516.1 KR 1020210014780-A/2048: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCATTTAGTCAA
>OF249512.1 KR 1020210014780-A/2044: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATTCCGATGT
>OF249508.1 KR 1020210014780-A/2040: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGTCCAGATT
>OF249504.1 KR 1020210014780-A/2036: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATGGTGCATAC
>OF249500.1 KR 1020210014780-A/2032: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCATTCTATA
>OF249496.1 KR 1020210014780-A/2028: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATAAGCGGAAA
>OF249492.1 KR 1020210014780-A/2024: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATGAAACGAGT
>OF249488.1 KR 1020210014780-A/2020: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGTCCAGATTA
>OF249610.1 KR 1020210014780-A/2142: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCCGTGAAT
>OF249606.1 KR 1020210014780-A/2138: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGAGTGCTG
>OF249602.1 KR 1020210014780-A/2134: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGGTCACTGATT
>OF249598.1 KR 1020210014780-A/2130: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCATGAGAATTG
>OF249594.1 KR 1020210014780-A/2126: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCCACAGCCA
>OF249590.1 KR 1020210014780-A/2122: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGCTGAAACC
>OF249586.1 KR 1020210014780-A/2118: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTACCATGAGAA
>OF249582.1 KR 1020210014780-A/2114: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAGTCAGGAACT
>OF249578.1 KR 1020210014780-A/2110: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTGTGGTTTAT
>OF249574.1 KR 1020210014780-A/2106: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATTAATAAA
>OF249570.1 KR 1020210014780-A/2102: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATCACTGTA
>OF249566.1 KR 1020210014780-A/2098: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAACTAATGTGT
>OF249562.1 KR 1020210014780-A/2094: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATAAGCGGAAAG
>OF249558.1 KR 1020210014780-A/2090: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGAATGGTGC
>OF249554.1 KR 1020210014780-A/2086: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGCAACCGAA
>OF249550.1 KR 1020210014780-A/2082: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAATAACTAAT
>OF249546.1 KR 1020210014780-A/2078: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGGTTGAATGT
>OF249542.1 KR 1020210014780-A/2074: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAGTGCTGAA
>OF249538.1 KR 1020210014780-A/2070: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGCATACAAG
>OF249534.1 KR 1020210014780-A/2066: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATGAGCATT
>OF249530.1 KR 1020210014780-A/2062: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCAACGAAAG
>OF249526.1 KR 1020210014780-A/2058: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTGGAAATAA
>OF249522.1 KR 1020210014780-A/2054: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGACGAGGACAT
>OF249518.1 KR 1020210014780-A/2050: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTGATGAGTCT
>OF249514.1 KR 1020210014780-A/2046: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTCAGGAACTT
>OF249510.1 KR 1020210014780-A/2042: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATTTAGTCAAA
>OF249506.1 KR 1020210014780-A/2038: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGATGGCCGA
>OF249502.1 KR 1020210014780-A/2034: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACCAAGGAAA
>OF249498.1 KR 1020210014780-A/2030: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCAGTTAAACA
>OF249494.1 KR 1020210014780-A/2026: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTCCAGATTAT
>OF249490.1 KR 1020210014780-A/2022: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTGAATGTGT
>OF249486.1 KR 1020210014780-A/2018: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGAAAGCGA
>OF249484.1 KR 1020210014780-A/2016: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCCAGCAATT
>OF249480.1 KR 1020210014780-A/2012: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTGTATCTATT
>OF249476.1 KR 1020210014780-A/2008: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATTGATAGTCA
>OF249472.1 KR 1020210014780-A/2004: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGATGAGAGCAA
>OF249468.1 KR 1020210014780-A/2000: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCTCATGAATAG
>OF249464.1 KR 1020210014780-A/1996: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGCCTTCTGATT
>OF249460.1 KR 1020210014780-A/1992: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGATGATAT
>OF249456.1 KR 1020210014780-A/1988: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCGTATTTCT
>OF249452.1 KR 1020210014780-A/1984: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGGAAAGCCAAT
>OF249448.1 KR 1020210014780-A/1980: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATGACCACAT
>OF249444.1 KR 1020210014780-A/1976: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAAGCCAA
>OF249440.1 KR 1020210014780-A/1972: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTCACCATTC
>OF249436.1 KR 1020210014780-A/1968: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGAGGTCAAA
>OF249432.1 KR 1020210014780-A/1964: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGACTGAGGTCA
>OF249428.1 KR 1020210014780-A/1960: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCTGGATGA
>OF249424.1 KR 1020210014780-A/1956: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGGTCAATTAA
>OF249420.1 KR 1020210014780-A/1952: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCAATTAAA
>OF249416.1 KR 1020210014780-A/1948: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCATGAATTAGA
>OF249482.1 KR 1020210014780-A/2014: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTATAGAAGAA
>OF249478.1 KR 1020210014780-A/2010: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATAGTGCATCT
>OF249474.1 KR 1020210014780-A/2006: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAGGAGTTGAA
>OF249470.1 KR 1020210014780-A/2002: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCAACGAAA
>OF249466.1 KR 1020210014780-A/1998: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCTCATGAAT
>OF249462.1 KR 1020210014780-A/1994: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATTTCGTATT
>OF249458.1 KR 1020210014780-A/1990: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAGCCATGACCA
>OF249454.1 KR 1020210014780-A/1986: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTTCGTATTT
>OF249450.1 KR 1020210014780-A/1982: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCATGACCAC
>OF249446.1 KR 1020210014780-A/1978: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCACATGGATGA
>OF249442.1 KR 1020210014780-A/1974: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCGGAAAGCCA
>OF249438.1 KR 1020210014780-A/1970: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACAGCCATGAA
>OF249434.1 KR 1020210014780-A/1966: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTCTCACCATT
>OF249430.1 KR 1020210014780-A/1962: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATGAATCT
>OF249426.1 KR 1020210014780-A/1958: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGAGGTCAAT
>OF249422.1 KR 1020210014780-A/1954: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGAGGTCAATT
>OF249418.1 KR 1020210014780-A/1950: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGAGGTCAATTA
>OF288413.1 KR 1020210079309-A/52: BARCODING OF NUCLEIC ACIDS
GTCTCCGACTCAG
>OF288374.1 KR 1020210079309-A/13: BARCODING OF NUCLEIC ACIDS
GTCTCCGACTCAG
>OF288387.1 KR 1020210079309-A/26: BARCODING OF NUCLEIC ACIDS
GCTCTTCCGATCT
>OF249020.1 KR 1020210014780-A/1552: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>OF249018.1 KR 1020210014780-A/1550: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>OF249016.1 KR 1020210014780-A/1548: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>OF249008.1 KR 1020210014780-A/1540: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>OF249004.1 KR 1020210014780-A/1536: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>OF249000.1 KR 1020210014780-A/1532: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>OF248996.1 KR 1020210014780-A/1528: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>OF248992.1 KR 1020210014780-A/1524: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>OF248980.1 KR 1020210014780-A/1512: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>OF248976.1 KR 1020210014780-A/1508: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>OF248972.1 KR 1020210014780-A/1504: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>OF249014.1 KR 1020210014780-A/1546: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>OF249010.1 KR 1020210014780-A/1542: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>OF249002.1 KR 1020210014780-A/1534: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>OF248990.1 KR 1020210014780-A/1522: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>OF248986.1 KR 1020210014780-A/1518: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>OF248982.1 KR 1020210014780-A/1514: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>OF248978.1 KR 1020210014780-A/1510: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>OF248974.1 KR 1020210014780-A/1506: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>OF248970.1 KR 1020210014780-A/1502: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>OF248966.1 KR 1020210014780-A/1498: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>OF248962.1 KR 1020210014780-A/1494: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>OF248958.1 KR 1020210014780-A/1490: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>OF287985.1 KR 1020210069075-A/180: METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY
NNNNNNNNAGAAW
>OF248647.1 KR 1020210014780-A/1179: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGAATAAATCTA
>OF248643.1 KR 1020210014780-A/1175: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGAGTTCATCTA
>OF248639.1 KR 1020210014780-A/1171: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGGCAGGCAAA
>OF248635.1 KR 1020210014780-A/1167: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCATTTTAA
>OF248631.1 KR 1020210014780-A/1163: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGGCAAACTTA
>OF248627.1 KR 1020210014780-A/1159: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTCTCAGTTCA
>OF248623.1 KR 1020210014780-A/1155: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGAGAAAGAAA
>OF248649.1 KR 1020210014780-A/1181: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAATAAATCTTA
>OF248645.1 KR 1020210014780-A/1177: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGAATAAATCA
>OF248641.1 KR 1020210014780-A/1173: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGAGGCAGGCAA
>OF248637.1 KR 1020210014780-A/1169: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACCACTGTAA
>OF248633.1 KR 1020210014780-A/1165: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTTACAGGAAA
>OF248629.1 KR 1020210014780-A/1161: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGGAACAGCA
>OF248625.1 KR 1020210014780-A/1157: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGTCACTATA
>OF248621.1 KR 1020210014780-A/1153: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAAATAGAA
>OF248619.1 KR 1020210014780-A/1151: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTCGTTGTTTCA
>OF248617.1 KR 1020210014780-A/1149: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>OF248615.1 KR 1020210014780-A/1147: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>OF248613.1 KR 1020210014780-A/1145: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>OF248611.1 KR 1020210014780-A/1143: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>OF248609.1 KR 1020210014780-A/1141: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>OF248607.1 KR 1020210014780-A/1139: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>OF248605.1 KR 1020210014780-A/1137: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>OF248603.1 KR 1020210014780-A/1135: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>OF248601.1 KR 1020210014780-A/1133: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>OF248599.1 KR 1020210014780-A/1131: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>OF248597.1 KR 1020210014780-A/1129: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>OF248595.1 KR 1020210014780-A/1127: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>OF248593.1 KR 1020210014780-A/1125: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>OF248591.1 KR 1020210014780-A/1123: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>OF248589.1 KR 1020210014780-A/1121: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>OF248587.1 KR 1020210014780-A/1119: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>OF248585.1 KR 1020210014780-A/1117: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>OF248583.1 KR 1020210014780-A/1115: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>OF248579.1 KR 1020210014780-A/1111: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>OF248575.1 KR 1020210014780-A/1107: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>OF248571.1 KR 1020210014780-A/1103: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>OF248567.1 KR 1020210014780-A/1099: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>OF248563.1 KR 1020210014780-A/1095: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>OF248559.1 KR 1020210014780-A/1091: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>OF248555.1 KR 1020210014780-A/1087: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>OF248553.1 KR 1020210014780-A/1085: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTGCTCTGCAA
>OF248551.1 KR 1020210014780-A/1083: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGGCCTGTTAA
>OF248549.1 KR 1020210014780-A/1081: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAACACACTGCA
>OF248547.1 KR 1020210014780-A/1079: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACACACTGCAAA
>OF248545.1 KR 1020210014780-A/1077: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTGAATAAAA
>OF248543.1 KR 1020210014780-A/1075: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGGAAAATAAA
>OF248541.1 KR 1020210014780-A/1073: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATGCAGCTAAA
>OF248539.1 KR 1020210014780-A/1071: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATCACGGTGAA
>OF248537.1 KR 1020210014780-A/1069: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAGTCTGAGAA
>OF248535.1 KR 1020210014780-A/1067: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGTTAGTGTA
>OF248533.1 KR 1020210014780-A/1065: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTTGTATGTAA
>OF248531.1 KR 1020210014780-A/1063: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCTCGGTATA
>OF248529.1 KR 1020210014780-A/1061: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGTGACAATGAA
>OF248525.1 KR 1020210014780-A/1057: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGTTGATTAA
>OF248523.1 KR 1020210014780-A/1055: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>OF248521.1 KR 1020210014780-A/1053: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>OF248519.1 KR 1020210014780-A/1051: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>OF248517.1 KR 1020210014780-A/1049: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>OF248515.1 KR 1020210014780-A/1047: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>OF248513.1 KR 1020210014780-A/1045: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>OF248511.1 KR 1020210014780-A/1043: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>OF248509.1 KR 1020210014780-A/1041: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>OF248507.1 KR 1020210014780-A/1039: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>OF248505.1 KR 1020210014780-A/1037: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>OF248503.1 KR 1020210014780-A/1035: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>OF248501.1 KR 1020210014780-A/1033: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>OF248499.1 KR 1020210014780-A/1031: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>OF248497.1 KR 1020210014780-A/1029: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>OF248495.1 KR 1020210014780-A/1027: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>OF248493.1 KR 1020210014780-A/1025: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>OF248489.1 KR 1020210014780-A/1021: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>OF248485.1 KR 1020210014780-A/1017: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>OF248481.1 KR 1020210014780-A/1013: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>OF248477.1 KR 1020210014780-A/1009: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>OF248473.1 KR 1020210014780-A/1005: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>OF248469.1 KR 1020210014780-A/1001: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>OF248465.1 KR 1020210014780-A/997: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>OF248461.1 KR 1020210014780-A/993: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>OF248457.1 KR 1020210014780-A/989: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>OF168052.1 KR 1020210003811-A/42: NOVEL RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION
GCCGCCACCATGG
>OF168051.1 KR 1020210003811-A/41: NOVEL RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION
GCCGCCACCATGG
>OF167785.1 KR 1020210005074-A/27: METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH VIRUS
GAAACCCATTCCC
>OF167784.1 KR 1020210005074-A/26: METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH VIRUS
AGGGGACATTCCC
>OF247993.1 KR 1020210014780-A/525: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGATTCAAGTCA
>OF247991.1 KR 1020210014780-A/523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAAAACCAA
>OF247989.1 KR 1020210014780-A/521: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAGCAAAGAA
>OF247987.1 KR 1020210014780-A/519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGCAACA
>OF247985.1 KR 1020210014780-A/517: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>OF247983.1 KR 1020210014780-A/515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATCTATGACAA
>OF247981.1 KR 1020210014780-A/513: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCAAAGATAA
>OF247979.1 KR 1020210014780-A/511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCTACCAGAAA
>OF247977.1 KR 1020210014780-A/509: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCTACCAGAA
>OF247975.1 KR 1020210014780-A/507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAAGATAATGA
>OF247973.1 KR 1020210014780-A/505: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAACTCTACCAGA
>OF247971.1 KR 1020210014780-A/503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATATAGCAAA
>OF247967.1 KR 1020210014780-A/499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCTATGACAAGA
>OF247965.1 KR 1020210014780-A/497: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGTTCAAGCA
>OF247963.1 KR 1020210014780-A/495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAACACATCAGA
>OF247961.1 KR 1020210014780-A/493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAACGAAATCTA
>OF247959.1 KR 1020210014780-A/491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGACTTCCGCAA
>OF247957.1 KR 1020210014780-A/489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACGAAATCTATA
>OF247955.1 KR 1020210014780-A/487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACACACAGCATA
>OF247953.1 KR 1020210014780-A/485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAAGTTCAAA
>OF247951.1 KR 1020210014780-A/483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGAGTACACAA
>OF247949.1 KR 1020210014780-A/481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>OF247947.1 KR 1020210014780-A/479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>OF247945.1 KR 1020210014780-A/477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>OF247943.1 KR 1020210014780-A/475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>OF247941.1 KR 1020210014780-A/473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>OF247937.1 KR 1020210014780-A/469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>OF247935.1 KR 1020210014780-A/467: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>OF247931.1 KR 1020210014780-A/463: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>OF247929.1 KR 1020210014780-A/461: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>OF247927.1 KR 1020210014780-A/459: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>OF247925.1 KR 1020210014780-A/457: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>OF247921.1 KR 1020210014780-A/453: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>OF247919.1 KR 1020210014780-A/451: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>OF247915.1 KR 1020210014780-A/447: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>OF247911.1 KR 1020210014780-A/443: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>OF247909.1 KR 1020210014780-A/441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>OF247907.1 KR 1020210014780-A/439: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>OF247903.1 KR 1020210014780-A/435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>OF247899.1 KR 1020210014780-A/431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>OF247895.1 KR 1020210014780-A/427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>OF247891.1 KR 1020210014780-A/423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>OF247889.1 KR 1020210014780-A/421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>OF247887.1 KR 1020210014780-A/419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>OF247885.1 KR 1020210014780-A/417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>OF247883.1 KR 1020210014780-A/415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>OF247881.1 KR 1020210014780-A/413: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>OF247879.1 KR 1020210014780-A/411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>OF247875.1 KR 1020210014780-A/407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>OF247873.1 KR 1020210014780-A/405: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>OF247871.1 KR 1020210014780-A/403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>OF247869.1 KR 1020210014780-A/401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>OF247867.1 KR 1020210014780-A/399: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>OF247863.1 KR 1020210014780-A/395: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>OF247861.1 KR 1020210014780-A/393: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>OF247857.1 KR 1020210014780-A/389: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>OF247855.1 KR 1020210014780-A/387: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>OF247853.1 KR 1020210014780-A/385: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>OF247851.1 KR 1020210014780-A/383: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>OF247847.1 KR 1020210014780-A/379: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>OF247845.1 KR 1020210014780-A/377: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>OF247841.1 KR 1020210014780-A/373: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>OF247839.1 KR 1020210014780-A/371: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>OF247837.1 KR 1020210014780-A/369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>OF247531.1 KR 1020210014780-A/63: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>OF247529.1 KR 1020210014780-A/61: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>OF247527.1 KR 1020210014780-A/59: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>OF247525.1 KR 1020210014780-A/57: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>OF247523.1 KR 1020210014780-A/55: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>OF247521.1 KR 1020210014780-A/53: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>OF247519.1 KR 1020210014780-A/51: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>OF247517.1 KR 1020210014780-A/49: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>OF247515.1 KR 1020210014780-A/47: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>OF247513.1 KR 1020210014780-A/45: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>OF247511.1 KR 1020210014780-A/43: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>OF247509.1 KR 1020210014780-A/41: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>OF247507.1 KR 1020210014780-A/39: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>OF247505.1 KR 1020210014780-A/37: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>OF247503.1 KR 1020210014780-A/35: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>OF247501.1 KR 1020210014780-A/33: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>OF247499.1 KR 1020210014780-A/31: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>OF247497.1 KR 1020210014780-A/29: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>OF247495.1 KR 1020210014780-A/27: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>OF247493.1 KR 1020210014780-A/25: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>OF247491.1 KR 1020210014780-A/23: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>OF247489.1 KR 1020210014780-A/21: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>OF247487.1 KR 1020210014780-A/19: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>OF247485.1 KR 1020210014780-A/17: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>OF247483.1 KR 1020210014780-A/15: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>OF247481.1 KR 1020210014780-A/13: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>OF247479.1 KR 1020210014780-A/11: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>OF247477.1 KR 1020210014780-A/9: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>OF247475.1 KR 1020210014780-A/7: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>OF247473.1 KR 1020210014780-A/5: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>OF247471.1 KR 1020210014780-A/3: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>OF247469.1 KR 1020210014780-A/1: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>OF247441.1 KR 1020210016078-A/2299: CHIRAL CONTROL
GCCAGGTAAGTAT
>OF245252.1 KR 1020210016078-A/107: CHIRAL CONTROL
AATCGATCGATCG
>OF245243.1 KR 1020210016078-A/98: CHIRAL CONTROL
TGTCGTTGTCGTT
>OF244850.1 KR 1020210040060-A/2: OLIGONUCLEOTIDES COMPRISING A PHOSPHOROTRITHIOATE INTERNUCLEOSIDE LINKAGE
GCATTGGTATTCA
>OF283331.1 KR 1020210063379-A/2: BARCODED PEPTIDE-MHC COMPLEXES AND USES THEREOF
AAAGAATATACCC
>OF241635.1 KR 1020210025075-A/2: COMPOSITIONS AND METHODS FOR MEDIATING EPS
WATCAANNNNTTR
>OF278780.1 KR 1020210060521-A/207: TRANSCRIPTIONAL RECORDING BY CRISPR SPACER ACQUISITION FROM RNA
GGTGATGAGCGAC
>OF278195.1 KR 1020210057088-A/14: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF LYMPHATIC SYSTEM DISORDERS
TCCACGYCCACTC
>OF278194.1 KR 1020210057088-A/13: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF LYMPHATIC SYSTEM DISORDERS
TCCACGTCCACTC
>OF277240.1 KR 1020210037750-A/30: METHODS FOR IMPROVED ISOLATION OF GENOMIC DNA TEMPLATES FOR ALLELE DETECTION
TACACGGACCACA
>OF277239.1 KR 1020210037750-A/29: METHODS FOR IMPROVED ISOLATION OF GENOMIC DNA TEMPLATES FOR ALLELE DETECTION
TACACGGACCGCA
>OF237997.1 KR 1020210027389-A/54: COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES
TTTTTTTCTTTTT
>OF197292.1 KR 1020210013080-A/7: COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
CACCCCGTCCTCG
>OF197291.1 KR 1020210013080-A/6: COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
CACCCCATCCTCG
>OF195057.1 KR 1020210041537-A/1: OLIGONUCLEOTIDES COMPRISING A PHOSPHOROTRITHIOATE INTERNUCLEOSIDE LINKAGE
GCATTGGTATTCA
>OF195035.1 KR 1020210037611-A/2: CODON OPTIMIZATION
TGYYGATGYYYYY
>OF194867.1 KR 1020210008381-A/54: METHODS AND COMPOSITIONS FOR TARGETED EDITING OF POLYNUCLEOTIDES
CAGCGCAGCACGC
>MY545273.1 Sequence 10 from patent US 11124844
ATGTCCTGGCGTG
>MY545268.1 Sequence 5 from patent US 11124844
TACAGGACCGCAC
>MY542096.1 Sequence 23 from patent US 11124819
AATCTGTGGTAGG
>MY539407.1 Sequence 104 from patent US 11124782
ATTATTATTATTC
>MY539405.1 Sequence 102 from patent US 11124782
ATTATTATTATTC
>MY538007.1 Sequence 366 from patent US 11123409
CTCGTCGGACGGC
>MY533998.1 Sequence 42 from patent US 11123360
AGATGATCTCTTA
>MY533956.1 Sequence 1 from patent US 11123359
TAGGGTTAGACAA
>MY532424.1 Sequence 86 from patent US 11118207
AAAAAAAAAAAAA
>MY532411.1 Sequence 73 from patent US 11118207
AAAAAAAAAAAAA
>MY532410.1 Sequence 72 from patent US 11118207
TTTTTTTTTTTTT
>MY532404.1 Sequence 66 from patent US 11118207
AAAAAAAAAAAAA
>MY532402.1 Sequence 64 from patent US 11118207
TTTTTTTTTTTTT
>MY531856.1 Sequence 1274 from patent US 11118194
TGAGAAGTGGCAC
>MY524885.1 Sequence 71 from patent US 11118179
CCTCGGCTTACCT
>MY524884.1 Sequence 70 from patent US 11118179
AGATGGCATTTCT
>MY524883.1 Sequence 69 from patent US 11118179
AGATGGCATTTCT
>MY524814.1 Sequence 614 from patent US 11118178
CNGNGGAAGNCNA
>MY524812.1 Sequence 612 from patent US 11118178
AGAGTAAAGTCAA
>MY524747.1 Sequence 547 from patent US 11118178
AGAGTAAAGTCAA
>MY524741.1 Sequence 541 from patent US 11118178
AGAGTAAAGTCAA
>MY524727.1 Sequence 527 from patent US 11118178
CTGTGGAAGNCNA
>MY524726.1 Sequence 526 from patent US 11118178
CNGNGGAAGTCTA
>MY524709.1 Sequence 509 from patent US 11118178
CNGNGGAAGNCTA
>MY524696.1 Sequence 496 from patent US 11118178
CCGAAAAACCCGC
>MY524680.1 Sequence 480 from patent US 11118178
CTGTGGAAGTCTA
>MY524677.1 Sequence 477 from patent US 11118178
CTGTGGAAGTCTA
>MY524674.1 Sequence 474 from patent US 11118178
GCACCTTTCTAGA
>MY524671.1 Sequence 471 from patent US 11118178
GCACCTTTCTAGA
>MY524668.1 Sequence 468 from patent US 11118178
AGAGTAAAGTCAA
>MY524665.1 Sequence 465 from patent US 11118178
AGAGTAAAGTCAA
>MY524663.1 Sequence 463 from patent US 11118178
GCATCTACGGTGA
>MY524661.1 Sequence 461 from patent US 11118178
GATGGCAAGCATG
>MY524659.1 Sequence 459 from patent US 11118178
AACTTCAAACTGA
>MY524657.1 Sequence 457 from patent US 11118178
ATTCCATCGTGTA
>MY524655.1 Sequence 455 from patent US 11118178
GAACTTCAAACTG
>MY524653.1 Sequence 453 from patent US 11118178
GCACCAAGACAGA
>MY524651.1 Sequence 451 from patent US 11118178
AGGAAAGAGCATC
>MY524649.1 Sequence 449 from patent US 11118178
GCATCTACGGTGA
>MY524647.1 Sequence 447 from patent US 11118178
GATGGCAAGCATG
>MY524645.1 Sequence 445 from patent US 11118178
AACTTCAAACTGA
>MY524643.1 Sequence 443 from patent US 11118178
ATTCCATCGTGTA
>MY524641.1 Sequence 441 from patent US 11118178
GAACTTCAAACTG
>MY524639.1 Sequence 439 from patent US 11118178
GCACCAAGACAGA
>MY524637.1 Sequence 437 from patent US 11118178
AGGAAAGAGCATC
>MY524633.1 Sequence 433 from patent US 11118178
AACTTCAAACTGA
>MY524631.1 Sequence 431 from patent US 11118178
AACTTCAAACTGA
>MY524629.1 Sequence 429 from patent US 11118178
TAATCAAGGACTT
>MY524627.1 Sequence 427 from patent US 11118178
AATTCCATCGTGT
>MY524625.1 Sequence 425 from patent US 11118178
GGCTACAAAAACA
>MY524623.1 Sequence 423 from patent US 11118178
GGCTACAAAAACA
>MY524621.1 Sequence 421 from patent US 11118178
ATTTGGCTACAAA
>MY524619.1 Sequence 419 from patent US 11118178
ATTTGGCTACAAA
>MY524617.1 Sequence 417 from patent US 11118178
ATTTGGCTACAAA
>MY524615.1 Sequence 415 from patent US 11118178
AAGGATTTGGCTA
>MY524611.1 Sequence 411 from patent US 11118178
AATTCCATCGTGT
>MY524561.1 Sequence 361 from patent US 11118178
ACTGCCAAGGGAA
>MY524559.1 Sequence 359 from patent US 11118178
GCGTGCTCAACTG
>MY524557.1 Sequence 357 from patent US 11118178
GCAAGTGTGACAG
>MY524555.1 Sequence 355 from patent US 11118178
GTGGACCTCTTTG
>MY524553.1 Sequence 353 from patent US 11118178
TGTGGACCTCTTT
>MY524551.1 Sequence 351 from patent US 11118178
AGTGTGACAGTCA
>MY524549.1 Sequence 349 from patent US 11118178
GAGTTTATTCGGA
>MY524547.1 Sequence 347 from patent US 11118178
GTTTATTCGGAAA
>MY524545.1 Sequence 345 from patent US 11118178
ACTGCCAAGGGAA
>MY524543.1 Sequence 343 from patent US 11118178
GCGTGCTCAACTG
>MY524541.1 Sequence 341 from patent US 11118178
GCAAGTGTGACAG
>MY524539.1 Sequence 339 from patent US 11118178
GTGGACCTCTTTG
>MY524537.1 Sequence 337 from patent US 11118178
CAAGTGTGACAGT
>MY524535.1 Sequence 335 from patent US 11118178
TGTGGACCTCTTT
>MY524533.1 Sequence 333 from patent US 11118178
AGTGTGACAGTCA
>MY524531.1 Sequence 331 from patent US 11118178
GAGTTTATTCGGA
>MY524529.1 Sequence 329 from patent US 11118178
GTTTATTCGGAAA
>MY524527.1 Sequence 327 from patent US 11118178
AGTTTATTCGGAA
>MY524525.1 Sequence 325 from patent US 11118178
TTATGTTGAAACA
>MY524523.1 Sequence 323 from patent US 11118178
CAGTACAAATTAA
>MY524521.1 Sequence 321 from patent US 11118178
TACACACAGAAAA
>MY524519.1 Sequence 319 from patent US 11118178
AAAGGTTTACTAA
>MY524517.1 Sequence 317 from patent US 11118178
GAATTCCAGCTTA
>MY524515.1 Sequence 315 from patent US 11118178
AATACCAAGTCAA
>MY524513.1 Sequence 313 from patent US 11118178
GAATCTCAGTTAA
>MY524509.1 Sequence 309 from patent US 11118178
GAGCAATATTCTA
>MY524507.1 Sequence 307 from patent US 11118178
AGTTGGCAAGTAA
>MY524505.1 Sequence 305 from patent US 11118178
ACCTTGAAGTAAA
>MY524503.1 Sequence 303 from patent US 11118178
GCCTCTAAGACTA
>MY524501.1 Sequence 301 from patent US 11118178
GTTGAAAGATTTA
>MY524499.1 Sequence 299 from patent US 11118178
GACTAAAGGAACA
>MY524497.1 Sequence 297 from patent US 11118178
GATTACTATGAAA
>MY524495.1 Sequence 295 from patent US 11118178
AATGGTTCAGAAA
>MY524493.1 Sequence 293 from patent US 11118178
TTGATTTTCTGAA
>MY524491.1 Sequence 291 from patent US 11118178
CAGTGAAATATTA
>MY524489.1 Sequence 289 from patent US 11118178
GATAGTCAGTCTA
>MY524487.1 Sequence 287 from patent US 11118178
TAATGGTTCAGAA
>MY524485.1 Sequence 285 from patent US 11118178
ACTCTCAAGTCAA
>MY524483.1 Sequence 283 from patent US 11118178
GAAGGATGGCATA
>MY524481.1 Sequence 281 from patent US 11118178
GGATCTGAGTTAA
>MY519633.1 Sequence 100 from patent US 11118169
GCCGCCRCCATGG
>MY477514.1 Sequence 22 from patent US 11111535
NAAGGAGAAGTTG
>MY477500.1 Sequence 8 from patent US 11111535
CAAGGAGAAGTTG
>MY477499.1 Sequence 7 from patent US 11111535
CAAGGAGAAGTTG
>pdb|7L4Y|E Chain E, YTH Domain of Human YTHDC1 with dsDNA Comprising Single N6mA joined by Two Six-bp DNA Duplexes in P212121 Crystal
CAGCTGNGTCGAC
>pdb|7L4Y|F Chain F, YTH Domain of Human YTHDC1 with dsDNA Comprising Single N6mA joined by Two Six-bp DNA Duplexes in P212121 Crystal
CAGCTGNGTCGAC
>pdb|7L4X|E Chain E, YTH Domain of Human YTHDC1 with dsDNA Comprising Single N6mA joined by two six-bp DNA duplexes in P3221 Crystal
CAGCTGNGTCGAC
>PA274216.1 WO 2021157730-A/36: Nucleic acid medicine and use thereof
TTTTTATGGCGGG
>PA274215.1 WO 2021157730-A/35: Nucleic acid medicine and use thereof
TTTTATGGCGGGA
>PA274200.1 WO 2021157730-A/20: Nucleic acid medicine and use thereof
GAGTTTTTTATGG
>PA274199.1 WO 2021157730-A/19: Nucleic acid medicine and use thereof
AGTTTTTTATGGC
>PA272273.1 JP 2021119751-A/3: Identification of microorganisms
CTTCGGTGGCTTC
>MQ311406.1 Sequence 44 from Patent WO2021224809
CCTGCGTTCTCAG
>MQ311402.1 Sequence 40 from Patent WO2021224809
TGTCGCAGAGCGC
>MQ281363.1 Sequence 34 from Patent WO2021222719
AAAAGATATACAT
>MQ281362.1 Sequence 33 from Patent WO2021222719
AAGAGATATACAT
>MQ281361.1 Sequence 32 from Patent WO2021222719
AGGAGATATACAT
>MQ281360.1 Sequence 31 from Patent WO2021222719
AAGGAGGTAAAAA
>pdb|2Z6A|D Chain D, S-Adenosyl-L-methionine-Dependent Methyl Transfer: Observable Precatalytic Intermediates during DNA Cytosine Methylation
TGATAGCGCTATC
>pdb|2H3A|D Chain D, Structural basis for nucleic acid and toxin recognition of the bacterial antitoxin CcdA
NCGGGTATACATA
>pdb|2H3C|D Chain D, Structural basis for nucleic acid and toxin recognition of the bacterial antitoxin CcdA
NCGGGTATACATA
>pdb|3E54|E Chain E, Archaeal Intron-encoded Homing Endonuclease I-Vdi141I Complexed With DNA
TTGGCTACCTTAA
>pdb|3E54|C Chain C, Archaeal Intron-encoded Homing Endonuclease I-Vdi141I Complexed With DNA
CTGACTCTCTTAA
>pdb|2OQ4|F Chain F, Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli (E2Q) in complex with AP-site containing DNA substrate
CCAGGANGAAGCC
>pdb|2OQ4|E Chain E, Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli (E2Q) in complex with AP-site containing DNA substrate
GGCTTCATCCTGG
>pdb|2OQ4|D Chain D, Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli (E2Q) in complex with AP-site containing DNA substrate
CCAGGANGAAGCC
>pdb|2OQ4|C Chain C, Crystal structure of the DNA repair enzyme endonuclease-VIII (Nei) from E. coli (E2Q) in complex with AP-site containing DNA substrate
GGCTTCATCCTGG
>pdb|2ZCJ|D Chain D, Ternary structure of the Glu119Gln M.HhaI, C5-Cytosine DNA methyltransferase, with unmodified DNA and AdoHcy
TGATAGCGCTATC
>pdb|2Z6U|D Chain D, Ternary structure of the Glu119Ala M.HhaI, C5-Cytosine DNA methyltransferase, with unmodified DNA and AdoHcy
TGATAGCGCTATC
>pdb|2H3C|C Chain C, Structural basis for nucleic acid and toxin recognition of the bacterial antitoxin CcdA
NTATGTATACCCG
>pdb|2H3A|C Chain C, Structural basis for nucleic acid and toxin recognition of the bacterial antitoxin CcdA
NTATGTATACCCG
>pdb|7RSU|P Chain P, TNA polymerase, n+2 product
NGCGAACTGCGNN
>pdb|1KLN|B Chain B, DNA POLYMERASE I KLENOW FRAGMENT (E.C.2.7.7.7) MUTANT/DNA COMPLEX
GCCTCGCGGCGGC
>pdb|1QRI|M Chain M, X-RAY STRUCTURE OF THE DNA-ECO RI ENDONUCLEASE COMPLEXES WITH AN E144D MUTATION AT 2.7 A
TCGCGAATTCGCG
>pdb|1QRH|M Chain M, X-RAY STRUCTURE OF THE DNA-ECO RI ENDONUCLEASE COMPLEXES WITH AN R145K MUTATION AT 2.7 A
TCGCGAATTCGCG
>pdb|2PVI|D Chain D, PVUII ENDONUCLEASE COMPLEXED TO AN IODINATED COGNATE DNA
TGACCAGNTGGTC
>pdb|2PVI|C Chain C, PVUII ENDONUCLEASE COMPLEXED TO AN IODINATED COGNATE DNA
TGACCAGNTGGTC
>pdb|6GAT|C Chain C, SOLUTION NMR STRUCTURE OF THE L22V MUTANT DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13 BP DNA CONTAINING A TGATA SITE, REGULARIZED MEAN STRUCTURE
GTCTCTATCACTG
>pdb|6GAT|B Chain B, SOLUTION NMR STRUCTURE OF THE L22V MUTANT DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13 BP DNA CONTAINING A TGATA SITE, REGULARIZED MEAN STRUCTURE
CAGTGATAGAGAC
>pdb|7GAT|C Chain C, SOLUTION NMR STRUCTURE OF THE L22V MUTANT DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13 BP DNA CONTAINING A TGATA SITE, 34 STRUCTURES
GTCTCTATCACTG
>pdb|7GAT|B Chain B, SOLUTION NMR STRUCTURE OF THE L22V MUTANT DNA BINDING DOMAIN OF AREA COMPLEXED TO A 13 BP DNA CONTAINING A TGATA SITE, 34 STRUCTURES
CAGTGATAGAGAC
>pdb|1VAS|C Chain C, ATOMIC MODEL OF A PYRIMIDINE DIMER SPECIFIC EXCISION REPAIR ENZYME COMPLEXED WITH A DNA SUBSTRATE: STRUCTURAL BASIS FOR DAMAGED DNA RECOGNITION
TAGCGCAACGCGA
>pdb|1VAS|B Chain B, ATOMIC MODEL OF A PYRIMIDINE DIMER SPECIFIC EXCISION REPAIR ENZYME COMPLEXED WITH A DNA SUBSTRATE: STRUCTURAL BASIS FOR DAMAGED DNA RECOGNITION
ATCGCGTTGCGCT
>MQ264932.1 Sequence 45 from Patent WO2021212085
CCCATATAAGAAA
>MQ262311.1 Sequence 171 from Patent WO2021209813
TATCTTTTTTTAT
>MQ262310.1 Sequence 170 from Patent WO2021209813
GATCTATTCTTTT
>pdb|7KLF|P Chain P, Ternary structure of Dpo4 bound to G in the template base paired with incoming dCTP
GGGGGAAGGATTC
>pdb|7KLE|P Chain P, Ternary structure of Dpo4 bound to N7mG in the template base paired with incoming dCTP
GGGGGAAGGATTC
>pdb|1T38|C Chain C, HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE BOUND TO DNA CONTAINING O6-METHYLGUANINE
TACTAGCCATGGC
>pdb|1T38|B Chain B, HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE BOUND TO DNA CONTAINING O6-METHYLGUANINE
GCCATGNCTAGTA
>pdb|1Q9X|L Chain L, Crystal structure of Enterobacteria phage RB69 gp43 DNA polymerase complexed with tetrahydrofuran containing DNA
GCGGACTGCTTAC
>pdb|1Q9X|K Chain K, Crystal structure of Enterobacteria phage RB69 gp43 DNA polymerase complexed with tetrahydrofuran containing DNA
GCGGACTGCTTAC
>pdb|1Q9X|J Chain J, Crystal structure of Enterobacteria phage RB69 gp43 DNA polymerase complexed with tetrahydrofuran containing DNA
GCGGACTGCTTAC
>pdb|1Q9X|I Chain I, Crystal structure of Enterobacteria phage RB69 gp43 DNA polymerase complexed with tetrahydrofuran containing DNA
GCGGACTGCTTAC
>pdb|1P4E|F Chain F, Flpe W330F mutant-DNA Holliday Junction Complex
TAAGTTCCTATTC
>pdb|1P4E|E Chain E, Flpe W330F mutant-DNA Holliday Junction Complex
TAAGTTCCTATTC
>pdb|1LO1|C Chain C, ESTROGEN RELATED RECEPTOR 2 DNA BINDING DOMAIN IN COMPLEX WITH DNA
CGTGACCTTGAGC
>pdb|1LO1|B Chain B, ESTROGEN RELATED RECEPTOR 2 DNA BINDING DOMAIN IN COMPLEX WITH DNA
GCTCAAGGTCACG
>pdb|1M6X|F Chain F, Flpe-Holliday Junction Complex
TAAGTTCCTATTC
>pdb|1M6X|E Chain E, Flpe-Holliday Junction Complex
TAAGTTCCTATTC
>pdb|1KFV|H Chain H, Crystal Structure of Lactococcus lactis Formamido-pyrimidine DNA Glycosylase (alias Fpg or MutM) Non Covalently Bound to an AP Site Containing DNA.
GAGAAACAAAGAG
>pdb|1KFV|G Chain G, Crystal Structure of Lactococcus lactis Formamido-pyrimidine DNA Glycosylase (alias Fpg or MutM) Non Covalently Bound to an AP Site Containing DNA.
CTCTTTNTTTCTC
>pdb|1KFV|E Chain E, Crystal Structure of Lactococcus lactis Formamido-pyrimidine DNA Glycosylase (alias Fpg or MutM) Non Covalently Bound to an AP Site Containing DNA.
GAGAAACAAAGAG
>pdb|1KFV|D Chain D, Crystal Structure of Lactococcus lactis Formamido-pyrimidine DNA Glycosylase (alias Fpg or MutM) Non Covalently Bound to an AP Site Containing DNA.
CTCTTTNTTTCTC
>PA269199.1 WO 2021141082-A/63: Enhancer
GGGCTGGGCGCTG
>PA268721.1 WO 2021132528-A/99: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGAGCGAGCGTT
>PA271965.1 JP 2021511309-A/54: METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID
AGATCGGAAGAGC
>MQ250804.1 Sequence 6 from Patent WO2021205155
CAATCAGGTGTTT
>MQ250803.1 Sequence 5 from Patent WO2021205155
CAATCAGGTGTTT
>MQ250802.1 Sequence 4 from Patent WO2021205155
CAATCAGGTGAAC
>MQ250801.1 Sequence 3 from Patent WO2021205155
CAATCAGGTGAAT
>MQ250800.1 Sequence 2 from Patent WO2021205155
CAATCAGGTGAAA
>MQ250799.1 Sequence 1 from Patent WO2021205155
CAATCAGGTGAAG
>MQ247676.1 Sequence 47 from Patent WO2021204877
TTACTTAAAGATG
>MQ212734.1 Sequence 7 from Patent EP3886887
AAAAAAAAAAAAA
>MQ212717.1 Sequence 2 from Patent EP3883617
CAGAAACGGGATT
>MQ212716.1 Sequence 1 from Patent EP3883617
CAGAAAYGGGATT
>MQ212696.1 Sequence 124 from Patent EP3862443
CCGCCCGTCACAC
>MQ211852.1 Sequence 11 from Patent EP3886886
ACCAGGTCTTCTG
>MQ210367.1 Sequence 1 from Patent EP3887537
TAGGGTTAGACAA
>MQ235162.1 Sequence 14 from Patent EP3890473
CAGCGCAGCACGC
>MQ234919.1 Sequence 5 from Patent WO2021202425
TGGTGGTGGTGGT
>MQ234435.1 Sequence 7 from Patent WO2021202938
GCATTGGTATTCA
>MQ234013.1 Sequence 120 from Patent WO2021202509
ACCCTGACCCAGT
>MQ234011.1 Sequence 118 from Patent WO2021202509
CATTCAAGAGATG
>MQ229860.1 Sequence 19 from Patent WO2021186081
TMTMTMTMTMTMT
>MQ229859.1 Sequence 18 from Patent WO2021186081
MTMTMTMTMTMTT
>MQ227181.1 Sequence 167 from Patent WO2021189047
GGGCATTGGCTTC
>pdb|3BKZ|B Chain B, X-ray structure of E coli AlkB crosslinked to dsDNA in the active site
TAGGTAANATCGT
>pdb|3BU0|B Chain B, crystal structure of human ABH2 cross-linked to dsDNA with cofactors
CTGTATNATTGCG
>pdb|3BTZ|B Chain B, Crystal structure of human ABH2 cross-linked to dsDNA
AGGTGANAATGCG
>pdb|3BTX|B Chain B, X-ray structure of human ABH2 bound to dsDNA through active site cross-linking
CTGTATNATTGCG
>pdb|3BI3|B Chain B, X-ray structure of AlkB protein bound to dsDNA containing 1meA/A with cofactors
TAGGTAANANCGT
>pdb|3EYZ|C Chain C, Cocrystal structure of Bacillus fragment DNA polymerase I with duplex DNA (open form)
ATGCGAGTCAGGA
>pdb|3G96|H Chain H, Crystal structure of the Bacillus anthracis glmS ribozyme bound to MaN6P
ANGCGCCAGAACT
>pdb|3G96|G Chain G, Crystal structure of the Bacillus anthracis glmS ribozyme bound to MaN6P
ANGCGCCAGAACT
>pdb|3G96|F Chain F, Crystal structure of the Bacillus anthracis glmS ribozyme bound to MaN6P
ANGCGCCAGAACT
>pdb|3G96|E Chain E, Crystal structure of the Bacillus anthracis glmS ribozyme bound to MaN6P
ANGCGCCAGAACT
>pdb|3G8T|H Chain H, Crystal structure of the G33A mutant Bacillus anthracis glmS ribozyme bound to GlcN6P
ANGCGCCAGAACT
>pdb|3G8T|G Chain G, Crystal structure of the G33A mutant Bacillus anthracis glmS ribozyme bound to GlcN6P
ANGCGCCAGAACT
>pdb|3G8T|F Chain F, Crystal structure of the G33A mutant Bacillus anthracis glmS ribozyme bound to GlcN6P
ANGCGCCAGAACT
>pdb|3G8T|E Chain E, Crystal structure of the G33A mutant Bacillus anthracis glmS ribozyme bound to GlcN6P
ANGCGCCAGAACT
>pdb|3G8S|H Chain H, Crystal structure of the pre-cleaved Bacillus anthracis glmS ribozyme
ANGCGCCAGAACT
>pdb|3G8S|G Chain G, Crystal structure of the pre-cleaved Bacillus anthracis glmS ribozyme
ANGCGCCAGAACT
>pdb|3G8S|F Chain F, Crystal structure of the pre-cleaved Bacillus anthracis glmS ribozyme
ANGCGCCAGAACT
>pdb|3G8S|E Chain E, Crystal structure of the pre-cleaved Bacillus anthracis glmS ribozyme
ANGCGCCAGAACT
>pdb|3CFR|P Chain P, Structure of the replicating complex of a POL Alpha family DNA Polymerase, ternary complex 2
GCGGACTGCTTAN
>pdb|3E6C|A Chain A, CprK OCPA DNA Complex
NGCATGTTAATGC
>pdb|3E6C|B Chain B, CprK OCPA DNA Complex
NCATTAACATGCC
>pdb|3BUC|C Chain C, X-ray structure of human ABH2 bound to dsDNA with Mn(II) and 2KG
TCGCAGTTATACA
>pdb|3BUC|B Chain B, X-ray structure of human ABH2 bound to dsDNA with Mn(II) and 2KG
CTGTATNACTGCG
>pdb|3BU0|C Chain C, crystal structure of human ABH2 cross-linked to dsDNA with cofactors
TCGCAATAATACA
>pdb|3BTZ|C Chain C, Crystal structure of human ABH2 cross-linked to dsDNA
TCGCATTATCACC
>pdb|3BTY|C Chain C, Crystal structure of human ABH2 bound to dsDNA containing 1meA through cross-linking away from active site
TCGCAGTTATACA
>pdb|3BTY|B Chain B, Crystal structure of human ABH2 bound to dsDNA containing 1meA through cross-linking away from active site
CTGTATNACTGCG
>pdb|3BTX|C Chain C, X-ray structure of human ABH2 bound to dsDNA through active site cross-linking
TCGCAATAATACA
>pdb|3BKZ|C Chain C, X-ray structure of E coli AlkB crosslinked to dsDNA in the active site
AACGATATTACCT
>pdb|3BIE|C Chain C, X-ray structure of E coli AlkB bound to dsDNA containing 1meA/T with Mn and 2KG
AACGGTTTTACCT
>pdb|3BI3|C Chain C, X-ray structure of AlkB protein bound to dsDNA containing 1meA/A with cofactors
AACGGTATTACCT
>pdb|2NZ4|H Chain H, Structural investigation of the GlmS ribozyme bound to its catalytic cofactor
ANGCGCCAGAACT
>pdb|2NZ4|G Chain G, Structural investigation of the GlmS ribozyme bound to its catalytic cofactor
ANGCGCCAGAACT
>pdb|2NZ4|F Chain F, Structural investigation of the GlmS ribozyme bound to its catalytic cofactor
ANGCGCCAGAACT
>pdb|2NZ4|E Chain E, Structural investigation of the GlmS ribozyme bound to its catalytic cofactor
ANGCGCCAGAACT
>pdb|2I9K|D Chain D, Engineered Extrahelical Base Destabilization Enhances Sequence Discrimination of DNA Methyltransferase M.HhaI
TGATAGCGCTATC
>pdb|2I9K|C Chain C, Engineered Extrahelical Base Destabilization Enhances Sequence Discrimination of DNA Methyltransferase M.HhaI
TGATAGCGCTATC
>pdb|2GM4|K Chain K, An activated, tetrameric gamma-delta resolvase: Hin chimaera bound to cleaved DNA
TTATCGGACACTG
>pdb|2GM4|Y Chain Y, An activated, tetrameric gamma-delta resolvase: Hin chimaera bound to cleaved DNA
TTATCGGACACTG
>pdb|1ZR4|N Chain N, Structure of a Synaptic gamma-delta Resolvase Tetramer Covalently linked to two Cleaved DNAs
TTATCGGACACTG
>pdb|1ZR4|V Chain V, Structure of a Synaptic gamma-delta Resolvase Tetramer Covalently linked to two Cleaved DNAs
TTATCGGACACTG
>pdb|1ZR4|K Chain K, Structure of a Synaptic gamma-delta Resolvase Tetramer Covalently linked to two Cleaved DNAs
TTATCGGACACTG
>pdb|1ZR4|Y Chain Y, Structure of a Synaptic gamma-delta Resolvase Tetramer Covalently linked to two Cleaved DNAs
TTATCGGACACTG
>pdb|1ZR2|K Chain K, Structure of a Synaptic gamma-delta Resolvase Tetramer Covalently Linked to two Cleaved DNAs
TTATCGGACACTG
>pdb|1ZR2|Y Chain Y, Structure of a Synaptic gamma-delta Resolvase Tetramer Covalently Linked to two Cleaved DNAs
TTATCGGACACTG
>pdb|1YQM|B Chain B, Catalytically inactive human 8-oxoguanine glycosylase crosslinked to 7-deazaguanine containing DNA
NGTAGACCTGGAC
>pdb|1YQL|B Chain B, Catalytically inactive hOGG1 crosslinked with 7-deaza-8-azaguanine containing DNA
NGTAGACCTGGAC
>pdb|6AZ1|5 Chain 5, Cryo-EM structure of the small subunit of Leishmania ribosome bound to paromomycin
NACCATGTTCAAA
>pdb|3J0Q|G Chain G, Core of mammalian 80S pre-ribosome in complex with tRNAs fitted to a 10.6A cryo-em map: rotated PRE state 2
NCACGCGCGTTAC
>MY477055.1 Sequence 44623 from patent US 11111545
CCNCCNTNNCCNC
>MY432164.1 Sequence 3 from patent US 11111538
AGATCGGAAGAGC
>MY432056.1 Sequence 15 from patent US 11111529
TCTCGTCAGAATG
>MY432048.1 Sequence 7 from patent US 11111529
CTCGTCAGAATGA
>MY432000.1 Sequence 16 from patent US 11111526
GCTGCTGGCGTAG
>MY421927.1 Sequence 27 from patent US 11111497
GCCAGACCCCCGC
>MY421926.1 Sequence 26 from patent US 11111497
GCCANACCACCGC
>MY421925.1 Sequence 25 from patent US 11111497
TCCATACCACCGT
>MY421924.1 Sequence 24 from patent US 11111497
GCGACACCCCCGC
>MY421923.1 Sequence 23 from patent US 11111497
GCCAGACCCCCGA
>MY421922.1 Sequence 22 from patent US 11111497
GCATCACCCCCGA
>MY421921.1 Sequence 21 from patent US 11111497
GCCTGACCCCCGA
>MY421920.1 Sequence 20 from patent US 11111497
GCTGGACCACCGT
>MY421919.1 Sequence 19 from patent US 11111497
GCGACACCCCCGC
>MY421918.1 Sequence 18 from patent US 11111497
GCTGGGACACCGC
>MY415724.1 Sequence 359 from patent US 11110166
GGGTTTTTTTGGG
>MY415714.1 Sequence 348 from patent US 11110166
GGTTTTTTTTTGG
>MY415569.1 Sequence 3 from patent US 11110157
NCCACCCNTCNCC
>MY415406.1 Sequence 2 from patent US 11110125
ATTTATTTATTTA
>MY415340.1 Sequence 52 from patent US 11110114
GCTAGAGAAGTCG
>MY415339.1 Sequence 51 from patent US 11110114
CGACNTCTCNAGC
>MY415338.1 Sequence 50 from patent US 11110114
CGACTTCTCTAGC
>MY415337.1 Sequence 49 from patent US 11110114
GCTGCAAGCGTCG
>MY415336.1 Sequence 48 from patent US 11110114
GCTGCAAGCGTCG
>MY415335.1 Sequence 47 from patent US 11110114
CGACGCNTGCAGC
>MY415334.1 Sequence 46 from patent US 11110114
CGACGNTTGCAGC
>MY415333.1 Sequence 45 from patent US 11110114
CGACGCTTGCAGC
>MY415328.1 Sequence 40 from patent US 11110114
GCTAGAGAAGTCG
>MY415327.1 Sequence 39 from patent US 11110114
GCTGGAGAGGTCG
>MY415326.1 Sequence 38 from patent US 11110114
CGANNTCTNNAGC
>MY415325.1 Sequence 37 from patent US 11110114
CGANNTCTNNAGC
>MY415324.1 Sequence 36 from patent US 11110114
GCTGCAGGCGTCG
>MY415323.1 Sequence 35 from patent US 11110114
GCTGCAGGCGTCG
>MY415322.1 Sequence 34 from patent US 11110114
CGACGNNTGCAGC
>MY415321.1 Sequence 33 from patent US 11110114
CGACGNTTGCAGC
>MY415320.1 Sequence 32 from patent US 11110114
CGACGNNTGCAGC
>MY415319.1 Sequence 31 from patent US 11110114
CGACGNNTGCAGC
>MY415313.1 Sequence 25 from patent US 11110114
AGCAGATAGTGAG
>MY415312.1 Sequence 24 from patent US 11110114
AGCAGATAGTGAG
>MY415306.1 Sequence 18 from patent US 11110114
GCTAGAGAAGTCG
>MY415304.1 Sequence 16 from patent US 11110114
CTCACTATCTGCT
>MY415302.1 Sequence 14 from patent US 11110114
CGANNTCTNNAGC
>MY415301.1 Sequence 13 from patent US 11110114
CGANNTCTNNAGC
>MY415300.1 Sequence 12 from patent US 11110114
CGACGNNTGCAGC
>MY415299.1 Sequence 11 from patent US 11110114
CGACGNNTGCAGC
>MY415298.1 Sequence 10 from patent US 11110114
CGANTTCTNTAGC
>MY415297.1 Sequence 9 from patent US 11110114
CGANNTCTNNAGC
>MY415296.1 Sequence 8 from patent US 11110114
CGACGNNTGCAGC
>MY415295.1 Sequence 7 from patent US 11110114
CGACGNTTGCAGC
>MY415294.1 Sequence 6 from patent US 11110114
CGACGNTTGCAGC
>MY415293.1 Sequence 5 from patent US 11110114
CGACGNNTGCAGC
>MY412081.1 Sequence 42 from patent US 11104887
GGGAGACGCCAAG
>MY412079.1 Sequence 40 from patent US 11104887
GGGAGACGCCACC
>MY412055.1 Sequence 14 from patent US 11104887
GGGAGACGCCAAG
>MY412052.1 Sequence 10 from patent US 11104887
GGGAGACGCCACC
>MY410070.1 Sequence 40 from patent US 11104700
GCTAGAGAAGTCG
>MY410069.1 Sequence 39 from patent US 11104700
GCTGGAGAGGTCG
>MY410068.1 Sequence 38 from patent US 11104700
GCTAGAGAAGTCG
>MY410067.1 Sequence 37 from patent US 11104700
GCTAGAGAAGTCG
>MY410066.1 Sequence 36 from patent US 11104700
CGACNTCTCNAGC
>MY410065.1 Sequence 35 from patent US 11104700
CGACTTCTCTAGC
>MY410064.1 Sequence 34 from patent US 11104700
GCTGCAAGCGTCG
>MY410063.1 Sequence 33 from patent US 11104700
GCTGCAAGCGTCG
>MY410058.1 Sequence 28 from patent US 11104700
CGACNTCTCNAGC
>MY410057.1 Sequence 27 from patent US 11104700
CGACCTCTCCAGC
>MY410056.1 Sequence 26 from patent US 11104700
CGACGCNTGCAGC
>MY410055.1 Sequence 25 from patent US 11104700
CGACGCTTGCAGC
>MY410054.1 Sequence 24 from patent US 11104700
GCTGCAGGCGTCG
>MY410053.1 Sequence 23 from patent US 11104700
GCTGCAGGCGTCG
>MY410052.1 Sequence 22 from patent US 11104700
CGACGCNTGCAGC
>MY410051.1 Sequence 21 from patent US 11104700
CGACGCCTGCAGC
>MY410044.1 Sequence 14 from patent US 11104700
CGANNTCTNNAGC
>MY410043.1 Sequence 13 from patent US 11104700
CGANNTCTNNAGC
>MY410042.1 Sequence 12 from patent US 11104700
CGACGNNTGCAGC
>MY410041.1 Sequence 11 from patent US 11104700
CGACGNNTGCAGC
>MY410040.1 Sequence 10 from patent US 11104700
CGANTTCTNTAGC
>MY410039.1 Sequence 9 from patent US 11104700
CGANNTCTNNAGC
>MY410038.1 Sequence 8 from patent US 11104700
CGACGNNTGCAGC
>MY410037.1 Sequence 7 from patent US 11104700
CGACGNTTGCAGC
>MY410036.1 Sequence 6 from patent US 11104700
CGACGNTTGCAGC
>MY410035.1 Sequence 5 from patent US 11104700
CGACGNNTGCAGC
>MY406411.1 Sequence 6301 from patent US 11098317
TTCACGTCATGCT
>MY406290.1 Sequence 6180 from patent US 11098317
AGCTTCAATAGTA
>MY406197.1 Sequence 5402 from patent US 11098317
TGCATGCGCAGTA
>MY400745.1 Sequence 7413 from patent US 11098316
AAAGTGTCATGCC
>MY400744.1 Sequence 7412 from patent US 11098316
GGAGAAACAACTG
>MY393306.1 Sequence 42 from patent US 11098306
GTGTGGAATTGTG
>MY391868.1 Sequence 11 from patent US 11096926
CAGAGCAAGGACG
>MY389733.1 Sequence 114 from patent US 11091799
GGAGGGTGGAGGT
>MY389616.1 Sequence 1518 from patent US 11091798
NCCACTGTTAAAA
>MY389613.1 Sequence 1515 from patent US 11091798
NCCACTGTTAAAA
>MY389499.1 Sequence 1398 from patent US 11091798
AGACTTTTAACAG
>MY389482.1 Sequence 1381 from patent US 11091798
AGACTTTTAACAG
>MY389464.1 Sequence 1363 from patent US 11091798
ATCTACAACAGTA
>MY389463.1 Sequence 1362 from patent US 11091798
ATCTACAACAGTA
>MY389462.1 Sequence 1361 from patent US 11091798
ATCTACAACAGTA
>MY389461.1 Sequence 1360 from patent US 11091798
ATCTACAACAGTA
>MY389460.1 Sequence 1359 from patent US 11091798
ATCTACAACAGTA
>MY389459.1 Sequence 1358 from patent US 11091798
ATCTACAACAGTA
>MY389446.1 Sequence 1345 from patent US 11091798
GCCACTGTTAAAA
>MY384007.1 Sequence 45 from patent US 11091764
CGCTTCCACAGAC
>MY384006.1 Sequence 44 from patent US 11091764
GTCTGTGGAAGCG
>MY384003.1 Sequence 41 from patent US 11091764
GTCTGTGGAAGCG
>MY384002.1 Sequence 40 from patent US 11091764
GTCTGTGGAAGCG
>MY384001.1 Sequence 39 from patent US 11091764
GCATTGGTATTCA
>MY367471.1 Sequence 82 from patent US 11091475
TGCTAGCTGAGGA
>MY367457.1 Sequence 68 from patent US 11091475
TAGCAGGTAAGCA
>MY367439.1 Sequence 50 from patent US 11091475
GAGCAGGTAAGCT
>MY365710.1 Sequence 2 from patent US 11085076
CACATTGTCAAGG
>MY365650.1 Sequence 11 from patent US 11085070
GTTGATGTTTCAA
>MY365642.1 Sequence 3 from patent US 11085070
CGCCCCTCAGATA
>MY364410.1 Sequence 24 from patent US 11085030
GTTTGAGAGTGTT
>MY295755.1 Sequence 78364 from patent US 11078247
GCCGCCACCATGG
>MY295754.1 Sequence 78363 from patent US 11078247
GCCGCCACCATGG
>MY230353.1 Sequence 3 from patent US 11079388
CGTAATCGTAATC
>MY222836.1 Sequence 233 from patent US 11078490
CCCNNNNNRTTGY
>MY222832.1 Sequence 229 from patent US 11078490
TAGNNNNNNRTGG
>MY222830.1 Sequence 227 from patent US 11078490
TTCANNNNNNTCC
>MY222827.1 Sequence 224 from patent US 11078490
GAGNNNNNNNTCC
>MY222825.1 Sequence 222 from patent US 11078490
CRAANNNNNNCTC
>MY222824.1 Sequence 221 from patent US 11078490
GGCANNNNNNTTA
>MY222820.1 Sequence 217 from patent US 11078490
GGTANNNNNNTCG
>MY222816.1 Sequence 213 from patent US 11078490
GGANNNNNNRTAA
>MY222815.1 Sequence 212 from patent US 11078490
CCANNNNNNTTGA
>MY222813.1 Sequence 210 from patent US 11078490
TTTAYNNNNNGTG
>MY222809.1 Sequence 206 from patent US 11078490
GYAYNNNNNCTTG
>MY222807.1 Sequence 204 from patent US 11078490
AGTNNNNNNRTGC
>MY222804.1 Sequence 201 from patent US 11078490
CCANNNNNNNCTC
>MY222803.1 Sequence 200 from patent US 11078490
AGYNNNNNNCTTC
>MY222795.1 Sequence 192 from patent US 11078490
GACNNNNNNCTGG
>MY222791.1 Sequence 188 from patent US 11078490
TCAGNNNNNNTGC
>MY222785.1 Sequence 182 from patent US 11078490
GCANNNNNNTTAA
>MY222784.1 Sequence 181 from patent US 11078490
GTANNNNNNNCTC
>MY222782.1 Sequence 179 from patent US 11078490
CGGANNNNNNTTC
>MY222780.1 Sequence 177 from patent US 11078490
GGANNNNNNRTAA
>MY222779.1 Sequence 176 from patent US 11078490
CCANNNNNNTTGA
>MY222778.1 Sequence 175 from patent US 11078490
GAAYNNNNNRTAC
>MY222777.1 Sequence 174 from patent US 11078490
ATAYNNNNNCTAY
>MY222775.1 Sequence 172 from patent US 11078490
ACANNNNNNRTGG
>MY222771.1 Sequence 168 from patent US 11078490
GGANNNNNNCTTT
>MY222764.1 Sequence 161 from patent US 11078490
RTAYNNNNNRTAY
>MY222763.1 Sequence 160 from patent US 11078490
GANNNNNNNTAYG
>MY222755.1 Sequence 152 from patent US 11078490
GAANNNNNNRTGC
>MY222753.1 Sequence 150 from patent US 11078490
ATTYNNNNNCTTC
>MY222752.1 Sequence 149 from patent US 11078490
TAGNNNNNRTGAA
>MY222750.1 Sequence 147 from patent US 11078490
GCAYNNNNNNCTC
>MY222748.1 Sequence 145 from patent US 11078490
AGCNNNNNNTACA
>MY222746.1 Sequence 143 from patent US 11078490
GAGNNNNNNRTGC
>MY222742.1 Sequence 139 from patent US 11078490
CATCNNNNNNTCC
>MY222736.1 Sequence 133 from patent US 11078490
CCAYNNNNNTTAA
>MY222733.1 Sequence 130 from patent US 11078490
GACNNNNNNGATC
>MY222731.1 Sequence 128 from patent US 11078490
ATGNNNNNNCCTC
>MY222729.1 Sequence 126 from patent US 11078490
TCCANNNNNNCGT
>MY222724.1 Sequence 121 from patent US 11078490
CACNNNNNNNCTT
>MY222722.1 Sequence 119 from patent US 11078490
CACNNNNNNNCTG
>MY222714.1 Sequence 111 from patent US 11078490
TTAGNNNNNNTTC
>MY222710.1 Sequence 107 from patent US 11078490
AGTNNNNNNRTTG
>MY222706.1 Sequence 103 from patent US 11078490
AAGNNNNNNCATC
>MY222705.1 Sequence 102 from patent US 11078490
CCAYNNNNNNGTA
>MY222704.1 Sequence 101 from patent US 11078490
CCAYNNNNNNTGT
>MY222702.1 Sequence 99 from patent US 11078490
CCCANNNNNNTCG
>MY222695.1 Sequence 92 from patent US 11078490
AAGNNNNNNCATC
>MY222692.1 Sequence 89 from patent US 11078490
GCANNNNNNTTAA
>MY222690.1 Sequence 87 from patent US 11078490
GGYANNNNNNTCG
>MY222687.1 Sequence 84 from patent US 11078490
GGTANNNNNNTCG
>MY222670.1 Sequence 22 from patent US 11078490
CCAYNNNNNGTTY
>MY222663.1 Sequence 15 from patent US 11078490
GNAGNNNNRTDCA
>MY222662.1 Sequence 14 from patent US 11078490
RTCANNNNNNCTC
>MY222661.1 Sequence 13 from patent US 11078490
GAANNNNNNRTCG
>MY222660.1 Sequence 12 from patent US 11078490
GATGNNNNNNTAC
>MY222658.1 Sequence 10 from patent US 11078490
TGANNNNNNCTTC
>MY222657.1 Sequence 9 from patent US 11078490
AGCANNNNNNTGA
>MY222650.1 Sequence 2 from patent US 11078490
AACNNNNNNGTGC
>MY217830.1 Sequence 3 from patent US 11078229
CCAAGCACGATGT
>MY215686.1 Sequence 20 from patent US 11072797
TGAATGCATGATC
>MY206781.1 Sequence 52 from patent US 11066707
AGCTGGTGGCGTA
>MY206780.1 Sequence 51 from patent US 11066707
AGCTGATGGCGTA
>MY206779.1 Sequence 50 from patent US 11066707
CTTGTGGTAGTTG
>MY206777.1 Sequence 48 from patent US 11066707
AGCTGGTGGCGTA
>MY206776.1 Sequence 47 from patent US 11066707
AGCTGCTGGCGTA
>MY206775.1 Sequence 46 from patent US 11066707
CTTGTGGTAGTTG
>MY206773.1 Sequence 44 from patent US 11066707
AGCTGGTGGCGTA
>MY206772.1 Sequence 43 from patent US 11066707
AGCTGTTGGCGTA
>MY206771.1 Sequence 42 from patent US 11066707
CTTGTGGTAGTTG
>MY206769.1 Sequence 40 from patent US 11066707
AGCTGGTGGCGTA
>MY206768.1 Sequence 39 from patent US 11066707
AGCTAGTGGCGTA
>MY206767.1 Sequence 38 from patent US 11066707
CTTGTGGTAGTTG
>MY206765.1 Sequence 36 from patent US 11066707
AGCTGGTGGCGTA
>MY206764.1 Sequence 35 from patent US 11066707
AGCTCGTGGCGTA
>MY206763.1 Sequence 34 from patent US 11066707
CTTGTGGTAGTTG
>MY206761.1 Sequence 32 from patent US 11066707
AGCTGGTGGCGTA
>MY206760.1 Sequence 31 from patent US 11066707
AGCTTGTGGCGTA
>MY206759.1 Sequence 30 from patent US 11066707
CTTGTGGTAGTTG
>MY206757.1 Sequence 28 from patent US 11066707
CTGGTGACGTAGG
>MY206756.1 Sequence 27 from patent US 11066707
CTGGTGGCGTAGG
>MY206755.1 Sequence 26 from patent US 11066707
CTTGTGGTAGTTG
>MY206753.1 Sequence 24 from patent US 11066707
TCATCATGCAGCT
>MY206752.1 Sequence 23 from patent US 11066707
TCATCACGCAGCT
>MY206748.1 Sequence 19 from patent US 11066707
TTTTGGGCTGGCG
>MY206682.1 Sequence 36 from patent US 11066700
ATGCTTGCGGTAG
>MY206680.1 Sequence 34 from patent US 11066700
GATGGCATTCGTA
>MY206679.1 Sequence 33 from patent US 11066700
TACGAATGCCATC
>MY206670.1 Sequence 18 from patent US 11066700
CCACACAAAGATT
>MY206560.1 Sequence 7 from patent US 11066696
CAATCACTAGCTT
>MY198999.1 Sequence 483 from patent US 11066667
ATTCTCAGTGCTT
>MY198763.1 Sequence 242 from patent US 11066667
TCGTGACTCTTAT
>MY198548.1 Sequence 25 from patent US 11066667
ATTCTCAGTGCTT
>MY198225.1 Sequence 48 from patent US 11066657
AAGGAGATATACC
>MY181407.1 Sequence 544 from patent US 11066464
TGGGTTTTGTCCT
>MY180640.1 Sequence 42 from patent US 11065311
CCCCGTTGCCCGG
>MY179110.1 Sequence 36 from patent US 11060152
CCCGGAAGGGGTC
>MY179109.1 Sequence 35 from patent US 11060152
CCCGGAAGGGGCT
>MY179075.1 Sequence 33 from patent US 11060149
TTCCCGAGACATG
>MY175546.1 Sequence 36 from patent US 11060096
TCAATCATGGCAA
>MY175545.1 Sequence 35 from patent US 11060096
CATACTTTGTTGA
>MY152153.1 Sequence 15 from patent US 11058752
GCCGCCNCCATGG
>pdb|3H8X|B Chain B, Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
CTGTNTNATTGCG
>pdb|3H8R|B Chain B, Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
CTGTATNATNGCG
>pdb|3H8O|B Chain B, Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
CTGTATNATNGCG
>pdb|3IH7|C Chain C, Crystal structure of catalytically active human 8-oxoguanine glycosylase distally crosslinked to guanine-containing DNA
ACGTCCAGGTCTA
>pdb|3KTU|B Chain B, Structure of human 8-oxoGuanine Glycosylase 1 bound to fluorninated oxoG-containing DNA
GGTAGACCTGGAC
>pdb|3LZJ|P Chain P, RB69 DNA Polymerase (Y567A) ternary complex with dCTP Opposite 7,8-Dihydro-8-oxoguanine
GCGGACTGCTTAN
>pdb|3LZI|P Chain P, RB69 DNA Polymerase (Y567A) ternary complex with dATP Opposite 7,8-dihydro-8-oxoguanine
GCGGACTGCTTAN
>pdb|3H8X|C Chain C, Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
TCGCAATAAGACA
>pdb|3H8R|C Chain C, Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
TCGCTATAATACA
>pdb|3H8O|C Chain C, Structure determination of DNA methylation lesions N1-meA and N3-meC in duplex DNA using a cross-linked host-guest system
TCGCTATAATACA
>pdb|3L8B|F Chain F, Crystal structure of a replicative DNA polymerase bound to the oxidized guanine lesion guanidinohydantoin
GCGGACTGCTTAA
>pdb|3L8B|D Chain D, Crystal structure of a replicative DNA polymerase bound to the oxidized guanine lesion guanidinohydantoin
GCGGACTGCTTAA
>pdb|3KHR|H Chain H, Dpo4 post-extension ternary complex with the correct C opposite the 2-aminofluorene-guanine [AF]G lesion
TTGGATGGTAGCN
>pdb|3KHR|D Chain D, Dpo4 post-extension ternary complex with the correct C opposite the 2-aminofluorene-guanine [AF]G lesion
TTGGATGGTAGCN
>pdb|3KHL|H Chain H, Dpo4 post-extension ternary complex with misinserted A opposite the 2-aminofluorene-guanine [AF]G lesion
TTGGATGGTAGAN
>pdb|3KHL|D Chain D, Dpo4 post-extension ternary complex with misinserted A opposite the 2-aminofluorene-guanine [AF]G lesion
TTGGATGGTAGAN
>pdb|3KHH|H Chain H, Dpo4 extension ternary complex with a C base opposite the 2-aminofluorene-guanine [AF]G lesion
NTTGGATGGTAGN
>pdb|3KHH|D Chain D, Dpo4 extension ternary complex with a C base opposite the 2-aminofluorene-guanine [AF]G lesion
GTTGGATGGTAGN
>pdb|3KHG|H Chain H, Dpo4 extension ternary complex with misinserted A opposite the 2-aminofluorene-guanine [AF]G lesion
GTTGGATGGTAGN
>pdb|3KHG|D Chain D, Dpo4 extension ternary complex with misinserted A opposite the 2-aminofluorene-guanine [AF]G lesion
GTTGGATGGTAGN
>pdb|3K59|P Chain P, Crystal structure of E.coli Pol II-normal DNA-dCTP ternary complex
GTGCCTAGCGTAN
>pdb|3K58|P Chain P, Crystal structure of E.coli Pol II-normal DNA-dTTP ternary complex
GTGCCTAGCGTAN
>pdb|3K57|P Chain P, Crystal structure of E.coli Pol II-normal DNA-dATP ternary complex
GTGCCTAGCGTAN
>pdb|3K5N|P Chain P, Crystal structure of E.coli Pol II-abasic DNA binary complex
GTGCCTAGCGTAG
>pdb|3K5M|P Chain P, Crystal structure of E.coli Pol II-abasic DNA-ddGTP Lt(-2, 2) ternary complex
GTGCCTAGCGTAG
>pdb|3K5L|P Chain P, Crystal structure of E.coli Pol II-abasic DNA-dATP Lt(0, 3) ternary complex
GTGCCTAGCGTAN
>pdb|3I0X|C Chain C, Crystal structure of Clostridium acetobutylicum 8-oxoguanine glycosylase/lyase in complex with dsDNA containing adenine opposite to 8-oxoG
ATCCANGTCTACC
>pdb|3I0W|B Chain B, Crystal structure of Clostridium acetobutylicum 8-oxoguanine glycosylase/lyase in complex with dsDNA containing cytosine opposite to 8-oxoG
ATCCANGTCTACC
>pdb|7MJY|M Chain M, MiaB in the complex with s-adenosyl-L-homocysteine and RNA
GGACTGATAATCC
>pdb|7MJX|M Chain M, MiaB in the complex with 5'-deoxyadenosine, methionine and RNA
GGACTGAANATCC
>pdb|7MJX|D Chain D, MiaB in the complex with 5'-deoxyadenosine, methionine and RNA
GGACTGAANATCC
>pdb|7MJW|G Chain G, Methylated MiaB in the complex with 5'-deoxyadenosine, methionine and RNA
GGACTGAANATCC
>pdb|7MJW|M Chain M, Methylated MiaB in the complex with 5'-deoxyadenosine, methionine and RNA
GGACTGAANATCC
>pdb|3NCI|P Chain P, RB69 DNA Polymerase Ternary Complex with dCTP Opposite dG at 1.8 angstrom resolution
GCGGACTGCTTAN
>pdb|3MAQ|P Chain P, Crystal structure of E.coli Pol II-normal DNA-dGTP ternary complex
GTGCCTAGCGTAN
>MQ209291.1 Sequence 5 from Patent WO2021180702
CACCGTCAAAATG
>MQ208433.1 Sequence 7 from Patent WO2021180791
TGTGGTAGCAATG
>MQ208432.1 Sequence 6 from Patent WO2021180791
GGCAAATGCAATG
>MQ205615.1 Sequence 27 from Patent WO2021181118
GCCGCCACCATGG
>MQ204120.1 Sequence 167 from Patent WO2021184017
GGGCATTGGCTTC
>MQ193587.1 Sequence 34 from Patent EP3868874
GGGGCAAATAACA
>MQ193585.1 Sequence 32 from Patent EP3868874
GGGGCAAATAACA
>MQ193580.1 Sequence 27 from Patent EP3868874
GGGGCAAATAACA
>MQ193086.1 Sequence 12 from Patent WO2021175786
CCGGCTGGGACCG
>MQ193085.1 Sequence 11 from Patent WO2021175786
CGGCTGGAACCGC
>PA264977.1 WO 2021117122-A/19: Agent for preventing and treating Lysosomal Acid Lipase Deficiency
AACCAAATGATCT
>PA264975.1 WO 2021117122-A/17: Agent for preventing and treating Lysosomal Acid Lipase Deficiency
CCAAATGATCTGG
>pdb|7ABS|E Chain E, Structure of human DCLRE1C/Artemis in complex with DNA - re-evaluation of 6WO0
CACAGCTGATCGC
>pdb|6XBU|F Chain F, polymerase domain of polymerase-theta
GCGGCTGTCATTG
>MQ173041.1 Sequence 2224 from Patent WO2021168478
AATCTGTCAAGCA
>MQ172827.1 Sequence 2010 from Patent WO2021168478
TGCAAATGCATAA
>MQ172658.1 Sequence 1841 from Patent WO2021168478
TGCGTTCTCCATT
>MQ172615.1 Sequence 1798 from Patent WO2021168478
CACTGCGTTCTCC
>MQ172599.1 Sequence 1782 from Patent WO2021168478
ACTGCGTTCTCCA
>MQ172267.1 Sequence 1450 from Patent WO2021168478
TGAGCTTTCATGG
>MQ189225.1 Sequence 78 from Patent EP3873505
CTGTTGTTGCTCT
>MQ182860.1 Sequence 2 from Patent EP3846808
ATGCAGTTCGCTA
>MQ164315.1 Sequence 32 from Patent WO2021156316
TGCTGANTCAGCA
>MQ156347.1 Sequence 52 from Patent EP3867402
GTCTCCGACTCAG
>MQ156321.1 Sequence 26 from Patent EP3867402
GCTCTTCCGATCT
>MQ156308.1 Sequence 13 from Patent EP3867402
GTCTCCGACTCAG
>MQ155427.1 Sequence 64 from Patent EP3854888
TCGTTTAGACCTT
>MQ155425.1 Sequence 62 from Patent EP3854888
TCGTTTAGACCTT
>MQ146053.1 Sequence 409 from Patent WO2021154738
GGAGCAATTCAAC
>MQ146051.1 Sequence 407 from Patent WO2021154738
AACACACAGAGAA
>MQ146046.1 Sequence 402 from Patent WO2021154738
TTTCCATACACTG
>MQ146045.1 Sequence 401 from Patent WO2021154738
CACAGAGAATGGT
>MQ144963.1 Sequence 5 from Patent WO2021152587
RRAARTGAAACTG
>MQ144752.1 Sequence 9 from Patent WO2021154745
CTCGAGCGTTCTC
>MQ144656.1 Sequence 93 from Patent WO2021152301
TAGTCTTAATTAG
>MQ144655.1 Sequence 92 from Patent WO2021152301
TAGCGATAAGTAG
>MQ143453.1 Sequence 180 from Patent EP3861357
TGCATTCCTTAGC
>MQ143342.1 Sequence 69 from Patent EP3861357
CAAAAACAACKGG
>MQ143313.1 Sequence 40 from Patent EP3861357
CAAAAACAACKGG
>MQ142869.1 Sequence 69 from Patent EP3860452
CAAAAACAACKGG
>MQ142840.1 Sequence 40 from Patent EP3860452
CAAAAACAACKGG
>MQ143186.1 Sequence 180 from Patent EP3860629
TGCATTCCTTAGC
>MQ143075.1 Sequence 69 from Patent EP3860629
CAAAAACAACKGG
>MQ143046.1 Sequence 40 from Patent EP3860629
CAAAAACAACKGG
>MQ142980.1 Sequence 180 from Patent EP3860452
TGCATTCCTTAGC
>MQ142461.1 Sequence 151 from Patent EP3861120
CTCGGTTAACTCG
>MQ141862.1 Sequence 11 from Patent EP3860634
GCCGCCRCCATGG
>MQ141825.1 Sequence 180 from Patent EP3861345
TGCATTCCTTAGC
>MQ141714.1 Sequence 69 from Patent EP3861345
CAAAAACAACKGG
>MQ141685.1 Sequence 40 from Patent EP3861345
CAAAAACAACKGG
